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Cyanobactins are N-to-C macrocyclic peptides that contain diverse modifications 
such as heterocyclization of Cys, Ser, or Thr, and isoprenylation of Ser, Thr, and Tyr. 
Although the above can be inferred to occur based on the final products, none of the 
enzymatic steps en route to cyanobactin biosynthesis had been characterized prior to this 
work.  Indeed, until very recently, nothing at all was known about cyanobactin 
biosynthesis.  Only after cloning and sequencing of the genetic elements required for 
cyanobactin biosynthesis was their biosynthetic origin deduced.  Surprisingly, these 
complex natural products are biosynthesized by extensive posttranslational modification 
of ribosomally synthesized precursor peptides.  As noted, these precursors are initially 
synthesized on the ribosome.  Following ribosomal synthesis, various modifying enzymes 
carry out posttranslational modification of the aforementioned amino acids, as well as 
proteolysis of the precursor peptide to liberate 6-12 amino acid peptidyl groups, which 
are then macrocyclized.  However, the manner in which the disparate genetic components 
required for cyanobactin biosynthesis functioned enzymatically to create these highly 
diverse and medicinally interesting compounds was unknown prior to this work.  Herein 
the results of several studies that elucidate the steps en route to cyanobactin biosynthesis 
are described.  The characterized steps include: N- and C-terminal proteolysis, 
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1.1 Literature Review 
 
1.1.1 Natural Products 
 
 Natural products constitute a very large fraction of approved drugs and drug 
leads.  The great utility of natural products stems from the diversity of structures and the 
incredible range of bioactivities found in these molecules.   Because natural products are 
so incredibly vast in scope, many different classes have been delineated, which include 
but are not limited to: alkaloids, isoprenoids, polyketides, nonribosomal peptides, and 
ribosomal peptides.  Of particular relevance here are the nonribosomal and ribosomal 
peptide natural products.  The chemical logic that underlies molecules of both 
nonribosomal and ribosomal classes is identical.  To wit, both classes are polymers of 
amino acid monomers that have been joined to form peptide chains linked through amide 
bonds.  Although at a chemical level there are many similarities between ribosomal and 
nonribosomal peptides, biosynthetically they are quite different. 
 
 
1.1.2 Nonribosomal and Ribosomal Peptide Natural Products 
Nonribosomal peptides (NRPs) derive from extraordinarily large biosynthetic 
assembly lines, in which roughly 75 kDa of enzyme are required to activate and 
incorporate a single amino acid.  Among NRPs, much of the chemical diversity is created 
at the level of the monomers that are incorporated.  Notably, these monomers are not 
limited by the 20 canonical amino acids.  Added diversity can be introduced by tailoring 
domains, which may or may not be localized within the main assembly line.   
 In contrast, ribosomal peptide natural products (RPs), as the name would suggest, 
derive from ribosomal biosynthesis.  Unlike NRPs, which encompass all peptides 
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biosynthesized on nonribosomal peptide synthetases, defining RPs is not so 
straightforward.  That is, nearly all proteins and peptides in nature are synthesized on the 
ribosome, and yet the vast majority of ribosomally-synthesized polypeptides are not 
considered RPs.  Here RPs will be defined as posttranslationally modified peptides that 
function as secondary metabolites.  In turn, secondary metabolites have been defined as 
molecules that are nonessential for the survival of an organism, but which nevertheless 
confer some benefit.(1)  As noted, RPs share a common biosynthetic framework which 
centers on the posttranslational modification of a ribosomally derived precursor peptide.   
Interestingly, although the precursor peptides themselves could be seen as passive players 
in the course of biosynthesis, many conserved features can frequently be observed among 
precursor peptides from diverse groups (Figure 1.1).  In particular, many precursors 
frequently contain N-terminal signal sequences to direct export of posttranslationally 
modified natural products.  Export is especially crucial for larger, more sparsely modified 
RPs, which would otherwise be unable to cross the membrane of the producing cell, and 
thus be prevented from reaching their molecular targets.  Other conserved features 
include a so-called ‘leader sequence’, which is a highly conserved N-terminal peptide 
sequence that is thought to serve as a binding handle for modifying enzymes, but which 
itself is not a substrate for modification.  Moving from the N- to the C-terminus, 
precursor peptides will frequently contain a proteolytic recognition site, which in several 
studied examples takes the form of a double-glycine motif.  Proteolytic cleavage of the 
signal sequence and leader peptide from the core natural product peptide sequence is 
presumably nearly always required for activity, and indeed among studied examples, this 




















residues compose the bulk of the final natural product.  Lastly, and somewhat 
infrequently, precursor peptides may contain a C-terminal sequence, which is also 
cleaved from the final natural product.  Interestingly, RPs that do contain C-terminal 
recognition sequences are frequently found to be macrocyclic in nature.   
Early work on RPs was largely limited to a few closely related molecules.  In 
particular, some of the earliest work was done on the lantibiotics, which are named for 
the presence of lanthionine crosslinks that constrain the peptide backbone.  Chemically, 
lanthionine bonds are simply thioethers derived from the condensation of a cysteine thiol 
with a dehydrated serine or threonine residue.  Of the lantibiotics, the oldest and most 
well-characterized is nisin, whose antibacterial activity was discovered in 1928.(2, 3)  
Despite this early discovery, the chemical structure, and the genetic basis for nisin were 
not revealed until many years later.(3, 4)  Overall, lantibiotic biosynthesis proceeds first 
via enzymatically catalyzed dehydration of serine and threonine residues, and then by 
regio- and stereoselective attack of cysteine thiols on the dehydrated residues.  Although 
the aforementioned sequence was hypothesized to occur for many years,(3, 5) a 
biochemical demonstration of this process was not achieved until relatively recently.(6)  
As noted, lantibiotics are chiefly modified via introduction of lanthionine crosslinks.  
However, other modifications among the lantibiotics were known for several years, 
including the presence of standalone dehydrated serine and threonine (i.e., dehydrations 
that do not proceed to form lanthionine bonds), as well as thioethers that cross link 
cysteine thiols to α-carbons,(7) and other unusual modifications such as aminovinyl 
cysteine.(8-10)   
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 Other pioneering work on RPs focused on microcins, which are defined as low-
molecular weight antimicrobial peptides biosynthesized by Escherichia coli.  Of these 
only microcins B17 and C7 were long known to be posttranslationally modified.(11-13)  
Microcin B17 is predominantly modified by heterocyclization of cysteine and serine 
residues to yield oxazoles and thiazoles, some of which occur in tandem.  Microcin C7 is 
a mimick of aspartyl adenylate, and as such the mature form contains only a single amino 
acid, aspartate, which is conjugated to a modified adenosine nucleotide at its carboxy 
terminus.   
 Of the above mentioned RPs, only microcin C7 could plausibly be synthesized via 
a nonribosomal pathway.  In contrast, the lantibiotics and microcin B17 are such large 
molecules (30-40 residues) that their synthesis by nonribosomal peptide synthetases 
(which typically require ~75 kDa of enzyme per amino acid incorporated) would be 
grossly inefficient from an energetic perspective, and contribute relatively little to the 
overall structural diversity (since the majority of the residues in each case are derived 
from simple proteinogenic L-amino acids).  
 
 
1.1.3 Biosynthetic Origin of the Patellamides 
Overall, in the 1990s and early 2000s, the possibilities for structural modification 
of ribosomally derived peptides were underestimated.  Likewise, it was far better 
appreciated how nonribosomal peptide synthetases could produce highly derived peptide-
like molecules.  In light of this intellectual context, it is unsurprising that most complex 
peptide-like molecules were reflexively assigned as deriving from nonribosomal 
biosynthesis.(14)  In particular, one class whose biosynthetic origin was frequently 
  
7 
assigned as nonribosomal were the patellamides (Figure 1.2).  The patellamides were 
initially isolated from marine animals known as ascidians, more commonly referred to as 
‘sea squirts.’(15-18) These molecules possessed not only intruiging bioactivities, but also 
interesting chemical features as well.  To wit, patellamides are small, (6-8 amino acids) 
circular peptides that contain heterocycles derived from cysteine, serine and threonine, as 
well as D-amino acids.(19)  Although there was much speculation as to their origin, one 
hypothesis held that they derived from a nonribosomal biosynthesis.(20)  This hypothesis 
was based upon (1) the presence of a macrocyclic framework, which is common among 
NRPs, but had not been previously observed in RPs (2) the presence of multiple 
heterocycles, of varying oxidation states (3) the presence of several D-amino acids 
residues in known cyanobactins.  With regard to (2) above, although microcin B17 
contains heterocycles, many more NRPs were known containing this modification.  
Moreover, the variability in oxidation states observed in patellamides was not observed in 
microcin B17, and itself suggests a domain-swapping mode of evolution, which is 
thought to obtain among NRPs.  
Another mystery surrounding the patellamide family of compounds had to do 
with the organism responsible for their biosynthesis.  Given that these compounds were 
not found to be localized within any symbiont, it was natural to hypothesize that the 
animals themselves might have been the relevant producers.(21)  Had this hypothesis 
been supported, these would doubtless have been some of the most complex natural 
products known to be produced by higher eukaryotes.  An alternative hypothesis held that 













the benefit of their animal host.  Intriguingly, several patellamide-containing ascidians 
were already well-known to contain an abundance of photosynthetic microorganisms—
cyanobacteria.  In particular, one species of cyanobacteria, Prochloron didemni had been 
found to be particularly abundant in several ascidians.  Additionally, there was evidence 
for a symbiotic relationship between the Prochloron and its ascidian hosts, as the animals 
live in nutrient limited conditions, and Prochloron had been shown to supply them with 
much of their carbon requirements.  Thus, given the already extant symbiotic relationship 
between Prochloron and their ascidian hosts, it was not unreasonable to hypothesize that 
an added dimension to this symbiotic relationship might revolve around the production of 
natural products, such as the patellamides, which given their cytotoxicity,(17) could 
potentially serve to deter predation (though it must be said that to impose purpose on 
natural products is to venture into epistemologically murky waters; that is, although the 
production of natural products is doubtless favorable under certain conditions, it is 
difficult to establish with a high degree of certainty exactly which selection pressures 
promote specific natural products).    
Remarkably, the Prochloron hypothesis was confirmed in 2005, with the isolation 
of a gene cluster that was shown via heterologous expression experiments to be sufficient 
for patellamide production in E. coli.(22)  This work also demonstrated, again to great 
surprise, that the patellamides derived from a ribosomal mode of biosynthesis, and were 
thus RPs (Figure 1.3).  That the patellamides were RPs could be deduced by inspection of 
the gene cluster alone.  Out of six open-reading frames (A-G), one—patE—contained 
near its C-terminus two 8-amino acid sequences that (after accounting for 
posttranslational modification) were identical with the sequences found in two natural 
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products, patellamides A and C (Figure 1.3).  In light of the work done on the microcins 
and lantibiotics, the following biosynthetic hypothesis could be proposed: (1) PatE, a 70 
amino acid peptide, is synthesized ribosomally (2) posttranslational modifications such as 
heterocyclization of cysteine, serine and threonine occur, yielding a heterocycle-
containing PatE (3) oxidation of thiazoline and/or oxazoline affords thiazoles and/or 
oxazoles (4) proteolytic cleavage frees the natural product encoding sequences (5) N-to-C 
terminal macrocyclization yields the circular structures (6) nonenzymatic epimerization 
of α-carbons next to thiazole or oxazole (which is known to be facile) affords the final 
isolated structures (Figure 1.4).  Supporting this hypothesis was the presence of several 
open reading frames clustered with patE, some of which had bioinformatically 
predictable functions consistent with the above biosynthetic steps (vide infra).   
Further work then showed that several other families of macrocyclic peptides 
isolated from marine animals, such as the patellins and lissoclinamides, were also RPs 
(Figure 1.5).  Indeed patellamide-like pathways were found to be so widespread within 
cyanobacteria (not just Prochloron) and encompassed so many previously isolated 
compounds, all with divergent compound family names, that in 2008, a overall group 
nomenclature was proposed, leading to the umbrella term ‘cyanobactins’. which 
describes any homologous pathway to macrocyclic RPs.(23, 24)  Quite interestingly, in 
several cases the gene clusters responsible for cyanobactin biosynthesis were virtually 
identical to that initially isolated for the patellamide family.  Consequently, it became 







Figure 1.3 The patellamide pathway.  Top: gene cluster isolated in 2005 to the 
patellamides.  Middle: patellamide precursor peptide, highlighted in bold and with 
modified residues colored blue or red are the modified ‘cassettes’ that encode compounds 














Figure 1.5 Lissoclinamides and patellins.  
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afford these different metabolites.  First, without significant change to any predicted 
biosynthetic gene, point mutagenesis of the natural product encoding ‘cassettes’ within 
patE was occurring. The occurrence of large numbers of point mutations within the 
natural product encoding cassettes leads to the hypothesis that the enzymes responsible 
for posttranslational modification of the precursor peptide are broadly substrate 
tolerant.(25)  Second, whole pathways were recombining to yield natural products with 
both altered cassette sequences and novel posttranslational modifications (Figure 1.6).  In 
particular, comparison of the patellamide and trunkamide pathways provided a very clear 
example whereby recombination could afford a new set of posttranslational 
modification.(24)   
As noted, the patellamide family of compounds contain heterocycles derived from 
cysteine, serine and threonine.  In patellamide family metabolites, between three and four 
heterocycles per compound of variable oxidation states are frequently observed.  In 
contrast, the trunkamide family of compounds typically contains only a single cysteine-
derived heterocycle per compound, and only in the unoxidized state (thiazoline).  At 
serine and threonine, in lieu of the oxygen-based heterocycles found in the patellamide 
family, trunkamide (tru) pathway metabolites contain 5-carbon alkylations of oxygen on  
these residues.  Based upon a structural inspection, these alkylations almost certainly 
derive from dimethylallyl pyrophosphate (DMAPP), representing a nearly unprecedented 
intersection of RPs and isoprene natural products.(26)  What is most interesting about the 
chemical differences in the trunkamide and patellamide pathway metabolites is that these 
chemical differences are obviously correlated with a recombination event that occurred 







Figure 1.6 Alignment of pat and tru pathways.  Red portions denote regions of high 
homology.  Discontinuity suggests recombination event.  Adapted from (24).  
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several differences between these two pathways, which are 95-99% identical otherwise.  
In particular, the C-termini of PatD and TruD and N-termini of PatG and TruG are highly 
divergent, while PatF is duplicated in the tru pathway to give TruF1 and TruF2, all of 
which are only about 50% identical to one another.  Observation of this large 
discontinuity in the conservation of the pathways can readily be invoked to explain the 
chemical differences in the product.  Further, this allowed for the narrowing of 
biosynthetic hypothesis concerning the differences in serine and threonine modification 
between pat and tru pathways.  That is, whatever the enzymatic cause for the chemical 
changes in products, it most likely to be contained within PatD/TruD, PatF/TruF1/F2, or 
PatG/TruG.   
 
 
1.2 Research Objectives 
Overall our goals were first to define the enzymatic causes of posttranslational 
modification and, second to elucidate the order of enzymatic reactions en route to the 
cyanobactins.  Scientifically, the pursuit of these goals could be justified given the 
widespread occurrence and structural novelty of cyanobactin natural products.  
Practically, the heterologous synthesis of extant and novel cyanobactin molecules in E. 
coli constituted a holy grail for natural products based drug discovery, and a more 
complete biochemical understanding of cyanobactin biosynthesis could be expected to 
aid these efforts.  Additional background to the fascinating world of RPs are presented in 







1.2.1 Specific Aim I 
Perhaps the most clear-cut roles to be proposed based on bioinformatic analyses 
for any enzymes within the pat or tru pathways were for PatA/TruA and PatG/TruG.(22)  
Both enzymes could be related bioinformatically to subtilisin-like proteases.  Since the 
peptide sequences that are modified to produce cyanobactins are flanked at their N- and 
C-termini by peptide recognition sequences, it was clear that two proteolytic events 
would be required to liberate them from that context.  Consequently, the presence of two 
predicted proteases within cyanobactin gene clusters was highly suggestive of a role for 
these genes in proteolysis.  Thus, early biochemical experiments focused on in vitro 
characterization of the proteolytic activities of PatA/TruA and PatG/TruG.(27, 28)  The 
results of these experiments are presented in Chapters 3 and 4, and showed firstly that 
PatA/TruA were carrying out proteolysis N-terminal to cassette sequences, and secondly 
that PatG/TruG were carrying out proteolysis C-terminal to cassette sequences in tandem 
with macrocyclization.  Additionally, we found that PatG possesses an astonishingly 
relaxed substrate selectivity and can macrocyclize a wide variety of analogs.  
 
 
1.2.2 Specific Aim II 
Although experiments on the proteolytic enzymes were conducted first given the 
relative obviousness of the hypotheses, in terms of biosynthesis, one might hypothesize 
based upon earlier work on the lantibiotics and microcin B17 that many of the 
posttranslational modifications, such as heterocyclization and prenylation would occur on 
the full-length intact precursor peptide.(29-33)  Drawing further parallels to the 
groundbreaking microcin B17 work, it was possible to transitively relate PatD/TruD to 
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two enzymes McbD and McbB of the microcin B17 pathway, which were shown to 
participate in heterocyclization of cysteine and serine residues.(29)  Consequently, our 
primary hypothesis as to the enzymatic cause of heterocyclization held that PatD/TruD 
were most likely to be responsible.  Alternatively, another possibility was that PatD/TruD 
might only be responsible for cysteine heterocyclization, while in the patellamide 
pathway, PatF was responsible for heterocyclization of serine and threonine.  This 
alternative hypothesis was based on the differences in heterocyclization patterns between 
the pat and tru pathways, and the dissimilarity of PatF and TruF1/F2 genes.(24)  Still 
further support for this hypothesis was found in a cyanobactin pathway from the free-
living cyanobacterium, Trichodesmium erythraeum, which led only to Cys heterocycles, 
and lacked a PatF homolog.(34)  The results of these experiments are presented in 
Chapters 5 and 6, and showed that PatD/TruD are solely responsible for the differences in 
heterocyclization between the pat and tru pathways.   
 
 
1.2.3 Specific Aim III 
Finally, having defined all other posttranslational modifications leading to the 
cyanobactins, we set out to reveal the enzymatic cause of isoprenylation of serine and 
threonine in the trunkamide pathway.  As noted above, only PatD/TruD, PatF/TruF1/F2, 
and PatG/TruG were significantly different between the pat and tru pathways.  However, 
since by this time we had already assigned enzymatic roles to PatD/TruD and 
PatG/TruG,(28, 35-37) the most reasonable hypothesis left to us was that TruF1/F2 were 
the relevant enzymes for prenyltransfer, notwithstanding the fact that neither TruF1 nor 
TruF2 were sequence similar to any characterized prenyltransferase, nor even to any 
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other characterized enzyme.  However, in our attempts to test this hypothesis, we were 
stymied by the insolubility of TruF1 and TruF2 upon overexpression in E. coli.  A further 
difficulty was that although we recognized that earlier work on RPs generally suggested 
that the precursor peptide would be the substrate for posttranslational modification, given 
the complexity of cyanobactin biosynthesis it was nevertheless ineluctable that some 
other biosynthetic intermediate could be the relevant substrate for prenyltransfer.  To sail 
between the proverbial Scylla (which here can be taken to represent protein insolubility) 
and Charybdis (which here represents our profound ignorance of the prenyltransferase 
substrate), we turned to a wholly uncharacterized cyanobactin pathway from Lyngbya 
aestuarii, known as the lyn pathway.  This pathway had previously been predicted to 
carry out isoprenylation of tyrosine residues within cyanobactins.  Thus, possible 
substrates for each biosynthetic step were synthesized and tested for acceptability as 
substrates for prenyltransfer.  The results of these studies are presented in chapter 7, and 
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Figure S6. DAD-HPLC analysis of PatG scale-up reactions. PatG protease was treated with 
synthetic peptide QGGRGDWPAYDGE in a 1:3 enzyme:substrate ratio. A) DAD-HPLC of a 10 
!g synthetic standard of eptidemnamide.  B) DAD HPLC of a PatG reaction with 
QGGRGDWPAYDGE. 400 !L of a 1 mL reaction volume was injected. Integration indicates 
that 90 !g eptidemnamide was synthesized in this reaction from 200 !g of starting peptide, 
representing a 75% yield. C) A photograph of the purified, lyophilized product. (Note: 2 peaks 
are present in the synthetic standard because there is a Pro cis-trans isomerization, as defined by 
2D NMR experiments and previously reported.5 Only one isomer is present in the enzymatic 
product. Slight time differences are due to buffer differences; these peaks co-elute when co-
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Abstract: A protease from ribosomal peptide biosynthesis mac-
rocyclizes diverse substrates, including those resembling nonri-
bosomal peptide and hybrid polyketide-peptide products. The
proposed mechanism is analogous to thioesterase-catalyzed
chemistry, but the substrates are amide bonds rather than
thioesters.
Macrocyclization is a common strategy to improve the rigidity
and stability of bioactive metabolites.1,2 In polyketide and nonri-
bosomal peptide biosynthesis, macrocyclization via lactones or
lactams is typically catalyzed by thioesterase (TE) domains, which
contain a serine protease-like Asp-His-Ser catalytic triad (Figure
1).1 The TE domain transfers the peptide/polyketide chain from a
carrier protein to the active site serine, which is then displaced by
a nucleophile, generating either a linear product or more commonly
a macrocycle, as in tyrocidine A (1).
Quite interestingly, one of the major groups of macrocyclic
ribosomal peptides, the cyanobactins,3 is cyclized in a similar way:
a subtilisin-like serine protease catalyzes cleavage of a C-terminal
peptide sequence in tandem with N-C macrolactamization, leading
to compounds such as patellamide C (2).4-6 Among ribosomal
peptides, both the cyanobactins and cyclotides are N-C cyclic,
while other ribosomal peptides, such as capistruin,7 microcin J25,8
and the microviridins,9 are cyclized via side-chain residues using
ATP via wholly different biochemical mechanisms. There is indirect
evidence that cyclotides are circularized in a similar fashion to
cyanobactins,10 and circular ribosomal peptides are common in
diverse organisms. However, no definitive enzymatic or genetic
studies of N-C macrocyclization have been performed on any
ribosomal peptide system other than the cyanobactins.
Previously, we have shown that the subtilisin-like protease, PatG,
is solely responsible for catalyzing macrocyclization in the patel-
lamide pathway.6 Metagenomic and biochemical analyses of the
patellamide pathway showed that PatG is a broad-substrate enzyme,
processing 29 known precursor peptide sequences encoding mac-
rocycles of 7-8 amino acids.4,5 Every natural product residue is
mutated at least once in this series, and PatG could also produce
the unnatural compound eptidemnamide (3) both in ViVo and in
Vitro (Figure 2). Consequently, the cyanobactin macrocyclases
exhibit exceptionally relaxed substrate specificity. Furthermore,
unlike other ribosomal peptide natural product pathways,11,12 the
cyanobactin macrocyclases require only a C-terminal 4-5 amino
acid recognition sequence, AYDG(E), which allowed us to employ
short synthetic peptides as substrates.
We proposed that PatG performs macrocyclization in a manner
that is mechanistically analogous to TE domains, although the
proteins and the substrates are quite different. In particular, while
† University of Utah.
‡ Center for Biophysics and Computational Biology, University of Illinois.
§ Department of Biochemistry, University of Illinois.
Figure 1. Macrocyclization in ribosomal and nonribosomal synthesis. (A)
The nonribosomal TycC TE domain circularizes tyrocidines. PCP) peptidyl
carrier protein. (B) The ribosomally acting PatG protease circularizes
patellamides and many other compounds. The proposed catalytic mechanism
is indicated here. Tzl ) thiazol(ine); MOzl ) methyloxazoline.
Figure 2. Products of PatG macrocyclization. (A) Representative known
natural products cyclized by PatG, out of a total of 39 known natural products
in this series. (B) Macrocyclization products from this study, showing side-
chain circularization (28, 43) and polyketide-like cyclization (41, 42).
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as their name implies TEs require activated thioesters (or esters)13
to catalyze circularization, the PatG substrates are simple amides
readily accessible through standard solid phase peptide synthesis.
Based on this mechanistic hypothesis, in this study we probed the
capacity of PatG to circularize peptides containing nonproteinogenic
amino acids and polyketide-like linkers. We show that PatG
synthesizes macrocycles that are similar to those from the thiotem-
plate-based pathways,13 lending weight to the mechanistic hypoth-
esis and providing a significant step toward bridging ribosomal and
nonribosomal worlds for the synthesis of complex peptide metabolites.
In this study we tested 23 analogues (5-27) to define the
substrate tolerance of PatG. The analogues are of variable length
and amino acid composition, but nearly all contain Pro followed
by the macrocyclase recognition sequence AYDGE (Table 1). Pro
was used because all of the natural compounds contain heterocycles
immediately prior to AYDGE. These heterocycles are either Pro
or thiazol(in)e/oxazol(in)e derived from Cys, Ser, or Thr. One
exception (5) contained Ala in place of Pro to test this putative
heterocycle requirement.
Analogues 5-23 are based on the previously reported PatG
substrate 4, which leads to eptidemnamide (3). 6-9 contain
N-terminal residue substitutions that explore the potential for
cyclization via side-chain nucleophiles, including OH in glycolate
(Glyc) and NH2 in diaminopropionate (Dap), Lys, and ornithine
(Orn). 11-15 explore the tolerance for D-amino acids. In 10, 16-21,
24, and 27 cyclizable sequence lengths from 5 to 11 amino acids
are explored. 22 and 23 resemble polyketide-peptide hybrids,
containing alkyl spacers aminohexanoic acid (Ahx) and aminohep-
tanoic acid (Ahp) that replace portions of the eptidemnamide
sequence. Finally, to further explore substrate selectivity several
substrates with wholly different sequences were attempted. 24-26
are based on the hormone neurotensin, while 27 mimics the
neuropeptide galanin. The peptides were synthesized via standard
solid phase synthesis (Supporting Information).
To assay macrocyclization, analogues were incubated with
the PatG protease domain (Supporting Information). As controls,
substrates were also incubated in an equivalent manner using a site-
directed mutant in which the active-site Ser of PatG was replaced
with Ala. Products were analyzed via matrix-assisted laser desorp-
tion ionization-mass spectrometry (MALDI-MS), which allowed
us to readily observe the loss of starting material and the
accumulation of products of the expected mass; for the most part
these products are the only reasonable chemical entities that fit the
mass. Representative products from each compound family were
confirmed by high-resolution MS and MS-MS on a Fourier
transform ion cyclotron resonance (FT-ICR) instrument. This
method unambiguously establishes the position of circularization
because numerous ions are present that only could arise if the amide
bond was synthesized as shown in Figure 2. For full details, see
Supporting Information. The identity of 3 was previously further
confirmed by 2D NMR.5
For example, for compound 41 containing the polyketide-like
Ahx, the predicted linear m/z would be 743 while the cyclic product
would be m/z ) 725, indicating a peptide with a mass decreased
by 18 Da (-H2O). Both ions were observed as the major nonmatrix
peaks in the MALDI spectrum. This sample was then applied to
LC-MS using an FT-ICR instrument, providing parent ions for both
molecules that confirmed their molecular formulas, deviating by δ
0.5 ppm for the linear and δ 0.91 ppm for the cyclic variants. The
MS/MS data for the cyclic product provided a very complex series
of ions that overlapped the new cyclizing amide bond (Pro-Ahx)
and that were inconsistent with possible alternative structures. For
the linear product these ions arising from cyclization were absent,
while the peaks for the linear portion were much more intense,
and the resulting spectrum was much simpler.
Results are summarized in Table 1 and Figure 2b. As seen from
precursor 5, Ala is not accepted in place of Pro, supporting a
requirement for a heterocyclic motif at the last position. All of the
side-chain nucleophile peptides (6-9, 24, and 25) are substrates
for the enzyme, although the OH-containing glycolate peptide 9 is
linearized. Surprisingly, D-amino acids can be tolerated in some
central positions (12 and 13), but apparently not too close to the
C- or N-termini (11, 14, 15, and 26). However, even when
epimerization could be tolerated, MALDI-MS indicated that the
reactions did not approach completion. PatG synthesized products
in lengths from 6 to 11 amino acids (10, 17-21, 24), although
there was some substrate-dependence as 27 was not a substrate.
Peptide 16, which could only form a five amino acid cycle, was
not circularized.
Most significantly, peptides 22 and 23 containing polyketide-
like linker regions were also substrates for circularization by PatG.
Previously, it was shown that the tyrocidine TycC TE domain could
cyclize hybrid polyketide-peptide esters, indicating a fundamental
similarity in the biochemistry of these two enzyme classes despite
wholly different sequences and substrates.13
TE domains often catalyze hydrolysis rather than macrocycliza-
tion s unnatural substrate analogues often trigger the hydrolysis
reaction in place of a natural cyclization s and PatG was similar
in this regard. Depending upon the substrate, PatG synthesized
cyclic/linear products in ratios between 1:2 (for 22) and >10:1 (for
8) as determined by fluorescence HPLC and mass spectrometry.
These cyclic or linear (-AYDGE) products were not formed in the
active site Ser-Ala mutant of PatG. Products closely related to
eptidemnamide (3) were always either completely (>90%) circular-
ized or linearized, or else they were nonreactive. In short, they did
not exhibit combinations of linear and cyclic products. The only
Table 1. Synthetic Peptide Substrates and Macrocyclic PatG
Productsa
Compd Sequence Compd Products
4 QGGRGDWPAYDGE 3 C
5 QGGRGDWAAYDGE - NR
6 (Dap)GGRGDWPAYDGE 28 C R > "
7 (Orn)GGRGDWPAYDGE 29 C R:δ ∼1:1
8 KGGRGDWPAYDGE 30 C R . !
9 (Glyc)GGRGDWPAYDGE 31 L
10 GGRGDWPAYDGE 32 C
11 qGGRGDWPAYDGE 33 L
12 QGGrGDWPAYDGE 34 C
13 QGGRGdWPAYDGE 35 C
14 QGGRGDwPAYDGE - NR
15 QGGRGDWpAYDGE - NR
16 QGGWPAYDGE - NR
17 QGGGRGDWPAYDGE 36 C
18 QGGGGRGDWPAYDGE 37 C
19 QGGGGGRGDWPAYDGE 38 C
20 GGGRGDWPAYDGE 39 C
21 GGGGRGDWPAYDGE 40 C
22 (Ahx)RGDWPAYDGE 41 C:L 1:2
23 QGG(Ahp)WPAYDGE 42 C:L 1:2
24 KPYILPAYDGE 43 C:L 1:2, R , !
25 KKPYILPAYDGE 44 C:L 1:2
26 KKPYllPAYDGE - NR
27 GWTLNSAGYLLGPAYDGE - NR
a The PatG recognition element, AYDGE, is underlined. Residues in
bold indicate differences from canonical type sequences 4, 24, and 27,
while lower-case residues are in the D-configuration. C ) circular; NR
) no reaction; L ) linear with predicted cleavage between P and A. If
only C or L is indicated, >90% of products were in that form only.
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exceptions in this group were 22 and 23, with highly flexible linkers,
which were hydrolyzed in ratios reminiscent of nonribosomal TE
domains.
The regioselectivity of macrocyclization for 6-8 and 24 was
determined by derivatizing the HPLC purified cyclic peptide with
1-fluoro-2,4-dinitrobenzene, followed by acid hydrolysis. The
hydrolysates were compared using HPLC and/or LC-MS with
authentic standards of R- and !-amino dinitrophenyl (DNP) Dap,
R- and δ-amino DNP-Orn, or R- and ε-amino DNP-Lys. The results
show that side-chain cyclization via Dap, Orn, or Lys did occur in
some substrates (6-7, 24). Substrates with N-terminal Dap or Orn
residues yielded a mixture of regioisomers, while substrates with
N-terminal Lys showed nearly total selectivity for either backbone-
(as in 8) or side-chain-cyclized (as in 24) peptides.
Taken together, these results show that PatG circularizes a broad
array of substrates, including those with nonproteinogenic and
D-amino acids and those containing polyketide-like linkers. It should
be remarked that, based upon known natural products, PatG is also
known to circularize an additional 29 natural substrates that
encapsulate many extremely different amino acid sequences than
those examined in this study. There are some limitations to substrate
selectivity that are apparent in unreacted substrates, but the substrate
specificity is remarkably broad and comparable to TE domains,
especially given that lengths of 6-11 amino acids are effectively
circularized through the terminal amino acid. It is also a remarkably
broad-substrate enzyme, with a relatively short (4-5 amino acid)
recognition sequence directing reactions with many different
substrates and precluding water from the active site despite extreme
differences in substrate length and constitution.
In this and previous in Vitro studies using PatG, a limitation is
its exceptionally slow rate, with some reactions complete in ∼24
h using a 50% catalyst load. In previous work with PatG, lower
catalyst loads led to complete conversion in longer reaction periods,
demonstrating that PatG acts catalytically, albeit slowly in Vitro.6
Moreover, in ViVo other cyanobactin macrocyclases seem relatively
efficient, where yields of up to 2.5 mg of compound per L of culture
have been observed,14 indicating that in Vitro reactions could likely
be improved. To the best of our knowledge, this report represents the
first time that a ribosomal natural product catalyst has been shown to
accept such extremely diverse, unnatural substrates in Vitro.
In summary, although PatG is a catalyst from ribosomal peptide
natural product synthesis that operates on amide bonds, its behavior
is reminiscent of TE domains from nonribosomal and polyketide
synthesis. Although this enzyme is not optimal for in Vitro use,
ultimately, it is hoped that this and other studies will provide a
toolkit for genetic engineering of diverse small molecules in ViVo
and will help to bridge nonribosomal and ribosomal biosynthesis.15
It is relatively straightforward to engineer peptide production in
ViVo using ribosomal synthesis, but nonribosomal machinery leads
to much more chemically diverse products. Nonproteinogenic amino
acids, such as those found in nonribosomal peptides, can already
be ribosomally encoded using existing technology.16 Ultimately, a
combination of tools such as the enzymatic methods described here
in concert with the ability to add unusual functions using the
ribosome itself will enable the production of chemically diverse
products in ViVo. By bridging the biochemistry of these two worlds,
the goal is to take advantage of the engineering simplicity of the
ribosome while synthesizing the elaborate products more typical
of complex nonribosomal peptides.
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All HPLC separations were performed on a Hitachi LaChrom Elite system.  MALDI-MS 
analysis of peptide cyclization reactions was performed on a Micromass MALDI micro 
MX (Waters) instrument using an automated targeting protocol.  LC-FT-ICR analysis was 
performed on a LTQ FT Ultra Hybrid Mass Spectrometer (Thermo Scientific).  MALDI-
MS of DNP-Lys derivatives was performed on a DE-STR (PerSeptive Biosystems/ABI) 
instrument.  Low-resolution LC-MS of DNP-Dap derivatives was performed on a 
Micromass ZQ (Waters) instrument equipped with a Waters 2487 HPLC system.  13C and 
1H NMR were performed on a 400 MHz NMR spectrometer (Varian).  
 
Peptide synthesis 
Peptides were synthesized using Fmoc-based solid-phase peptide synthesis.  Fmoc-Amino 
acids, piperidine, N,N-diisopropylethylamine (DIPEA) and preloaded Rink-amide 
glutamate-resin (substitution 0.58 mM/g) were purchased from Chem-Impex, Intl. 
Coupling reagent benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP) was purchased from ChemPep, Inc.  All other chemicals were purchased from 
Sigma-Aldrich. Synthesis was carried out on a Protein Technologies, Inc. Symphony 
multichannel synthesizer.  Briefly, amino acids (200 mM in NMP) were mixed with resin 
(100 mM scale, 58 mg), PyBOP (200 mM), and DIPEA (400 mM) in a double coupling 
fashion (45 min and 30 min), washing with 70/30 DMF/NMP between couplings.  Fmoc 
was removed by 10 min treatments (x2) of 20% piperidine.  Peptides were cleaved from 







nH2O, 5% ethanedithiol, 2.5% thioanisole v/v, 75 mg/mL phenol) and filtered.  The flow-
through was treated with MTBE (3x volume) and chilled to -20 °C for 1 h. The 
precipitated peptides were then purified on a 219TP1010 semi-prep diphenyl column 
(Vydac) on a linear gradient from 95% buffer A (H2O with 0.1% TFA), 5% buffer B (90% 
acetonitrile, 10% nH2O, 0.1% TFA) to 60% buffer A, 40% buffer B.  Synthesis of the 
correct products was confirmed by MALDI-MS (see Table S1).  Initially, the neurotensin 
analogue 24 (KPYILPAYDGE) was synthesized as KKPYILPAYDGE 25 (see Table S1).  
During the course of enzyme reactions, however, a hydrolytic removal of the N-terminal 
Lys residue gave predominantly 24.   When the PatG Ser!Ala mutant was incubated with 
25, 24 was produced, indicating that PatG did not catalyze removal of the N-terminal Lys.  
Although both 24 and 25 were circularized to yield 43 and 44, respectively, owing to the 




The PatG clone used in this study was a 6X-His tagged truncation of PatG spanning 
residues 513-866.  An active site mutant was also cloned using the QuikChangeTM Site-
Directed Mutagenesis Kit (Stratagene).  Clones were verified by DNA sequencing.  PatG 
513-866 and the active site mutant, PatG 513-866 S783A, were expressed in BL21 DE3 
cells (Novagen) grown in 8 L of LB broth.  The outgrowth was performed at 30 ºC.  Once 
the cells reached an OD600 of 0.4, the temperature was reduced to 18 ºC, and the synthetic 
inducer isopropyl !-D-1-thiogalactopyranoside (IPTG) was added (0.2 mM).  Growth was 






shock lysis was performed according to previously established procedures.1   Cell debris 
was then pelleted by centrifugation for 20 minutes at 13,000 RPM in a JA-20 rotor.  
Cleared lysates were then filtered with 5, 0.45, and 0.2 µm  filters, and then applied to a 
gravity column containing 10 mL of Ni-NTA resin (Qiagen).  The column was washed 
with 10 column volumes of wash buffer (500 mM NaCl, 25 mM imidazole pH 8.0), 
followed by 3 x 15 mL of elution buffer (750 mM NaCl, 250 mM imidazole pH 8.0).  The 
eluents were analyzed by SDS-PAGE and dialyzed three times against 50 mM NaCl, 
20mM tris pH 8.0.  Finally, the protein was stocked in 50 mM NaCl, 20 mM tris pH 8.0, 
10% glycerol, and frozen at -80 ºC. 
 
Enzyme reactions 
Peptides (100  µM) were incubated with PatG (50 µM) along with tris pH 8.0 (20 mM), 
DTT (3 mM), CaCl2 (1 mM), and FMN (10 µM).  Reactions were incubated for 24 h at 34 
ºC, and then frozen at -80 ºC until analysis.  Control reactions were performed with a PatG 
active site mutant.  Samples analyzed by MALDI-MS were desalted and concentrated 
using C18 ZipTips (Millipore) according to the manufacturer’s instructions.  After MALDI 
analysis, reactions were submitted to the University of Utah Mass Spectrometry and 
Proteomics core facility for FT-ICR analysis.   The yield of reactions containing 22 and 24 
were calculated via comparison of enzyme reaction products to a calibration curve of 
fluorescence intensity of Tyr, Trp, and/or to starting material.  The relative ratios of cyclic 
to linear products for 6 and 23 were assessed via ion abundance in LC FT-ICR.  Lastly, 
the relative ratios of cyclic and linear products in reactions containing 7 and 8 was 







Determination of regioselectivity 
Products were purified from reaction mixtures by reversed phase HPLC (29 and 30 were 
purified using a 214TP1010 Vydac C4 semi-preparative column on a gradient from 100% 
buffer A (H2O with 0.05% TFA) to 50% buffer A / 50% buffer B (Acetonitrile); 28 and 43 
were purified using a 219TP54 Vydac Diphenyl column on a gradient from 100% buffer 
A (H2O with 0.07% TFA) to 40% buffer A / 60% buffer B (Acetonitrile with 0.07%  
TFA).  Purity of cyclic peptides was assessed by MALDI-MS.  The DNFB derivitizations 
were conducted according to previously established procedures.2  Briefly, cyclic peptide 
fractions were resuspended in buffer  in 0.65 mL PCR tubes (40 µL; 0.1 M borate pH 
9.0).  To the dissolved cyclic peptides a DNFB solution was added (60 µL; 10 mM in 
Acetonitrile).  The combined solutions were then mixed by vortexing and then placed in a 
thermocycler at 65 °C for 30 minutes, after which time they were frozen at -80 °C.  
Subsequently, the reactions were transferred to 1 mL glass reaction vessels and dried by 
speedvac.  The dried material was resuspended in a solution of HCl (0.1 mL; 6 M in H2O), 
capped with silicone lids, and placed in a sand bath at 110°C for approximately 12 h, 
when the temperature of the sand bath was lowered and the reactions were blown dry 
under a stream of argon.  Products were then directly analyzed by HPLC, LC-MS, or 
UHPLC-MS in comparison with authentic standards (Figure S4). 
 
Synthesis of DNP-Dap, -Orn and -Lys derivatives 
Standards of 3-amino-2-[(2,4-dinitrophenyl)amino]propanoic acid (!-DNP-Dap),  2-
amino-3-[(2,4-dinitrophenyl)amino]propanoic acid ("-DNP Dap), 5-amino-2[(2,4-






dinitrophenyl)amino]pentanoic acid (!-DNP Orn) as well as 6-amino-2-[(2,4-
dinitrophenyl)amino]hexanoic acid ("-DNP Lys) and 2-amino-6-[(2,4-
dinitrophenyl)amino]hexanoic acid (#-DNP Lys) were prepared via previously established 
procedures.3,4 Surprisingly, although DNP-amino acid derivatives have been used 
routinely in peptide chemistry for 50 years, we could not find NMR data for the above 
compounds.  We therefore subjected our derivatives to NMR analysis, the results of which 
are presented below.  DNP-Dap regioisomers were separated using a 214TP104 C4 
column (Vydac) on an isocratic gradient of aqueous ammonium sulfate (1 M).   DNP-Lys  
and DNP-Orn regioisomers were preparatively separated using a 100 x 10 mm Onyx 
monolithic semi-prep C18 column (Phenomenex) on a gradient from 99% H2O/1% 
acetonitrile (AcN) to 100% AcN over 2h.  
 
3-amino-2-[(2,4-dinitrophenyl)amino]propanoic acid ("-DNP-Dap) 
ESI-MS-(+): m/z=271.0 [M+H+]; expected=271.1.  By NMR, this derivative was observed 
as a mixture of two stable conformers: 1H NMR (D2O, 400 MHz) ! 9.12 (1H, t, J = 2.7 
Hz), 8.28 (1H, dd, J = 2.7, 7.0 Hz), 8.26 (1H, dd, J = 2.7, 7.4 Hz), 6.98 (1H, d, J = 9.8 
Hz), 6.94 (1H, d, J = 9.3 Hz), 4.32 (1H, m), 3.70 (1H, dd, J = 3.9, 14.5 Hz), 3.47 (1H, dd, 
J = 7.0, 14.5 Hz), 3.16 (1H, dd, J = 4.3, 13.7 Hz), 3.10 (1H, 5.9, 13.7 Hz).  13C NMR 
(D2O, 100 MHz) ! 176.8, 176.6, 171.5, 148.2, 135.8, 130.7, 130.5, 124.8, 115.2, 60.5, 
59.6, 42.8, 43.6.   
 
2-amino-3-[(2,4-dinitrophenyl)amino]propanoic acid ($-DNP Dap) 







s), 8.20 (1H, d, J = 9.8 Hz), 7.08 (1H, d, J = 9.0 Hz), 3.9 (3H, m).  13C NMR (D2O, 100 
Mhz) ! 173.4, 149.1, 141.9, 135.6, 130.6, 123.8, 115.0, 54.9, 47.3. 
 
6-amino-2-[(2,4-dinitrophenyl)amino]hexanoic acid ("-DNP Lys) 
MALDI-MS-(+): m/z=313.1 [M+H+]; expected=313.1.  1H NMR (D2O, 400 Mhz) ! 9.07 
(1H, s), 8.24 (1H, d, J = 9.5 Hz), 6.91 (1H, d, J = 9.0 Hz), 4.21 (1H, t, J = 6.25 Hz), 2.95 
(1H, t, J = 6 Hz), 2.85 (1H, t, J = 7.42 Hz), 1.94 (2H, m), 1.61 (2H, m), 1.44 (2H, m).  13C 
NMR (DMSO d6, 400 Mhz) ! 170.7, 147.2, 134.4, 130.5, 129.2, 124.8, 116.8, 58.3, 42.4, 
34.9, 32.2, 22.5.   
 
2-amino-6-[(2,4-dinitrophenyl)amino]hexanoic acid (#-DNP Lys) 
MALDI-MS-(+): m/z=313.0 [M+H+]; expected=313.1.  1H NMR (D2O, 400 Mhz) ! 9.11 
(1H, d, J = 2.7 Hz), 8.27 (1H, dd, J = 2.3, 9.8 Hz), 7.13 (1H, d, J = 9.8 Hz), 3.72 (1H, t, J 
= 6 Hz), 3.53 (2H, t, J=7 Hz), 1.89 (2H, m), 1.79 (2H, m), 1.51 (2H, m).  13C NMR 
(DMSO d6, 100 Mhz) ! 170.2, 148.3, 135.3, 130.7, 130.3, 124.4, 116.0, 54.8, 43.4, 31.5, 
28.6, 23.2. 
 
5-amino-2-[(2,4-dinitrophenyl)amino]pentanoic acid ("-DNP Orn) 
ESI-MS-(+): m/z=299.1 [M+H+]; expected=299.1.  1H NMR (D2O, 400 MHz) ! 8.99 (1H, 
d, J = 2.35 Hz), 8.16 (1H, dd, J = 2.34, 9.57 Hz),  6.82 (1H, d, J = 9.76 Hz), 4.17 (1H, t, J 
= 6 Hz),  2.87 (2H, t, J = 6.4 Hz), 1.88 (2H, m), 1.63 (2H, m).   13C NMR (DMSO d6, 100 







2-amino-5-[(2,4-dinitrophenyl)amino]pentanoic acid (!-DNP Orn) 
ESI-MS-(+): m/z=299.1 [M+H+]; expected=299.1. 1H NMR (D2O, 400 MHz) ! 8.96 (1H, 
d, J = 2.34 Hz), 8.14 (1H, dd, J = 2.73, 9.5 Hz), 7.00 (1H, d, J = 9.76), 3.53 (1H, t, J = 
6.25), 3.42 (2H, t, J = 6.64), 1.77 (2H, m), 1.65 (2H, m). 13C NMR (DMSO d6, 100 Mhz) 











Table S1.  Summary of MALDI-MS data 




# Products  






5      QGGRGDWAAYDGE 1381.6 1381.6 - - n/a n/a 
6  (Dap)GGRGDWPAYDGE 1365.6 1365.7 28 (Dap)GGRGDWP 812.4 812.5 
7  (Orn)GGRGDWPAYDGE 1393.6 1393.7 29 (Orn)GGRGDWP 840.4 840.5 
8      KGGRGDWPAYDGE 1407.6 1407.8 30 KGGRGDWP 854.4 854.6 
9 (Glyc)GGRGDWPAYDGE 1337.5 1337.4 31 (Glyc)GGRGDWP* 802.3 802.4 
10       GGRGDWPAYDGE 1279.5 1279.8 32 GGRGDWP 726.3 726.5 
11      qGGRGDWPAYDGE 1407.6 1407.7 33 qGGRGDWP* 872.4 872.4 
12      QGGrGDWPAYDGE 1407.6 1407.7 34 QGGrGDWP 854.4 854.4 
13      QGGRGdWPAYDGE 1407.6 1407.7 35 QGGRGdWP 854.4 854.5 
14      QGGRGDwPAYDGE 1407.6 1407.6 - - n/a n/a 
15      QGGRGDWpAYDGE 1407.7 1407.7 - - n/a n/a 
16         QGGWPAYDGE 1079.4 1079.4 - - n/a n/a 
17     QGGGRGDWPAYDGE 1464.6 1464.7 36 QGGGRGDWP 911.4 911.5 
18    QGGGGRGDWPAYDGE 1521.6 1521.6 37 QGGGGRGDWP 968.4 968.5 
19   QGGGGGRGDWPAYDGE 1578.7 1578.7 38 QGGGGGRGDWP 1025.5 1025.5 
20      GGGRGDWPAYDGE 1336.6 1336.6 39 GGGRGDWP 783.4 783.4 
21     GGGGRGDWPAYDGE 1393.6 1393.6 40 GGGGRGDWP 840.4 840.4 
22    (Ahx)RGDWPAYDGE 1278.6 1278.8 41 (Ahx)RGDWP 725.4 725.5 
23    QGG(Ahp)WPAYDGE 1206.5 1206.6 42 QGG(Ahp)WP 653.3 675.4 
(M+Na+) 
24        KPYILPAYDGE 1265.6 1265.7 43 KPYILP 840.5 840.5 
25       KKPYILPAYDGE 1393.7 1393.9 44 KKPYILP 712.4 712.4 
26       KKPYllPAYDGE 1393.7 1393.8 - - n/a n/a 
27 GWTLNSAGYLLGPAYDGE 1883.9 1885.2 - - n/a n/a 
 
 
Table S2.  Summary of FT-ICR data.  Note: for MS-MS data see figure S3 below. 





27 ", #-cyclo[(Dap)GGRGDWP] 812.3798, 406.6936 406.6940 0.98 
40 cyclo[(Ahx)RGDWP] 725.3729 725.3736 0.91 
41 cyclo[QGG(Ahp)WP] 653.3406 653.3413 1.1 
42 $-cyclo[KPYILP] 712.4392 712.4407 2.1 
43 cyclo[KKPYILP] 840.5342, 420.7707 420.7714 1.7 
 
Table S3.  Ratios of cyclic to linear products 
# Cyclic : Linear  % yield cyclic Method 
6 13:1 - FT-ICR 
7 9:1 - Fluorescence HPLC 
8 17:1 - Fluorescence HPLC 
22 1:2 13% Fluorescence HPLC 
23 1:2 - FT-ICR 






Figure S1.  Shown below are MALDI-MS data for reactions of PatG with substrates.  At the top of 
each page, reactions with active enzyme are shown, while at bottom, control reactions with active 
site Ser->Ala mutant are shown.  Each page shows the MALDI results for one synthetic peptide 
(i.e. 5-26).  (a) 5 (b) 6 (c) 7 (d) 8 (e) 9 (f) 10 (g) 11 (h) 12 (i) 13 (j) 14 (k) 15 (l) 16 (m) 17, 20 (n) 
18, 20, 21 (o) 19 (p) 22 (q) 23 (r) 24-25  



















































































(m) Reaction of 17 QGGGRGDWPAYDGE with PatG (top) and PatG S783A (bottom); 






(n) Reaction of 18 QGGGGRGDWPAYDGE with PatG (top) and PatG S783A (bottom); 
































































Figure S3.  Shown below are MS-MS data collected in tandem with LC-FT-ICR data for    
(a) 27 (b) 40 (c) 41 (d) 42 (e) 43  Tables assigning the major peaks of each spectrum are also 




























































Figure S4. (a) HPLC profile of DNFB-reacted hydrolysate of 27 compared with authentic 
standards of !- and "-DNP Dap (b) 13C, 1H and LC-MS spectra for !-DNP Dap (c) 13C, 1H 
and LC-MS spectra for "-DNP Dap.  (d) LC-MS profile of DNFB-reacted hydrolysate of 28 
compared with authentic standards of !- and #-DNP Orn (e) 13C, 1H, and LC-MS spectra for 
!-DNP Orn (f) 13C, 1H, and LC-MS spectra for #-DNP Orn (g) LC-MS profile of DNFB-
reacted hydrolysates of 29 compared with authentic standards of !- and $-DNP Lys.  (h)  
HPLC profile of DNFB reacted hydrolysates of 42 compared with authentic standards of !- 
and $-DNP Lys.  (i) UHPLC-MS analysis confirming HPLC analysis in 4(h) above (j) 13C, 

























































(d) LC-MS chromatograms selected for mass of DNP-Orn; top: hydrolysate, middle: !-DNP 

















































(g) LC-MS chromatograms selected for mass of DNP-Lys; top: hydrolysate, middle: !-DNP 
































































Figure S5. Shown below are pie and bar charts that depict the typical amino acid 
distribution found in selected analogues tested in this work compared to the distribution 
found in naturally occurring cyanobactins.   
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A problem for chemists in the metagenomic era is how to
approach the vast amounts of data coming from metagenome
sequences. Metagenomes are mixed samples of multiple organisms
from the environment, including symbiotic associations of bacteria
with animals.1-4 We have been developing the use of metagenomes
from symbiotic bacteria for pathway engineering, allowing natural
sequence variation to define parameters for gene-based organic
synthesis.5,6 Here, we provide an example of how metagenome
sequence analysis contributes to understanding biosynthetic enzyme
function using the thiazoline and oxazoline synthases, PatD and
TruD. These proteins in turn are useful in the synthesis of diverse
natural product libraries.
The first natural products pathways identified and characterized
by sequencing of metagenomic DNA and comparison are the
patellamide (pat) and trunkamide (tru) pathways to the cyanobac-
tins, ribosomal peptides that are extensively posttranslationally
modified (Figure 1A).5,7 We previously used a metagenome
sequence analysis method to determine that enzymes from pat and
tru are extremely broad-substrate selective and can be used for in
ViVo synthesis of diverse natural and unnatural cyanobactin deriva-
tives. Essentially identical (>99%) enzymes within the tru or pat
pathway accept numerous substrates. Although enzymes are identi-
cal within pathways, there are differences between pat and tru. In
particular, there are enzyme domains that are virtually identical
between pathways, and there are more divergent domains. These
changes have functional consequences that can be precisely tracked
(Figure 1).
Both pat and tru were initially cloned from bacteria living
symbiotically with marine animals, the ascidians. Over 60 cyano-
bactins, including the well-known metabolites trunkamide and
patellamide C,8,9 have been isolated from ascidians; sequencing of
metagenomic DNA has identified more than 30 additional relatives.6
Cyanobactins are ribosomal peptide natural products, and com-
parison of metagenomic sequencing data with known compounds
provided a natural mutagenesis in which evolution has mutated
every amino acid in the natural products while maintaining identical
modifying enzymes.5 The ribosomal peptides are encoded on
precursor peptides with length of ∼70 amino acids. Precursors
include leader sequences (∼35 amino acids) and two sets each of
recognition and product-coding sequences.
Despite their demonstrated usefulness in synthesizing diverse
compounds, the biosynthetic rules behind posttranslational modi-
fication patterns remained elusive. For example, products of the
pat pathway contain Cys, Ser, and Thr residues that are mostly
heterocyclic. By contrast, known representatives of the tru pathway
are heterocyclic at Cys but reverse prenylated at Ser and Thr (Figure
1).
Previous work has shown that essentially identical enzymes
within the pat or tru pathways lead to these diverse products.5,6,10
The enzymes modify precursor peptides that have conserved leader
sequences and enzyme recognition sequences. Between the con-
served recognition sequences are cassettes that directly encode the
final natural products. These cassettes are modified by heterocy-
clization, prenylation, and N-C circularization to yield the mature
natural products. Cassette sequences are hypervariable, with
substitutions accepted at any amino acid position, leading to large
natural product libraries.
Six, seven, or eight amino acids are found in ascidian cyano-
bactins. Numbering from C- to N-terminus, all positions except
position 2 naturally contain the heterocyclizable residues, Cys, Ser,
or Thr, in one or more of the 60 known cyanobactins. The pat
group includes members in which heterocycles occur in positions
1, 3, 5, 6, and 7 (Figure 2). By contrast, cycles are only found in
position 1 in the tru group. In tru products, only Cys is heterocy-
clized, while Ser and Thr are prenylated; Cys, Ser, or Thr are cyclic
in the pat products, and prenylation is not found. In all of these
peptides, there are numerous Ser residues outsitde of the cassettes
that are not modified.
These natural substitution patterns are particularly striking given
the overall enzyme conservation. Despite chemical differences
between pat and tru, all enzymes are homologous between these
pathways. In fact, the didomain heterocyclase enzymes, PatD and
TruD, are >99% identical in their N-terminal domains and only
Figure 1. Biosynthesis of heterocyclic cyanobactins. (A) Enzymes modify
ribosomal precursor peptides into mature products. Trunkamide group: top;
patellamide group: bottom. (B) An alignment of PatD and TruD proteins,
showing putative catalytic and peptide-binding domains. Catalytic domains
are >99% identical; peptide-binding domains are >77% identical.
Published on Web 03/08/2010
10.1021/ja9107116  2010 American Chemical Society J. AM. CHEM. SOC. 2010, 132, 4089–4091 9 4089
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∼77% identical in their C-terminal domains. The questions ad-
dressed in this study are how such similar enzymes and pathways
lead to different posttranslational products and how these enzymes
can be used to synthesize diverse chemical derivatives.
Microcin B17 and streptolysin S synthetases were the first and
second heterocyclase enzymes to be characterized in Vitro.11-13
Although they are only distantly related to PatD and TruD,
comparison of these enzymes showed that the PatD/TruD catalytic
domain is at the N-terminus, while the C-terminus functions
primarily to bind the substrate peptide. This led to the question, do
these enzymes operate in a chemoselective fashion (O vs S in
heterocycles), or is regioselectivity important, as might be impli-
cated by peptide binding differences? Here, we use biochemical
experiments to define PatD and TruD as regioselective heterocy-
clases, which catalyze thiazoline and oxazoline biosynthesis.
When the pat gene cluster encoding PatD was previously
expressed in Escherichia coli, we observed products containing the
natural heterocycle pattern, including thiazoline and oxazoline.6,7
Similarly, heterologous expression of the tru pathway led to
production of thiazoline-containing natural products with prenylated
Ser/Thr residues.5 Thus, PatD and TruD were implicated as probable
heterocyclases, but they had not been purified or characterized. Both
genes were cloned and expressed here as N-terminal His-tagged
proteins (Figure S1, Supporting Information). The patD clone
includes two point mutations in the N-terminal domain, which did
not change enzyme function. The truD gene was cloned into the
C-terminus of an existing patD construct because of toxicity
problems. Practically, this cloning strategy ensured that PatD and
TruD were in fact 100% identical (instead of merely >99%) in their
presumed catalytic N-terminal domains. A series of substrates were
constructed by cloning and expressed recombinantly, which was
extremely efficient in comparison to peptide synthesis because of
the large size of the substrates (∼70 amino acids).
Purified PatD or TruD were used in experiments with the
substrate analogues, PatEdm, PatER, TruE2, TruE4, and TruE5
(Figure 3). All enzyme experiments in this study were done with
varying substrate concentrations, with each condition performed
independently at least in triplicate. We first noticed that PatD and
TruD products exhibited band shift differences by SDS-PAGE. In
all cases, TruD products migrated more rapidly than unmodified
peptides, while PatD products migrated more rapidly still (Figure
3). The mobility shift was consistent with formation of thiazoline
and/or oxazoline rings given that these heterocycles introduce a
significant conformational restraint on the peptide backbone.14-17
Given that heterocycle formation causes a loss of 18 Da, we
employed an MS approach to confirm that each of the five precursor
peptides was modified by heterocyclization. First, intact mass
electrospray ionization (ESI) was used to determine the total number
of dehydrations catalyzed by PatD or TruD on these ∼9 kDa
substrates, in comparison to unmodified control (Figure S2,
Supporting Information). Subsequently, the enzyme products were
treated by a specific protease, PatA, that cleaves upstream from
each cassette’s start site.10 These smaller fragments were analyzed
by MALDI and ESI to localize dehydrations to single cassettes
(Figures S3 and S8, Supporting Information). Finally, these PatA-
digested cassettes were also subjected to LC-Fourier transform ion
cyclotron resonance (FT-ICR) and MS/MS to determine which
amino acids within cassettes were heterocyclized (Figures S4 and
S5, Supporting Information). For Cys, MS data confirmed that
thiazoline was formed and ruled out other possible dehydration
routes. In addition, for Thr, all available evidence supported
oxazoline formation. This evidence included observation of the same
type of fragmentation suppression seen in other heterocycle-
containing peptides,18 the absence of observed MS/MS fragments
consistent with other modifications, and the SDS-PAGE mobility
shift, which as noted above, is consistent with heterocycle formation.
Additionally, the facts that these genes lead to oxazoline formation
in ViVo and that no other type of Thr dehydration has been observed
in this compound family also support this interpretation. Despite
this evidence, we nevertheless sought to completely eliminate the
possibility of a reverse-Michael reaction (Figure S6, Supporting
Information). Because activated double bonds are not very reactive
with acids, while oxazolines are labile in acidic conditions,
substrates were subjected to very mild acidic conditions. The
resulting rehydrated products confirmed that all Thr modifications
Figure 2. Enzyme selectivity defined by metagenome sequence and
chemical analysis. Natural products from the pat (top) and tru (bottom)
pathways contain modified Cys, Ser, and Thr residues in the defined
positions. y-axis: % of natural products containing these modifications.
x-axis: amino acid position in cassette. Empty space above the bars denotes
hypervariability: diverse amino acids occupy these positions in isolated
natural products.
Figure 3. Reaction characterization and substrate specificity of TruD and
PatD. (A) MALDI MS of reaction products. (B) Position of modifications
identified by ESI-MS/MS. (C) Representative SDS-PAGE gel showing band
shifts of precursor peptides 1-4. The left of each triplet is a standard of
the peptide, middle is the TruD-modified peptide, and right is the PatD-
modified peptide.
4090 J. AM. CHEM. SOC. 9 VOL. 132, NO. 12, 2010




were indeed due to oxazolines (Figure S6, Supporting Information).
Therefore, PatD and TruD catalyzed the synthesis of thiazoline and
oxazoline; other products were not observed in extensive experi-
mental analysis.
TruE2 is a natural substrate that contains two Cys residues that
are found as thiazoline in the final natural products, as well as a
number of Ser and Thr residues that are prenylated naturally (Figure
1A). TruE2 contains two cassettes, with Cys in position 1 of each
cassette. When the tru cluster was expressed in E. coli, these natural
products were synthesized,5 indicating that tru gene products modify
TruE2 to produce thiazoline. When treated with TruD, both Cys
residues were heterocyclized as expected, while none of the Ser/
Thr residues in the molecule were modified. By contrast, when
treated with PatD, which is not normally associated with TruE2,
both Cys residues and an additional Thr residue in position 3 of
cassette I were cyclized (Figure 3). An unnatural analog of TruE2,
TruE4, contained only cassette II and only a single Cys residue;
this residue was also cyclized by both PatD and TruD.
We next analyzed reactivity using unnatural substrate analogs
from the pat pathway. In cassette I, both PatEdm and PatER encode
the natural patellamide C sequence which would normally be
modified to contain two thiazole and two oxazoline residues (Figure
1). Indeed, patellamide C is synthesized in E. coli when PatEdm is
coexpressed with pat enzymes.6,7 When these peptide substrates
were treated with PatD, two Cys and two Thr residues were cyclized
in both PatEdm and PatER, as found in ViVo in E. coli expression.
TruD, which is not normally associated with the pat pathway,
behaves differently. None of the tru products we have so far
examined contain Cys in position 5, as found in PatEdm. However,
TruD readily cyclized both Cys residues in position 1 and position
5 (Figure 3).
From these experiments, we could not determine whether TruD
was truly chemoselective for Cys or whether regioselectivity played
a role. We therefore synthesized an unnatural variant, TruE5, that
contained Thr in place of Cys at position 1 of cassette I. Both PatD
and TruD were able to cyclize this new Thr residue, indicating
that the reaction specificity of these enzymes is mainly due to
regioselectivity (Figure S7, Supporting Information), though this
reaction was much slower than Cys heterocyclization. Thus,
although the enzymes select residues for modification based
primarily on their position within cassettes, the chemical features
of the modified residue may influence selectivity as well.
The regioselectivity of these enzymes clearly explains the
observed product patterns in the∼60 ascidian-derived cyanobactins.
In fact, previously the cyanobactin comoramide A was isolated with
Thr heterocyclized in position 5 and prenylated in position 3.19
Although genes for comoramide synthesis have not been cloned,
the data described here allow this to be defined as a tru-like
pathway. Another pathway type contains a prenylated Ser in position
5. In TruE2, PatD did not modify a Ser in position 6.
These experiments also indicate that TruD and PatD do not
determine the regioselectivity of prenylation, since TruD leaves
unmodified the residues that are presumably later prenylated.
Although there are no prenyltransferase homologues in the path-
ways, our current hypothesis is that the TruF1 and TruF2 proteins
are involved in this step.
The usefulness of these enzymes is primarily for in ViVo synthesis
of new compounds, not necessarily for the in Vitro modification of
discrete substrates. Previously, we demonstrated that, in principle,
large libraries of natural and unnatural cyanobactin derivatives could
be synthesized and screened in E. coli.6 The enzymatic specificity
results reported here will be greatly helpful in determining which
sequences are appropriate for the development of a chemically
diverse cyanobactin library. Metagenome sequence analysis enabled
the discovery of methods to synthesize these libraries, and in this
study the sequencing methods allowed us to obtain new insights
into enzyme function. These methods should be applicable to other
enzyme systems. Because the underlying genetic methods are now
extremely fast and inexpensive, they are of practical utility in the
enzymatic synthesis of new molecules.
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Figure S1.  SDS-PAGE of purified TruD and PatD proteins. From the left, lanes are: (1) TruD (2) 



















Figure S2.  Intact analysis of TruD- and PatD-treated TruE2.  (a) shows ESI-(-) intact analysis of PatD-
treated TruE2.  Result is consistent with the formation of two thiazoline rings and a single oxazoline 
ring; (b) shows ESI-(-) intact analysis of TruD-treated TruE2.  Result is consistent with the formation of 
two thiazoline rings; (c) SDS-PAGE showing typical band shifts resulting from TruE2 modification 
reactions.  From right to left, lanes are as follows: (1) TruE2 standard (2) TruD-treated TruE2 (3) TruD-
treated TruE2 + TruE2 standard (4) PatD-treated TruE2 (5) PatD-treated TruE2 + TruE2 standard (6) 












Figure S3.  MALDI-MS spectra demonstrating modification of TruE2, PatE!, and PatEdm product 









































Figure S4.  (a) FT-ICR characterization of TruD- and PatD-treated TruE2, digested with PatA. (b) FT-

























Figure S5.  MS-MS of modified peptides and summary tables (a) MS-MS of  TruD- and PatD-modified 
TruE2 cassette  I (b) MS-MS of and TruD- and PatD-modified TruE2 cassette II (c) Tables 
summarizing MS-MS of TruE2 cassettes I and II (d) MS-MS of TruD- and PatD-modified PatEdm; one 
PatD-modified PatEdm cassette I is –3H2O an due to oxazoline ring-opening; fully modified is –4H2O 













































































Figure S6.  Shown below are intact ESI analyses of TruE2, demonstrating that one dehydration 
catalyzed by PatD is an oxazoline ring.  After treatment with mild base, PatD-modified TruE2 (a) is -
3H2O, while TruD-modified TruE2 (b) is -2H2O.  However, after treatment with mild acid, PatD-
modified TruE2 (c) is -2H2O, while the mass of TruD-modified TruE2 (d) is unchanged.  Thus, two 
acid- and base-stable dehydrations are catalyzed by both PatD and TruD, based on this and MS-MS 
analysis these are thiazoline rings.  Additionally, PatD catalyzes formation of a further base-stable, acid-
labile dehydration, which by MS-MS analysis localized to Thr.  Based on the chemical properties of this 









Figure S7.  ESI-MS-(-) and SDS-PAGE analyses demonstrating modification of TruE5 by TruD and 
PatD.  (a) From left-to-right unmodified TruE5, TruD-modified TruE5, and PatD-modified TruE5 are 
shown.  The predominant product of both TruD and PatD by MS is a singly dehydrated species that 
most likely represents a peptide with the Cys in the first cassette cyclized.  However, in both TruD and 
PatD reactions, some amount of fully modified TruE5 is present, corresponding to products that contain, 
respectively, one and two oxazoline rings in the first cassette. (b) SDS-PAGE gel showing modification 
of TruE5.  From left to right, lanes are: (1) ladder (2) TruE5 standard (3) TruE2 + PatD (4) TruE2 + 










Figure S8.  ESI-MS-(-) data demonstrating modification of TruE4 by a single dehydration event 
localized to the single product cassette that it contains.  At left is intact analysis of unmodified TruE4; 
middle is intact analysis of TruD-modified TruE4, and at right is ESI-MS-(-) of PatD-treated TruE4, 
digested with PatA, showing the cassette is -H2O (1164.6 Da). 
 
 




1 PatE-F AACATATGGACTTAAATTGACAGGCTTC 
2 PatE!-R GCATCACTTTTTGCGCTTATGATGGTGTGGAGCCATCTCATCACCACCACCATCACCATCACGCTTACGATGGTGAATAA 
3 TruE-R AATTCGGTACCTTAGTCGTCGTAAGAGCAGAG 
4 TruD-F TTCATGCAACCAACCGCCCTCCAAATTAAG 









General methods.  Isopropyl !-D-1-thiogalactopyranoside (IPTG), dithiothreitol (DTT), leupeptin, 
pepstatin, 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), and phenylmethanesulfonyl fluoride 
(PMSF) were purchased from ISC Bioexpress. Metal-free nitric acid (Optima, Fisher Scientific) was 
purchased from Fisher Scientific.  Ultra-pure MgCl2, !,"-methylene-adenosine triphosphate (!,"-
methylene-ATP) were purchased from Sigma-Aldrich.  "-32P-labeled ATP was purchased from Perkin-
Elmer.  Ni-NTA resin was purchased from Qiagen.  ZipTip C18 pipette tips were purchased from 
Millipore.  All expression vectors were purchased from Novagen.  Escherichia coli strain DH5# was 
used for all cloning steps, while E. coli strain BL21(DE3)Star was used for all protein expressions.  
Protein concentrations were determined by absorbance at 280 nm; extinction coefficients were predicted 
as described elsewhere.16 
Gene cloning.  Genes were obtained from ascidian symbiont metagenomes as previously described.2 
patD was cloned into pET15b with an N-terminal His-tag.  TruD was cloned into pCDF Duet-1.  Both 
patD and truD have an internal PstI site located 700 bp into the coding region and are 99% identical in 
this N-terminal region.  Thus, to construct truD, the His-tagged N-terminus of patD was obtained by 
PstI / NdeI digest and ligated into homologous restriction sites in the truD construct.  TruE2 and truE4 
were cloned untagged into pRSF-Duet vector between the Nde1 and Kpn1 restriction sites.  The N-
terminal His tag was then moved from pET28b into the pRSF vectors through the restriction sites MluI 
and NdeI. Clones were verified by restriction digests and DNA sequencing.  patE# was modified from a 
previously described patE variant, patE2.  TruE5 was modified from truE2 using the Quikchange site 
directed mutagenesis kit (Stratagene).  The patE2 gene was amplified using the primers PatEf and 
PatE#r, subcloned into pCR2.1-TOPO (Invitrogen), and then cloned into pRSFDuet-1.  PatA and 
PatEdm were cloned as previously described.17 
Expression of PatD and TruD.  Seed cultures were inoculated into 1 L of LB and grown in a 








with 0.1 mM IPTG at 15°C and left overnight.  Cells were pelleted by centrifugation and resuspended in 
40 mL of lysis buffer (1 M NaCl, 10 mM imidazole, 50 mM HEPES pH 7.5, 1 µg/mL leupeptin, 1 
µg/mL pepstatin, 1 mM AEBSF). Cells were lysed using a Vibracell sonicator and centrifuged. Filtered 
lysates were applied to a gravity column containing 10mL of wet Ni-NTA resin.  The column was then 
washed with 10 column volumes of lysis buffer, 10 column volumes of wash buffer (500 mM NaCl, 25 
mM Imidazole pH 7.8), and the protein was eluted with elution buffer (750 mM NaCl, 250 mM 
Imidazole pH 7.8).  The purified protein was dialyzed twice against dialysis buffer (200 mM NaCl, 25 
mM HEPES pH 7.5) at 4°C, and then against dialysis buffer w/ 10% glycerol.  Dialyzed protein was 
aliquoted, flash frozen with liquid nitrogen, and stored at -80°C.   
Expression of precursor peptides.  TruE2-expressing cells were grown to density in a manner 
identical to that for PatD and TruD.  Expression of TruE2 was induced by addition of IPTG up to a final 
concentration of 1 mM followed by overnight growth at 37°C.  Cell pellets were resuspended in lysis 
buffer at a concentration of 4 mL per gram of cell paste.  After centrifugation, supernatants were 
discarded, while the pellets were resuspended in 50 mL of buffer B (8 M urea, 0.1 M NaH2PO4, 10 mM 
tris pH 8.0) and then sonicated to affect further resolubilization.  The resuspended material was again 
centrifuged, and filtered lysates were applied to a Ni-NTA column, which was then washed with 2 x 25 
mL of buffer C (8 M urea, 0.1 M NaH2PO4, 10 mM tris pH 6.3), 4 x 12.5 mL of buffer D (8 M urea, 0.1 
M NaH2PO4, 10 mM tris pH 5.9), and eluted with 4 x 12.5 mL of buffer E (8 M urea, 0.1 M NaH2PO4, 
10 mM tris pH 4.5).  The eluents were dialyzed twice against dialysis buffer (200 mM NaCl, 100 mM 
proline, 1 mM DTT, 10% glycerol, 20 mM HEPES pH 8.0).  The eluents were then combined, 
aliquoted, flash frozen, and stored at -80°C. 
Expression of TruE4 was performed in a manner identical to that of TruE2, except that owing to the 
larger amount of insoluble material obtained, pellets were resuspended in 100 mL of buffer B, and the 
Ni-NTA column was washed with 100 mL of buffer C.   
Expression of PatE! was performed in a manner identical with that of TruE2, with the following 








resuspended in 8 M urea rather than buffer B, and the Ni-NTA column was washed using 500 mM 
NaCl, 25 mM imidazole, and protein was eluted using 3 x 10 mL of elution buffer (750 mM NaCl, 250 
mM imidazole pH 7.8).  Eluents were combined and dialyzed twice against dialysis buffer (500 mM 
NaCl, 2 mM DTT, 25 mM HEPES pH 7.8).   
Expression of TruE5 was performed in a manner identical with that of TruE2.   
PatA and PatEdm were expressed as previously described.17   
Enzyme reactions.  Reaction mixtures were incubated at 34°C in an MJ research minicycler for 
varying amounts of time.  Enzyme, precursor peptide, and ATP concentrations varied, and are described 
below.  The following additives were present in standard reactions but were varied in early optimization 
experiments: 40 mM tris pH 8.0, 8 mM DTT, and 4 mM MgCl2.  
Enzyme reactions generally contained the optimized additive mixture and 0.6 µM PatD or TruD, 8 
µM TruE2, or 12 µM TruE4, or 42 µM PatE!, or 22 µM PatEdm, and 0.8 mM ATP. Reactions were run 
using varying times, from 15 min to 27 h. To confirm modification, 10 µL of the reaction mixture was 
removed and analyzed by SDS-PAGE.  At minimum, at least three separate experiments were 
performed for each enzyme-substrate concentration. 
For reactions requiring cleavage by PatA, mixtures as described above were incubated for 27 h, with 
and without ATP and with and without PatD / TruD.  PatA was then added to 1.7 µM final 
concentration followed by incubation for a further 17 h.  After completion of PatA-containing reactions, 
reaction mixtures were frozen at -80°C until analyzed by MALDI-TOF, FT-MS, and / or ESI-MS.
  
SDS-PAGE assays.  18% acrylamide gels were used for all assays.  Prior to electrophoresis, samples 
were brought up in 1X SDS sample buffer diluted from 6X SDS sample buffer and then boiled for 3 
min.18  After electrophoresis, gels were placed in boiled fixing solution (53% H2O, 40% ethanol, 7% 
acetic acid), incubated 10-20 min with gentle rocking, and then placed in boiled stain (0.02% w/v 
Coomassie R250 in 85% H2O, 10% acetic acid, 5% ethanol), and then destained in (85% H2O, 10% 
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acetic acid, 5% ethanol) for several h, and then photographed.  For TruE4 inhibition experiments, gels 
were imaged using a Li-Cor Odyssey infrared scanner.  
Mass spectrometry analysis. Samples for MALDI-TOF were prepared by desalting with ZipTip C18 
pipette tips according to the manufacturer’s instructions.  Desalted peptide samples were mixed 1:1 with  
!-cyano-4-hydroxycinnamic acid resin (10 mg/mL CHCA in 50:50 H2O:methanol w/ 0.1% 
trifluoroacetic acid), and spotted.  MALDI was performed using a Micromass MALDI micro MX 
(Waters) instrument using an automated targeting protocol.  LC-FTMS, ESI-MS(+), and ESI-MS(-) 
were run at the University of Utah Mass Spectrometry and Proteomics Core Facility. FT was performed 
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Marine Molecular Machines: Heterocyclization in
Cyanobactin Biosynthesis
John A. McIntosh and Eric W. Schmidt*[a]
“A heterocycle sounds like a wonderful thing to ride, especially with someone you love.”—George Carlin[1]
Introduction
The heterocyclic thiazole, thiazoline, oxazole, and oxazoline
motifs are commonly found in natural products that possess
diverse biological activities. These Cys-, Ser-, and Thr-derived
heterocycles are present in approved drugs, as well as in drug
leads and in toxins produced by human pathogens.[2–5] For ex-
ample, in the ribosomal peptide group microcin B17 is a DNA
gyrase inhibitor produced by Escherichia coli,[6] thiostrepton
and relatives are potent antibiotics,[7] and cyanobactins are
ubiquitous bioactive peptides from cyanobacteria.[8] More re-
cently, heterocyclic relatives of the cyanobactin/microcin B17
group have been shown to occur commonly in diverse bacte-
ria.[5, 9] In the nonribosomal peptide group, an epothilone deriv-
ative is an FDA-approved anticancer agent, bacitracin is used
as an antibiotic, and certain siderophores are key virulence fac-
tors.[2, 3] In addition, the heterocyclic motif itself is potentially
bioactive depending upon the context : thiazol(in)e and oxazo-
l(in)e can interact with nucleic acid, protein, or metal ligands.[3]
Thus, routes to their enzymatic synthesis are of keen interest.
Despite extensive and groundbreaking studies of heterocyc-
lization enzymes in both ribosomal and nonribosomal peptide
natural products,[10,11] their chemical mechanism(s) remain un-
known.[12] Previous biochemical studies of biosynthesis in het-
erocycle-containing ribosomal peptides involve a complex of
three proteins whose activities are intertwined and difficult to
separate. In particular, ATPase, oxidase, and zinc-binding do-
mains are invariant requirements for heterocycle biosynthesis
in the cases of microcin B17 and streptolysin S.[5,13] These en-
zymes modify microcin and streptolysin precursor peptides in
multiple positions by synthesizing oxidized heterocycles, thia-
zoles and oxazoles, and not their unoxidized presumed precur-
sors, thiazolines and oxazolines. Of the apparent enzymatic ac-
tivities (oxidase, ATPase, and heterocyclase), none has been ob-
served in isolation from the others, and while ATPase and ox-
idase activities are readily attributable to specific proteins, their
respective roles in enzymatic heterocyclization are unclear. An
oxidase is required, and this explains the lack of observed thia-
zoline or oxazoline either in vitro or in vivo. It has been pro-
posed that ATP consumption fuels a molecular machine driv-
ing heterocyclization, although a direct effect on catalysis has
Natural products that contain amino-acid-derived (Cys, Ser,
Thr) heterocycles are ubiquitous in nature, yet key aspects of
their biosynthesis remain undefined. Cyanobactins are hetero-
cyclic ribosomal peptide natural products from cyanobacteria,
including symbiotic bacteria living with marine ascidians. In
contrast to other ribosomal peptide heterocyclases that have
been studied, the cyanobactin heterocyclase is a single protein
that does not require an oxidase enzyme. Using this simplify-
ing condition, we provide new evidence to support the hy-
pothesis that these enzymes are molecular machines that use
ATP in a product binding or orientation cycle. Further, we
show that both protease inhibitors and ATP analogues inhibit
heterocyclization and define the order of biochemical steps in
the cyanobactin biosynthetic pathway. The cyanobactin path-
way enzymes, PatD and TruD, are thiazoline and oxazoline syn-
thetases.
[a] J. A. McIntosh, Prof. E. W. Schmidt
Department of Medicinal Chemistry, College of Pharmacy
University of Utah
Salt Lake City, UT 84112 (USA)
Fax: (+1)801-585-9119
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Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201000196.
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not been ruled out. These conserved protein domains also
appear to be present in thiopeptide biosynthesis,[7] though to
our knowledge, they have not yet been studied in vitro. Heter-
ocyclization has also been studied in nonribosomal peptide
systems,[10,14] in which the enzymes and resulting chemical
mechanisms (excepting the oxidase) are nonhomologous to
the ribosomal peptide group.
Here we present results regarding the biosynthesis of het-
erocycles among the cyanobactins, which are a group of circu-
lar, heterocyclic, ribosomally derived peptides from cyanobac-
teria, including the marine animal symbionts, Prochloron spp.[8]
Two pathways to Prochloron-derived cyanobactins exist : the
patellamide (pat) pathway, the members of which contain het-
erocycles derived from Cys, Ser,
and Thr, and the trunkamide
pathway (tru), the members of
which contain heterocycles de-
rived only from Cys. Heterocycle
oxidation is somewhat variable,
with both oxidized (thiazole and
oxazole) and unoxidized (thiazo-
line and oxazoline) heterocycles
present in both families. By con-
trast, the products of the micro-
cin pathway, and presumably
the streptolysin pathways, are
always oxidized, although the
latter has not been completely
defined.
The biosynthetic gene clusters
of the patellamide and trunka-
mide pathways have been previ-
ously characterized, as have the
biochemical basis of circulariza-
tion and certain aspects of heter-
ocyclization.[12,15] In brief, PatE
and TruE are precursor peptides,
and each encodes two natural
products on a single short pep-
tide. Importantly, PatE and TruE
both contain a leader peptide
sequence and “enzyme recogni-
tion” sequences that flank the N
and C termini of the product
coding cassettes (Figure S1 in
the Supporting Information).
PatD and TruD are heterocyclas-
es that operate regioselectively
in vivo to modify Cys, Ser, and
Thr in the case of PatD, but only
Cys in the case of TruD. PatA or
TruA proteases cleave N-terminal
recognition sequences of cas-
settes 1 and 2,[15] though it was
not clear prior to this study
whether PatA/TruA acted prior
to or after heterocyclization.
Lastly, PatG or TruG proteases cleave the C-terminal recogni-
tion sequences in tandem with macrocyclization (Figure S2).[15]
All three of these enzyme groups are capable of modifying a
diverse set of cassette mutants to yield libraries of natural
products.[16]
TruD, which in vivo heterocyclizes only Cys residues, is a di-
domain protein with an N-terminal region that bears distant
similarity to heterocyclase proteins in the streptolysin and mi-
crocin systems. The C-terminal region is very distantly similar
to the protein proposed to be responsible for peptide binding
and ATPase activity in other heterocyclization systems. PatD is
>99% identical to TruD in the N-terminal domain, but only
77% identical in the C-terminal domain (Figure 1). No oxidase
Figure 1. A) Shown are alignments between PatD and TruD. Darker regions indicate regions of higher identity.
B) Sequence of TruE2 precursor peptide is shown, with naturally heterocyclized residues highlighted in red. C) A
zoomed-in view of the C-terminal cassette in TruE2. In vitro, PatD modifies one Thr and one Cys in this cassette,
while TruD modifies one Cys both in vitro and in vivo. In nature, in combination with other biosynthetic enzymes
the TruD product shown is converted to the prenylated, heterocyclic natural product patellin 6.
1414 www.chembiochem.org ! 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2010, 11, 1413 – 1421




domain is present in TruD or in the tru pathway, and unlike
the microcin or streptolysin cases, oxidation is not required to
reconstitute heterocyclase activity. Thus, TruD is a single pro-
tein that fully reconstitutes heterocyclization activity in a regio-
selective manner. The relative simplicity of this system in com-
parison to other studied heterocyclases enabled us to obtain
new insights into the function of this important enzyme family.
Here, we present evidence that strongly supports the molecu-
lar-machine hypothesis regarding the role of ATP. We also de-
termined the order of enzymatic steps en route to cyanobac-
tins, and describe inhibitors of heterocyclization.
Results and Discussion
Metal and cofactor requirements of PatD and TruD
The enzymes PatD and TruD, and substrates TruE2 and TruE4
were cloned as described elsewhere.[17] Two point mutations
were found in patD in these studies, but they lacked any ap-
parent functional consequence. In addition, patD was used as
a template to clone truD ; this ensures that both PatD and
TruD are 100% identical in their N-terminal catalytic domains.
As previously described, when incubated with substrates,
TruD and PatD are fully competent heterocyclase enzymes.[17]
A robust SDS-PAGE assay was developed in which heterocycli-
zation can clearly be tracked by mobility shift (Figure S3), as
described elsewhere.[17] In general, TruD products migrate
more rapidly by SDS-PAGE analysis than unreacted precursor,
while PatD products migrate more rapidly still. This assay al-
lowed enzyme requirements and timing to be rigorously de-
fined.
All enzyme reactions described in this work, including deter-
mination of enzyme requirements, substrate and product
measurements, and kinetic analysis, were performed at mini-
mum in triplicate in independent runs. ATP, MgCl2, and DTT
were found to be necessary for the heterocyclization reaction
with both PatD and TruD. The minimum Mg2+ concentration
that could support catalysis was 1 mm, which is somewhat
lower than the reported Mg2+ requirements of microcin B17
and streptolysin S synthetases (2–20 mm Mg).[5,11] Ultrapure
MgCl2 was used in some experiments and was found to sup-
port catalysis. Additionally, other additives (Tris, ATP, and DTT)
could be passed through Chelex resin without inhibiting catal-
ysis ; this indicates that traces of other metals were not re-
quired for catalysis.
Like McbB from the microcin B17 pathway,[18] PatD and TruD
are both strongly associated with zinc even after extensive di-
alysis, as indicated by ICP-OES experiments. The apparent bind-
ing stoichiometry of the enzyme-metal complex was found to
be roughly 1 mol of zinc per mol of enzyme. The role of this
zinc is unknown but has been proposed to be structural in the
microcin B17 context.[18] No other strong associations of metals
with enzyme were found using ICP-OES. Taken together, this
indicates that zinc and magnesium are the sole metal cofactors
required to catalyze the reaction.
The fate of ATP was probed by HPLC analysis. During the
course of the reaction, ATP was shown to be hydrolyzed into
ADP, as was found for microcin B17 synthetase (Figure S4).[19]
Overall, these requirements are quite similar to those defined
in microcin B17 biosynthesis; this indicates that the enzymes
could function in a similar manner despite their nearly com-
plete lack of protein sequence similarity. The major differences
between microcin B17 biosynthetic enzymes and PatD/TruD
are 1) the lack of a requirement for an oxdiase domain in our
system, and 2) the presence of putative heterocyclase and pep-
tide-binding domains on a single polypeptide, whereas in the
microcin B17 system these domains exist as separate polypep-
tides.
Order of heterocyclization events in TruE2
Enzymatic reactions with TruE2 and TruD, or PatD generally
went to completion within 2 h. Time-course experiments from
15 min to 24 h revealed that Cys reactivity was fast, with TruD-
TruE2 reactions being complete within 1 hour. Catalysis of the
third dehydration event (Thr cyclization) by using PatD was
slower and required up to 2 h for complete modification (Fig-
ure S5). No further reaction was observed with extended incu-
bation periods, even with batch addition of further enzyme.
In time-course experiments with TruD, TruE2 was observed
to proceed directly to the doubly dehydrated product. We ob-
served an appreciable accumulation of singly dehydrated prod-
uct only by supplying inadequate amounts of ATP, and even
under those conditions the amount of doubly dehydrated
product was still greater (Figure S6). These experiments are
most consistent with the idea that the substrate can dissociate
from the enzyme between heterocyclizations, but the singly
heterocyclized product is a much faster reactant than the un-
modified precursor peptide.
By contrast, heterocyclization of TruE2 to afford a third het-
erocycle (oxazoline) by PatD was slower, and intermediates
could be captured and readily observed by both SDS-PAGE
and mass spectrometry. Quite clearly then, the precursor pep-
tide leaves the enzyme after the second heterocyclization and
before the third heterocyclization. One of the most convincing
pieces of evidence was found upon incubation of PatD with
TruE2. A sample was taken prior to completion of the PatD re-
action and showed three bands (listed in order of increasing
mobility): 1) unmodified TruE2, 2) a band consistent with two
thiazolines, and 3) the fully modified TruE2.
Relative rates have also been determined in microcin B17
biosynthesis, and the results observed in that system are quite
similar to what we present here: in both cases, the reaction to
form oxygen-containing heterocycles is slower, as would be
expected from the reduced nucleophilicity of hydroxy substitu-
ents in comparison to thiol.[19]
Timing of biosynthetic steps in cyanobactin synthesis
Previous work has shown that PatA and PatG enzymes, which
cleave and circularize PatE, accept broadly different sub-
strates.[15,16] A mystery has been how these enzymes produce
only the natural products and not other derivatives. One idea,
consistent with work on microcin B17 and previous cyanobac-





tin coexpression experiments, is that the enzymes could form
a complex that would sequester substrates. With numerous
conditions, however, we could not observe any requirement
for complex formation. For example, PatA, PatG, and PatD are
all competent catalysts without the addition of other enzymes,
and addition of multiple enzymes does not appreciably in-
crease the reaction rate of single steps. Pull-down experiments
using various Pat proteins as bait in different conditions were
unsuccessful, as were experiments involving coexpression.
Thus, there is no evidence that protein complexes are required
for cyanobactin biosynthesis.
Nonetheless, when PatA is co-incubated with TruD or PatD
and TruE2 or other precursor peptides, we do not detect any
PatA cleavage fragments that lack heterocycle modifications.
This observation was surprising given that PatA is capable of
cleaving unmodified precursor peptides in the absence of
PatD or TruD.[15] To further probe this issue, PatA was added to
the reaction mixture and allowed to react prior to the addition
of PatD or TruD, and vice versa. Under no condition could we
observe predicted dehydration products if PatA was allowed
to react first ; this would cleave the leader sequence, whereas
the expected products were obtained if PatD or TruD were
added first or if the A/D combinations were co-incubated.
Therefore, it appears that the leader sequence, which PatA
cleaves, is required in cis for PatD/TruD modification, as ob-
served in the case of microcin B17.[20,21] In other words, the
products of PatD/TruD are substrates for PatA, but the reverse
is not true. Thus, the fidelity of cyanobactin synthesis is most
likely encoded at the level of substrate recognition, and not at
the level of protein complexes. Through these experiments,
the order of catalytic events in cyanobactin synthesis was
shown to be heterocyclization, followed by linearization and
N!C circularization. The relative preference of PatD or TruD for
heterocyclizing certain positions in competition with the rate
of PatA leader-sequence cleavage dictates the structures of the
natural products. The precise timing of O-prenylation (as ob-
served in the tru pathway) and heterocycle oxidation (as ob-
tained in the pat pathways) remains unclear, but oxidation
must take place after heterocyclization, and prenylation also
seems likely to occur after heterocyclization.
In comparison, these additional protease events are not tied
to the microcin B17 gene cluster,[22] nor are microcin B17 or
streptolysin S further modified beyond heterocycle synthesis,
with the exception of (as yet undefined in the case of strepto-
lysin S) leader sequence cleavage.
Kinetic analysis of TruD
TruD was used for all rate experiments because it is more read-
ily purified compared with PatD, and its reactivity (Cys-only in
natural precursor peptides) is substantially simpler than that of
PatD. Rates of reaction were analyzed using varying ATP, TruE2,
and TruD concentrations. With highly purified TruD, the back-
ground hydrolysis of ATP due to enzyme in absence of sub-
strate was virtually nonexistent. The background hydrolysis
with TruE2 alone is quite small, but is measurable. By contrast,
when substrate and enzyme are co-incubated, ATP hydrolysis
occurs at a robust pace. Reactions proceeded at an essentially
linear rate for the conditions attempted in the first 40 min.
Therefore, reactions were sampled at 0, 20, and 40 min and
analyzed by SDS-PAGE for TruE2 turnover and HPLC for ADP
formation. Results of this analysis were fitted by using the
Solver function in Excel to estimate kinetic constants.
By using variable TruE2 concentrations, from 2.5 to 7.4 mm,
TruE2 Km was estimated as ~1 mm. The apparent kcat for ATP hy-
drolysis under these conditions was 2.6 min!1 (Figures S7 and
S8). This study was not designed to specifically measure the
kcat of the enzyme for TruE2, which is a complex problem. For
example, the clear dissociation of the enzyme-substrate com-
plex—especially with oxazoline synthesis in which the rate of
reaction differs—indicates that different intermediates have
different kcat values, and possibly even different Km values.
However, it was possible to estimate a turnover number using
saturating substrate and enzyme conditions. Under standard
reaction conditions with 7.4 mm TruE2 and 140 nm TruD, the re-
action proceeded to ~90% completion at t=60 min (Figure 2).
Based upon this experiment, a TruE2 turnover number of
Figure 2. Stoichiometry of heterocycle formation. A) Rates of ADP formation
and thiazoline synthesis are overlaid ; corrected slope denotes the rate of
ATP hydrolysis when corrected for the background hydrolysis. B) %-comple-
tion of the heterocyclization reaction as determined by SDS-PAGE gel densi-
tometry. C) SDS-PAGE gel was used to derive the concentration of thiazoline
and%-completion.
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~0.8 enz!1 min!1, or a heterocycle turnover number of
~1.6 enz!1 min!1, could be calculated. This is not a true kcat but
gives an estimate of the speed of the enzyme under the reac-
tion conditions.
Using variable ATP from 200 to 800 mm, the Km for ATP was
estimated as 300 mm. The calculated kcat value was 2.4 min
!1,
which is in excellent agreement for that calculated using varia-
ble TruE2 concentration. These rates also scaled precisely as
enzyme concentration was doubled. At 104 nm TruD, TruE2
reactions were 1.5 times faster than at 69 nm TruD; at 140 nm
TruD, reactions were 2.1 times faster than 69 nm TruD.
The kinetic constants described above are strikingly similar
to those reported for microcin B17 synthetase,[11,19] despite the
greatly different experimental conditions and the absence of
both a protein complex and an oxidase. In particular, the rela-
tive Km (1 mm) measured here using kinetic methods is similar
to that reported for microcin B17 (2.3 mm),[11] but much higher
than that reported for the streptolysin S leader peptide
(6.7 nm), which was measured using surface-plasmon reso-
nance.[23] Overall, these studies indicate that the en-
zymes function similarly, and that results reported
here likely are applicable to the distant protein rela-
tives previously studied.
Inhibition of heterocyclization
In the course of our studies, two types of inhibitors
were shown to slow heterocyclization; these are pro-
tease inhibitors AEBSF and PMSF, and a nonhydrolyz-
able ATP analogue, b,g-methylene ATP. As found in
the case of microcin B17,[19] addition of the aforemen-
tioned nonhydrolyzable ATP analogue to reaction
mixtures inhibited heterocycle formation (Figure S11).
By contrast, the use of irreversibly acting protease in-
hibitors could not be anticipated, and this was dis-
covered in a serendipitous manner. In studies of pos-
sible AEBSF inhibition of PatA protease, it was ob-
served that the protease cleavage was not blocked,
but strikingly heterocyclization was inhibited. This led
to further studies demonstrating that AEBSF is a co-
valent inhibitor of heterocyclization; these studies are
described below.
An inhibition curve using 1–10 mm of AEBSF and
monitoring TruE2 by SDS-PAGE showed that inhibi-
tion was complete at 10 mm for both PatD and TruD
(Figure S12). Inhibition was monitored with an appro-
priate set of controls; this ensured that specific inhib-
ition was responsible and not an effect of solvent or
conditions. In principle, because AEBSF could act
competitively or allosterically instead of irreversibly,
reactions were also incubated with PMSF. At a con-
centration of 1 mm, the reaction was strongly inhibit-
ed by PMSF. These data implicate direct nucleophilic
displacement of fluoride in AEBSF and PMSF as the
mechanism of inhibition. Moreover, a kinetic analysis
was performed in which increasing concentrations of
AEBSF were applied to enzyme reactions with TruD;
this analysis measured ADP production from ATP (Figure S12).
The kinetic profile of reactions containing AEBSF strongly sug-
gests that AEBSF does indeed act as an irreversible inhibitor;
that is, ATP hydrolysis is not initially prevented by AEBSF, but
as time goes on, virtually all ATP hydrolysis is halted.
Role of ATP in heterocyclization
Upon beginning our study on this reaction, there were two
plausible, extant hypotheses regarding the role of ATP in heter-
ocyclization of ribosomal peptides. First, is the idea that ATP
could be a necessary cofactor in activating the electrophilic
carbonyl carbon for attack by sulfur or oxygen (Scheme 1B).[11]
An alternative hypothesis holds that ATP is used by the hetero-
cyclase enzyme in the manner of a molecular motor or G pro-
tein.[13] One of the main lines of evidence in favor of the molec-
ular-machine hypothesis was that ATP was used in super-stoi-
chiometric amounts by microcin B17 synthetase; ATP was not
used unless all enzyme components and the substrate were
Scheme 1. Shown above are mechanistic possibilities for heterocyclization. A) Oxidation
preceding heterocycle formation. B) Activation of the adjacent carbonyl oxygen, perhaps
with phosphate from ATP. C) Intein mechanism for thiazoline formation as a by-product.
D) Molecular-machine mechanism for heterocyclase enzymes.





present, but upon incubation with substrate “excess” ATP was
consumed. In addition, ATP hydrolysis could be uncoupled
from heterocyclization when a large excess of substrate was
employed.[19] We therefore performed several experiments to
illuminate the role of ATP in the PatD/TruD mechanisms, by
using TruD and TruE2.
Virtually no ATP was consumed in the absence of TruE2 sub-
strate. In addition, a negligible ATP background hydrolysis was
detected without enzyme. Upon addition of TruE2, a rapid
burst in ATP hydrolysis could be observed. In experiments to
determine the “minimum” amount of ATP leading to complete
TruE2 modification, it was found that addition of 40 mm ATP
led to complete modification of 9 mm TruE2 (or 18 mm of het-
erocycle formed). Although this ATP concentration is well
below the Km, this experiment indicated fewer than 2.5 ATP hy-
drolysis events are required per heterocycle formed (Figure S9).
Although no ATP is consumed when the TruE2 substrate is
absent, we wondered whether ATP would be used when only
fully modified TruE2 substrate is present. In a 6 h time-course
experiment with 140 nm TruD and 7.4 mm TruE2, heterocycle
formation is essentially complete after 1 h; during this initial
hour the rate of ADP production is 0.24 mmmin!1. During the
following five hours, the rate of ADP production is significantly
reduced, and remains linear with a rate of 0.06 mmmin!1 (Fig-
ures 2 and S10). When the background rate of hydrolysis due
to enzyme only, substrate only and buffer only is accounted
for, the “excess” rate of hydrolysis after heterocycle formation
is complete remains 0.05 mmmin!1; this is a value roughly 20%
of the initial fast rate of ATP hydrolysis.
These results strongly support the idea that TruD uses ATP
in the manner of a molecular machine, as TruD continues to
hydrolyze ATP even after all of the substrate for chemical reac-
tion has been consumed. These results are superficially differ-
ent than those obtained for the microcin B17 synthetase, in
which fivefold more of ATP was used than heterocycles formed
(whereas TruD uses closer to a stoichiometric amount of ATP
per heterocycle formed). However, the microcin enzymes and
substrates are quite different, and stoichiometry experiments
in that system involved a precursor peptide that was pro-
cessed to a tandem-heterocyclic system (McbA 1–46 where
GSC becomes G-oxazole-thiazole). The stoichiometry of ATP-
used to heterocycles formed was not calculated explicitly for a
single-turnover substrate in that system (McbA 1–47 where
GSC was mutated to GGC, which is processed to GG-thiazole).
However, other experiments showed that the rate of hetero-
cyclization was essentially unchanged compared to wild-type
McbA 1–46, but it induced a sevenfold lower level of ATP con-
sumption.[18] Consequently, our results, which show nearly stoi-
chiometric ATP consumption are actually quite consistent with
previously reported results, given that there might be some-
thing distinctly different about the synthesis of a bisheterocy-
clic system as found in wild-type McbA 1–46.
We considered several further mechanistic hypotheses con-
sistent with the hydrolysis of ATP in a molecular machine:
1) ATP binding and hydrolysis allows dissociation of a tightly
bound enzyme-substrate complex formed after heterocycliza-
tion; 2) ATP binding places the enzyme in an active conforma-
tion, in which heterocyclization can proceed readily ; 3) ATP is
used to autophosphorylate the enzyme, thus placing the
enzyme into an active conformation. To test hypothesis (1) we
conducted an extensive incubation of TruD with the single-cas-
sette precursor TruE4 in the presence and absence of ATP. We
used a very large amount of enzyme, such that a single turn-
over would be apparent in the resulting mass spectrum. No
turnover whatsoever was observable in the absence of ATP,
even after extended incubation, while the reaction proceeded
readily with ATP (Figure S11), a finding that does not support
hypothesis (1). To test hypothesis (2) the nonhydrolyzable ATP
analogue, b,g-methylene ATP was added in increasing amounts
to the TruD-TruE2 modification reaction; in addition, we at-
tempted to observe TruE4 modification when the nonhydrolyz-
able analogue was substituted for ATP in the reaction. We
found that the nonhydrolyzable ATP analogue strongly inhibit-
ed the TruE2 modification reaction, and that no modification
to TruE4 could be observed when nonhydrolyzable ATP was
employed (Figure S11); this argues for rejection of hypothesis
(2). Finally, hypothesis (3) was tested by incubating enzyme,
both alone and with substrate with radiolabeled 32P ATP. Reac-
tions were then analyzed by SDS-PAGE and autoradiography.
However, we were unable to trap any autophosphorylated
enzyme intermediate under any condition attempted. Conse-
quently, it seems that the molecular machine might function
through a more complicated mechanism than any proposed
mechanism above.
Sequence analysis and comparison
PatD and TruD are didomain proteins that are nearly identical
in their N-terminal domains (in the constructs used here, they
are 100% identical through residue 323). These N-terminal do-
mains have elsewhere been proposed to directly catalyze het-
erocyclization.[13] In addition, these enzymes share low similari-
ty with related heterocyclization enzymes from other families
such as goadsporin, streptolysin, thiostrepton and relatives,
and microcins. The percent identity to microcins is low enough
that the sequences are essentially unalignable, but they can be
transitively related as the streptolysin enzymes are related to
both microcin and cyanobactin enzymes.[5] Although there are
highly conserved residues within the cyanobactin genes that
could be involved in catalysis, there are no universally con-
served sequence features that are shared in common amongst
the different heterocyclizing proteins.
By contrast to the N-terminal domains, the C-terminal do-
mains of PatD and TruD are only 77% identical to each other
(Figure 1). These domains share homology with “YcaO” do-
mains, which have no known function. In the context of heter-
ocyclization, indirect experimental evidence indicates that they
are likely involved largely in substrate binding and ATP hydrol-
ysis, and not directly in catalysis of heterocycle formation.[13,19]
Interestingly, the N- and C-terminal domains of PatD and
TruD share short conserved sequence features with MccB, an
enzyme involved in adenylation of a peptide intermediate in
microcin C7 biosynthesis (though it must be emphasized that
microcin C7 does not contain any heterocycles and the biosyn-
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thetic purpose of adenylation is distinct from any reaction de-
scribed in this work). A recent crystal structure of MccB shows
that these residues line a substrate-recognition pocket that
strongly associates with the C-terminal residues of microcin
C7.[24] These microcin C7 residues are very similar to residues
found in the C-terminal regions of PatE/TruE. Within MccB, the
region of homology ends just before the ATP-binding site and
the reaction center. This alignment suggests that the homolo-
gous residues in PatD/TruD could bind to PatE/TruE in a similar
way, but it does not inform on the role of ATP in heterocycliza-
tion. Speculatively, PatE/TruE might be held in place in the
region adjacent to ATP binding, and hydrolysis of ATP leads to
substrate release. ATP binding and hydrolysis could be either
covalent (for example, to the C terminus of the substrate), or
noncovalent.
The conserved PatE/TruE leader sequence contains a short
region that is predicted to be helical by multiple methods.[25,26]
This region is of about the same length as an experimentally
determined helical region (in trifluoroethanol) of the micro-
cin B17 precursor peptide. This microcin helix was shown to be
critical in interaction with the peptide-binding protein,[27] and
it could serve the same function here. Indeed, without the
leader sequence PatD and TruD cannot synthesize heterocy-
cles, as shown in this study. The same precursor peptide
region has been studied through extensive mutagenesis in the
streptolysin S group.[23] It is clear from these studies and others
in the ribosomal peptide field that the leader sequence is criti-
cal to Cys/Ser/Thr modification in the lantibiotic- and microcin-
like peptides.[28]
Mechanistic hypothesis
Our results allow us to rule out a number of alternative hy-
potheses regarding the mechanism of ribosomal peptide het-
erocyclases. The apparent requirement for the oxidase in heter-
ocyclization of microcins and streptolysin led to the proposal
that oxidation could occur prior to formation of Ser- or Cys-
derived heterocycles (Scheme 1A); this means that the relevant
nucleophiles in the heterocyclization reaction would be ene-
hydroxyl and ene-thiol.[29] We have shown here that the flavin-
containing oxidase is not required for heterocyclization; thus,
this demonstrates that this mechanism cannot be correct. Ki-
netic analysis strongly supports the hypothesis that ATP drives
a molecular machine that promotes heterocyclization, as pro-
posed for microcin B17 synthesis (Scheme 1D). By contrast, a
mechanism wherein ATP is used to activate the adjacent car-
bonyl for attack by sulfur or oxygen (Scheme 1B) is rendered
less plausible by the results presented here.
Recently, it was shown that intein chemistry can yield heter-
ocyclic thiazolines as side products (Scheme 1C).[30] Thus, it
seems possible that heterocyclization chemistry could be quite
similar to that required for intein splicing, as well as the chemi-
cal strategy employed by many autoproteolyzing enzymes.[31]
On this account, the peptide merely needs to be held in the
right conformation, with appropriate nearby acids and bases
to accelerate nucleophilic attack on the carbonyl adjacent to
Cys or Ser/Thr.
Given intein chemistry (which proceeds without added
energy, that is, ATP), it seems mysterious why ATP would be re-
quired by heterocyclase enzymes. One possible explanation for
this discrepancy is found in the fact that inteins are, in effect,
single-turnover enzymes. In the case of multiple turnover het-
erocyclases, the enzyme-substrate complex could be so tightly
bound that ATP is needed for product release, or the enzyme-
substrate complex might be unable to form without the use of
ATP. In addition, this system is strongly reminiscent of AAA-
proteases, which require ATP for the detection of misfolded
proteins and then hydrolyze these aberrant proteins through
separate protease domains.[32] It is noteworthy that there is
sequence homology, both in substrate and enzyme, between
cyanobactin biosynthetic proteins and microcin C7 proteins,
which do not catalyze heterocyclization but instead adenyla-
tion. This similarity suggests a possible evolutionary relation-
ship connecting the microcin-group biosynthetic pathways.
Conclusions
We have characterized two heterocyclization enzymes from cy-
anobactin pathways, PatD and TruD. In both cases, single en-
zymes were sufficient to recapitulate heterocyclization activity;
this makes this the first single-protein reconstitution of hetero-
cyclization activity and the first thiazoline/oxazoline synthetas-
es to be characterized in ribosomal systems. Previous work in
the microcin B17 and streptolysin S systems had shown that
three protein domains are required for the biosynthesis of ri-
bosomal peptide-derived heterocycles: an ATPase, a zinc-bind-
ing domain, and a flavin-containing oxidase.[5,13] By contrast, in
the PatD/TruD group, oxidation is not a required component
of catalysis, and the heterocyclization activity exists within a
single polypeptide. These differences substantially simplified
our approaches to gain mechanistic insights into the function
and mechanism of heterocyclases in nature; this allowed us to
provide confirmatory evidence that ATP is used to drive a mo-
lecular-heterocyclization machine. These results also define the
order of steps in cyanobactin biosynthetic pathways, which
lead to diverse and ubiquitous cyanobacterial natural products.
Experimental Section
General methods : Isopropyl b-d-1-thiogalactopyranoside (IPTG),
dithiothreitol (DTT), leupeptin, pepstatin, 4-(2-aminoethyl) ben-
zenesulfonyl fluoride (AEBSF), and phenylmethanesulfonyl fluoride
(PMSF) were purchased from ISC Bioexpress. Metal-free nitric acid
(Optima) was purchased from Fisher Scientific. Ultrapure MgCl2,
and b,g-adenosine triphosphate (b,g-ATP) were purchased from
Sigma–Aldrich. g-32P-labeled ATP was purchased from Perkin–
Elmer. Ni-NTA resin was purchased from Qiagen. ZipTip C18 pipette
tips were purchased from Millipore. Krypton fluorescent protein
stain was purchased from Pierce. All expression vectors were pur-
chased from Novagen. Escherichia coli strain DH5a was used for all
cloning steps, while E. coli strain BL21(DE3)Star was used for all
protein expressions.
Gene cloning and expression : Genes were obtained from ascidian
symbiont metagenomes and cloned as previously described.[16,17]
Enzymes were expressed as previously described, except that for





kinetic analysis additional enzyme purification was performed.
Nickel-purified TruD was loaded onto a HiPrep 16/10 Q FF column
(GE Healthcare), and run on an AKTA purifier FPLC system. The
column was washed with 0.5 column volumes of buffer A, a linear
gradient from 100% buffer A–0% buffer B to 20% buffer A–80%
buffer B over 30 column volumes was run, followed by a five
column volume wash at 0% buffer A–100% buffer B. Buffer A con-
sisted of NaCl (0.1m) buffered to pH 8.0 with HEPES (25 mm), while
buffer B consisted of NaCl (1m) buffered to pH 8.0 with HEPES
(25 mm). TruE2 used for kinetic analysis was purified as previously
described,[17] except that the protein was stocked in a solution con-
taining NaCl (350 mm), DTT (10 mm), and sucrose (1% w/v) buf-
fered to pH 8.0 with HEPES (20 mm).
Enzyme reactions : All enzyme reactions used in this study were
performed at least in triplicate in independent runs. Reaction mix-
tures were incubated at 34 8C in an MJ research minicycler for vary-
ing amounts of time. Enzyme, precursor peptide, and ATP concen-
trations varied, as described below. The following additives were
present in standard reactions but were varied in early optimization
experiments: tris pH 8.0 (40 mm), DTT (8 mm), and MgCl2 (4 mm).
Enzyme reactions generally contained the optimized additive mix-
ture and PatD or TruD (0.6 mm), TruE2 (8 mm), or TruE4 (12 mm), and
ATP (0.8 mm). Reactions were run using varying times, from 15 min
to 27 h. To confirm modification, the reaction mixture (10 mL) was
removed and analyzed by SDS-PAGE. At minimum, at least three
separate experiments were performed for each enzyme-substrate
concentration.
Sulfonyl fluoride inhibition : AEBSF and PMSF were used with
standard concentrations of reagents, including TruE2 and TruD or
PatD. Concentrations of sulfonyl fluorides were tested at 1 mm and
10 mm and compared to controls containing equivalent amounts
of vehicle only (methanol for PMSF, water for AEBSF). PMSF was
tested only against TruD. After 1.5 h reactions, the mixtures were
analyzed by SDS-PAGE.
ATP conversion : To ascertain whether PatD and TruD hydrolyze
ATP to ADP, or to AMP, PatD or TruD (0.6 mm) were incubated with
TruE2 (2 mm), and ATP (100 mm) for 30 min. Reactions were then
quenched by adding 10 mL of a saturated solution of urea and ana-
lyzed by HPLC as described below.
ATP stoichiometry : All reactions were performed in triplicate, by
using standard reaction conditions with TruE2 and PatD or TruD.
No enzyme and no substrate controls were performed. Further
controls contained AEBSF (10 mm) and were performed with
enzyme and substrate or without substrate. In one round, reactions
were run with ATP (800 mm) for 0.5 h, then quenched with urea
(8m).
Nonhydrolyzable ATP inhibition : Reactions were performed ac-
cording to standard conditions except that two sets of reactions
were used, one containing ATP (800 mm) and the other ATP
(200 mm). b,g-methylene-ATP was added to each set (800 or
200 mm ATP) at the following concentrations: 0, 100, 200, 400, 800,
and 1600 mm. Reactions were allowed to proceed for 0.5 h, and
then analyzed by SDS-PAGE.
32P-ATP labeling experiments : g-32P-ATP (1 mCi) was doped into re-
actions containing cold ATP (40 mM). Standard reaction conditions
were used with TruD and TruE2. No substrate, no enzyme, and
AEBSF-inhibited controls were performed alongside these reac-
tions. Reactions were analyzed both by adsorption to Nytran paper
followed by scintillation counting, as well as by SDS-PAGE followed
by autoradiography.
SDS-PAGE assays : 18% acrylamide gels were used for all assays.
Prior to electrophoresis, samples were brought up in 1X SDS
sample buffer diluted from 6! SDS sample buffer: tris pH 6.8
(7 mL, 0.5m) glycerol (3 mL), SDS (1 g), DTT (0.93 g), bromophenol
blue (1.2 mg), H2O (up to 10 mL), and then boiled for 3 min.
[33]
After electrophoresis, gels were placed in boiled fixing solution
consisting of H2O (53% v/v), ethanol (40% v/v), and acetic acid
(7% v/v), incubated for 10–20 min with gentle rocking, and then
placed in boiled stain solution consisting of: Coomassie R250
(0.02% w/v) in H2O (85% v/v), acetic acid (10% v/v), and ethanol
(5% v/v). Gels were then destained in a solution consisting of H2O
(85% v/v), acetic acid (10% v/v), and ethanol (5% v/v) for several
hours, these gels were then photographed. For TruE2 time course
experiments, gels were stained using Krypton fluorescent protein
stain (Pierce) according to the manufacturer’s instructions, and
imaged using a Typhoon fluorescence reader (GE).
HPLC analysis : The HPLC method for all ATP-usage and stoichio-
metric experiments employed a Vydac 302IC4.6 ion-exchange
column, and a Hitachi LaChrom Elite HPLC system. A linear gradi-
ent proceeding from 100% buffer A, which consisted of formic
acid (45 mm), adjusted to pH 4.5 using NaOH, to 100% buffer B,
which consisted of NaH2PO4 (0.5m), adjusted to pH 2.5 using
formic acid over 12 min was used to effect separation of ATP, ADP,
and AMP. The elution profiles of the experimental runs were com-
pared to those of authentic ATP, ADP, and AMP standards. Peaks
were quantified by comparison with a calibration curve construct-
ed by injecting known quantities of AMP.
Metal requirements : To assess whether or not the enzymes bound
zinc as predicted, PatD and TruD were dialyzed over two days with
stirring at 4 8C against a solution (2 L) containing glycerol (5% v/v),
NaCl (500 mm), and Sepharose chelating resin (10 g) buffered to
pH 7.8 using HEPES (25 mm). The purified, dialyzed enzyme sam-
ples were then digested using metal-free nitric acid, heated to
95 8C, and read on a Perkin–Elmer Optima 3100 XL ICP-OES instru-
ment.
The potential requirement for other metals (aside from magnesium
and zinc) was tested by using ultrapure MgCl2 (Aldrich 255777)
with TruD (1.6 mm), and TruE2 (2 mm), using Chelex-treated ATP and
DTT in standard concentrations without tris buffer. ATP and DTT
were passed through Chelex 100 (Biorad) resin (700 mL) prior to
addition to the reaction. An additional set of controls were per-
formed without using Chelex treatment.
Enzyme kinetics : Reactions were performed in the same manner
as the standard conditions described above, except that enzyme,
substrate, ATP, and AEBSF concentrations were varied. In the
experiments where the concentration of ADP was measured at 0,
20, and 40 min, experiments were performed with variable TruD,
TruE2, ATP, and AEBSF. Experiments varying TruD were performed
as follows: TruD was added at variable concentrations (140, 104,
and 69 nm) while holding constant TruE2 (7.4 mm), ATP (800 mm),
and AEBSF (0 mm). Experiments varying TruE2 were performed as
follows: TruE2 was added at variable concentrations (7.4, 5, and
2.5 mm) while holding constant TruD (104 nm), ATP (800 mm), and
AEBSF (0 mm). Experiments varying ATP were performed as follows:
ATP was added at variable concentrations (800, 400, and 200 mm)
while holding constant TruD (104 nm), TruE2 (7.4 mm), and AEBSF
(0 mm). Experiments varying AEBSF were performed as follows:
AEBSF added at variable concentrations (10, 5, and 1 mm) while
holding constant TruD (104 nm), TruE2 (7.4 mm), and ATP (800 mm).
Controls were run that lacked TruD while holding constant TruE2
(7.4 mm), ATP (800 mm), and AEBSF (0 mm). Additionally, controls
1420 www.chembiochem.org " 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2010, 11, 1413 – 1421
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were run that lacked TruE2 while holding constant TruD (104 nm),
ATP (800 mm), and AEBSF (0 mm). In experiments measuring concen-
trations of ADP at 0, 60, 120, 240, and 360 min, the reactions con-
tained TruD (140 nm), TruE2 (7.4 mm), and ATP (800 mm). Controls
were run that lacked either enzyme, substrate, or both. All reac-
tions were performed in triplicate. After removal of aliquots at
each time point, the reactions were quenched by addition of an
equal volume of 8m urea, and then frozen at !80 8C until analysis.
Nucleotide content was assessed by HPLC as described above. Ad-
ditionally, selected reactions were analyzed by SDS-PAGE to ensure
that the heterocyclization reaction was proceeding at the expected
pace. Further, to analyze the stoichiometry of ATP-hydrolyzed to
heterocycles formed, samples of the 0, 60, 120, 240, and 360 min
time points described above were analyzed by SDS-PAGE, stained
with Krypton fluorescent protein stain according to the manufac-
turer’s instructions, and then imaged on a Typhoon fluorescence
reader. The resulting images were analyzed for band densitometry
using the program ImageJ.
Protein quantitation : TruE2 used for kinetic analysis was quantitat-
ed through amino-acid analysis. The protein was dialyzed exten-
sively against a solution containing NaCl (0.35m), DTT (10 mm), su-
crose (1% w/v), and then subjected to amino-acid analysis. The
concentration was calculated based on the nanomoles recovered
of Gly, Ala, Leu, Tyr, Phe, Lys, His, and Arg, which were averaged to-
gether between two separate runs.
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Marine Molecular Machines: Heterocyclization in
Cyanobactin Biosynthesis






Figure S1.  Precursor peptides of trunkamide and patellamide pathways.  Shown are 
amino acid sequences for TruE4, TruE2, and PatE2.  The second cassette of both 
TruE2 and TruE4 encodes the natural product trunkamide, while the first cassette of 
TruE2 encodes patellin-6.  The first, and second cassettes of PatE2 encode patellamide 
C, and ulithiacyclamide, respectively; PatE2 is not used in this study, and is shown here 





















Figure S2.  Patellamide pathway biosynthetic scheme.  Shown is modification of the 
patellamide C cassette of the PatE2 precursor shown above in Figure S1.  First, PatD 
catalyzes heterocyclization of Cys or Thr residues, PatA then cleaves the N-terminal 
side of the cassette, and then finally, PatG cleaves the C-terminal side of the cassette in 
tandem with macrocyclization; an oxidase domain of PatG also catalyzes oxidation at 





Figure S3.  Intact analysis of TruD- and PatD-treated TruE2.  A), B), and C) show, 
intact mass spectrometric analyses of A) unmodified TruE2, B) TruD-treated TruE2, and 
C) PatD-treated TruE2.  Change in mass is consistent with loss of water attendant upon 
thiazoline/oxazoline ring formation. D) SDS-PAGE showing typical band shifts resulting 
from TruE2 modification reactions.  From left to right, lanes are as follows: (1) TruE2 
standard (2) TruD-treated TruE2 (3) TruD-treated TruE2 + TruE2 standard (4) PatD-














Figure S4.  HPLC analysis of adenosine nucleotides produced after 1/2 hour reaction of 



















Figure S5.  SDS-PAGE gel showing time course of PatD reaction.  Letters beside gel 
bands in lane #2 denote the following: A) unmodified TruE2 B) Doubly modified TruE2 
C) Fully modified TruE2.  From the left lanes are: (1) TruE2 standard (2) 0.5h PatD + 




















Figure S6.  Deconvoluted mass spectrum showing TruE2 modification by TruD when 
an inadequate amount of ATP was supplied to drive the reaction to completion.  Most of 
the TruE2 remains unmodified (9048.1Da), while another portion is singly dehydrated 
(9030.6Da), still another portion has a mass consistent with two dehydrations 













Figure S7.  Estimated Michaelis-Menten parameters for TruD, varying either [TruE2] or 













Figure S8.  Full kinetics data.  Error bars represent standard deviations. Y-axes 
represent [ADP] in molar concentration; X-axes represent time in minutes. A), B), C) 
Variable TruD (140, 104, and 69 nM), constant TruE2 (7.4 µM) and ATP (800 µM);  D), 
E), F) Variable TruE2 (7.4, 5.0, and 2.5 µM), constant TruD (104 nM) and ATP (800 
µM).  G), H), I) Variable ATP (800, 400, 200 µM ATP), constant TruE2 (7.4 µM) and 
TruD (104 nM).  J) TruD (104nM), ATP (800 µM), no TruE2  K) ATP (800 µM), TruE2 















































Figure S9.  Minimum ATP required for complete heterocyclization.  A) Graph showing 
relation between [ATP] provided and [Thiazoline] present at completion of TruD-TruE2 
modification reaction as measured by gel densitometry.  B) Gel used to derive 
[Thiazoline]; from left to right, lanes are as follows: (1) TruE2 standard (2) ATP (10 µM) 















Figure S10.  Background rates of ATP hydrolysis are shown under various conditions: 
A) ATP hydrolysis due to TruE2 with buffer B) ATP hydrolysis due to buffer alone C) 
ATP hydrolysis due to TruD with buffer D) ATP hydrolysis due to TruE2, TruD and 

















Figure S11.  Intact ESI-MS and SDS-PAGE analyses of reactions including or lacking 
ATP, or including a non-hydrolyzable ATP analogue (β,γ-methylene-ATP).  A) TruD-
TruE4 reaction with ATP added B) TruE4 reaction lacking ATP, but containing a 1:4 
enzyme:substrate ratio C) TruD-TruE4 reaction to which non-hydrolyzable ATP 
analogue was added D) SDS-PAGE analysis of TruD-TruE2 reactions were titrated with 
increasing amounts of non-hydrolyzable ATP, and allowed to react for 0.5h.  From the 
left, lanes are: (1) TruE2 standard (2)  ATP (800 µM) (3) β,γ-methylene-ATP (100 µM), 
ATP (800 µM) (4) β,γ-methylene-ATP (200 µM), ATP (800 µM) (5) β,γ-methylene-ATP 
(400 µM), ATP (800 µM) (6) β,γ-methylene-ATP (800 µM), ATP (800 µM) (7) β,γ-
methylene-ATP (1.6 mM); ATP (800 µM) (8) ATP (200 µM) (9) β,γ-methylene-ATP (100 
µM), ATP (200 µM) (10) β,γ-methylene-ATP (200 µM), ATP (200 µM) (11) β,γ-
methylene-ATP (400 µM), ATP (200 µM) (12) β,γ-methylene-ATP (800 µM), ATP (200 






Figure S12.  SDS-PAGE gels showing inhibition of TruD and PatD by AEBSF and/or 
PMSF. A) SDS-PAGE gel showing inhibition of TruD-catalyzed TruE2 modification by 
AEBSF and PMSF; AEBSF (0.1 M) stock solution was made in water, PMSF (0.1M) 
stock solution was made in methanol.  From the left, lanes are: (1) TruE2 standard (2) 
TruD+TruE2 (3) TruD + TruE2 + AEBSF (10 mM) (4) TruD + TruE2 + MeOH (10% v/v) 
(5) TruD + TruE2  PMSF (10 mM) (6) TruD + TruE2 + AEBSF (1 mM) (7) TruD + TruE2 
+ MeOH (1%  v/v) (8) TruD + TruE2 + PMSF (1 mM) (9) TruE2 standard (10) Ladder. B) 
SDS-PAGE gel showing inhibition of TruD- and PatD-catalyzed TruE2 modification by 
AEBSF.  From the left, lanes are: (1) PatD + TruE2 + 10mM AEBSF (2) PatD + TruE2 
(3) TruE2 + 10mM AEBSF (4) TruD + TruE2 + 10mM AEBSF (5) TruD + TruE2 (6) 
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’ INTRODUCTION
Prenylation is a common biochemical modiﬁcation that has
been studied in detail in numerous systems.1,2 For example,
proteins are often farnesylated or geranylgeranylated on cysteine
residues, and numerous peptide natural products are known to
be prenylated at diverse positions. Prenylation is key to the
biological activity of these molecules.3,4 Several enzyme families
have been described that catalyze prenyl transfer, and indeed
whole new prenyltransferase (PT) families continue to be
discovered.5!9 For example, the ABBA family has been shown
to catalyze aromatic C-prenylation on a variety of substrates,10
especially ortho to phenolic oxygen. Several ribosomal peptide
natural products, such as ComX and the cyanobactins, are
prenylated in unique ways that greatly increase the chemical
diversity of the resulting compounds.11!13 PTs for this growing
ribosomal peptide natural product group have yet to be enzy-
matically characterized.14
Cyanobactins are a broadly distributed group of ribosomally
derived, macrocyclic peptides whose biosynthetic genes are
homologous. These compounds are often highly post-transla-
tionally modiﬁed. Indeed, many cyanobactins are prenylated by
dimethylallyl pyrophosphate (DMAPP) on the oxygen atom of
serine, threonine, or tyrosine (Figure 1), all of which are
biochemically unprecedented reactions in the context of riboso-
mal peptides. Among cyanobactins, prenylation is known to
occur in the “reverse” position (DMAPP 3-carbon) with serine
and threonine and in the “forward” position (DMAPP 1-carbon)
with tyrosine. However, no obvious candidate PTs exist in
cyanobactin gene clusters.11 By comparing several cyanobactin
pathways discovered by metagenome sequencing, we proposed
that the TruF family of proteins might be PTs.11 Given that the
TruF family lacks the typical sequence hallmarks of PTs, we
sought to obtain biochemical evidence for this proposal. Conse-
quently, we explored the set of sequenced gene clusters to ﬁnd a
soluble TruF relative for biochemical analysis.15 Among TruF
relatives, one protein, LynF from Lyngbya aestuarii,16,17 could be
solubly expressed in Escherichia coli. Although the other steps in
cyanobactin biosynthesis have been characterized,18!21 the PT
substrate was unknown prior to this study. Consequently,
substrate analogues for each possible biochemical step were
synthesized, and their products upon reaction with LynF were
analyzed (Figure 2). We show here that the LynF/TruF family
represents a remarkably broad substrate family of O-prenyltrans-
ferases, with LynF prenylating a wide variety of tyrosyl peptides
and phenol derivatives. Among biosynthetically relevant sub-
strates, only cyclic peptides are prenylated.
Unexpectedly, reactions catalyzed by LynF led to carbon-pre-
nylated phenolic products. Generally speaking, PTs catalyze elec-
trophilic alkylation of their substrates. In the case of aromatic
substrates, reactions are thought to proceed via electrophilic aro-
matic substitution.10 However, several alternative mechanisms exist.
For one, it has been proposed since at least the early 1970s that
C-prenylated phenols might also arise via reverse O-prenylation of
phenols followed by a Claisen rearrangement (Figure 1).22 This
chemical proposal was exploited in several elegant ‘biomimetic’ total
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ABSTRACT:The enzymatic basis of ribosomal peptide natural
product prenylation has not been reported. Here, we character-
ize a prenyltransferase, LynF, from the TruF enzyme family.
LynF is the ﬁrst characterized representative of the TruF
protein family, which is responsible for both reverse- and
forward-O-prenylation of tyrosine, serine, and threonine in
cyclic peptides known as cyanobactins. We show that LynF
reverse O-prenylates tyrosine in macrocyclic peptides. Based upon these results, we propose that the TruF family prenylates mature
cyclic peptides, from which the leader sequence and other enzyme recognition elements have been excised. This diﬀers from the
common model of ribosomal peptide biosynthesis, in which a leader sequence is required to direct post-translational modiﬁcations.
In addition, we ﬁnd that reverse O-prenylated tyrosine derivatives undergo a facile Claisen rearrangement at ‘physiological’
temperature in aqueous buﬀers, leading to forward C-prenylated products. Although the Claisen rearrangement route to natural
products has been chemically anticipated for at least 40 years, it has not been demonstrated as a route to prenylated natural products.
Here, we show that the Claisen rearrangement drives phenolic C-prenylation in at least one case, suggesting that this route should be
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syntheses of complex natural products.23,24 Despite a resur-
gence of biochemical studies of aromatic PTs in recent
years,6,8,10,25!30 the Claisen rearrangement proposal has not
been revisited. Here, in addition to characterizing a novel PT
family, we show that enzymatically synthesized aromatic C-pre-
nylated phenols can indeed arise via the Claisen rearrangement
pathway.
’RESULTS
Expression of LynF and Synthesis of Substrates.We found
that several of the TruF-group PTs were difficult to overexpress.
Fortuitously, in our search for candidate PTs, LynF (44% amino
acid identity with TruF1), from the lyn pathway of the cyano-
bacterium L. aestuarii, was readily expressed in E. coli in soluble
form. We predicted that LynF should prenylate phenols, but
there are no known natural products of the lyn pathway.16,17
Therefore, analogues of possible substrates were synthesized,
including linear peptides representing putative pathway inter-
mediates as well as cyclo[APMPPYP] (6), which is similar to the
predicted lyn pathway product (Figure 2, Table 1). Additionally,
reactions with several wholly unnatural phenol derivatives and
linear peptides containing tyrosine were attempted. The purity
and the identity of the synthetic substrates were assessed
spectroscopically.
LynF is a Tyrosine PT. When incubated with DMAPP and
MgCl2, LynF catalyzed the prenylation of peptides and a subset
of phenols related to tyrosine (Table 1).Mg2+ was added because
many PTs require it for function.10 Indeed, LynF does not
function in the absence of either Mg2+ or Mn2+. Tyrosine
prenylation was demonstrated by Fourier-transform ion cyclo-
tron resonance (FT-ICR) and MS/MS fragmentation, which
revealed the presence of the expected ions (Table S2, Supporting
Information) and also localized the prenylation to tyrosine
(Figure S1, Supporting Information).
LynFprenylated several tyrosine-containing substrates and showed
a strong preference for reaction with cyclic over linear peptides
(Table 1). In contrast to typical ribosomal peptide biosynthesis,31
LynFdid not act on pathway intermediates (3!5) that still contained
a leader sequence or enzyme “recognition elements” (Figures 2 and
S1 and S2, Supporting Information). Of biosynthetically relevant
Figure 1. Prenylation in natural products. (A) Representative cyano-
bactin peptide natural products, showing groups derived from DMAPP
in blue. (B) Two possible enzymatic mechanisms of phenol ortho-C-
prenylation. First, DMAPP is dephosphorylated to yield a cation that can
react either at oxygen (pathway I) or at carbon (pathyway II). In
principle, a Claisen rearrangement from pathway I could then yield the
C-prenylated product. Only pathway II has been previously linked to
enzymatic modiﬁcation.
Figure 2. Deﬁning the biosynthetic route to prenylated cyanobactins. Proposed biosynthetic scheme for Lyn pathway showing modiﬁcation of
precursor peptide by heterocyclization, proteolysis, macrocyclization, and prenylation. The ﬁrst steps in this route are supported by previous
enzymological studies, but the timing of prenylation was not known. Enzyme recognition elements are highlighted. Analogues (3!6) were used to assess
prenylation of each possible biosynthetic intermediate and are shown in analogous colors beneath each proposed biosynthetic intermediate. Pro was
substituted as an approximate isostere for thiazole in later analogues. No reaction was observed with any intermediate except the ﬁnal cyclic peptide,
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substrates, LynF acted only on the mature cyclic peptides, such as 6.
Overall, LynF was capable of prenylating a broad variety of cyclic
peptides, including substrates (9!12) containing 6-, 7-, 13-, and
14-amino acid residues. Surprisingly, LynF also prenylated several
tyrosine-containing substrates that are not relevant to the natural
biosynthetic pathway. Tyrosine itself was not a substrate, but boc-
L-tyrosine and other N-terminally blocked tyrosine derivatives were
readily prenylated (14, 15 and 21). Derivatives lacking a free phenolic
!OHwerenot substrates (16!20).Overall, LynF appears to require
a blocked N-terminus but otherwise exhibits relaxed substrate
speciﬁcity.
LynF Products are ortho-C-Prenylated. Based upon the
known products of cyanobactin pathways, we expected that
LynF would catalyze forward O-prenylation of phenol.11,32 We
performed large-scale enzymatic reactions with long incubation
times to generate sufficient quantities of products for NMR
analysis. Products of two different LynF substrates, 6 and 14,
were isolated by HPLC and characterized by NMR and high-
resolution MS. Surprisingly, by comparison to previously de-
scribed compounds,33 we established that both 6 and 14 were
forward C-prenylated, ortho to the phenolic hydroxyl group
(Figures 3 and S3, Supporting Information).
C-Prenylation is the Result of a Claisen Rearrangement.
Initially, we assumed that LynF catalyzed electrophilic aromatic
substitution at the ortho position in a manner identical with that
reported for ABBA PTs. With an eye toward constructing a
Hammett plot of reactivity, we assayed the LynF catalyzed
prenylation of a series of 4-substituted Tyr derivatives
(16!20) (Table 1). However, all of these reactions failed. If
LynF-catalyzed prenylation were to occur via electrophilic aro-
matic substitution, then one would expect a broader scope of
reactivity, as was found for dimethylallyl tryptophan synthase.34
An alternative mechanism for the formation of ortho-C-pre-
nylated phenols involves reverse O-prenylation followed by
Claisen rearrangement of the resulting O-allyl intermediate.22 In
Table 1. Substrates Assayeda
no. substrate yield
3 TruLy1 precursor peptide NR
























aAll yield quantitations are based on HPLC (for 6!8 and 14!25) or MS
(3!5 and 9!13) analyses of 24 h reactions and do not represent isolated
yields. NR (“no reaction”) denotes no detectable prenylation of tyrosine or
derivatives. All substrates were run at 100μMexcept 3, 4, and 9, 10, 11, and
12 (14, 14, 70, 30, 20, and 20 μM, respectively). Both full (100 μM) and
reduced concentrations (28, 56 μM) were employed with substrates 6 and
14 in order to compare data for substrates tested at reduced concentration.
Figure 3. LynF is ortho-C-prenylating. The aromatic/oleﬁn region of
the heteronuclear quantum coherence NMR spectra is shown for (A)
boc-tyrosine (14) and (B) its puriﬁed enzymatic product with LynF,
clearly indicating a single, forward C-prenylation event. Similar spectra
were also observed for reactions containing 6. NMR and MS character-
ization of compounds is presented in Figures S1, S3, and S5, Supporting
Information.
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that vein, careful examination of LC-FT-ICR analyses of reaction
mixtures showed that upon reaction with LynF, all substrates gave
rise to two products (Figure S1, Supporting Information). These
products were isobaric and prenylated on tyrosine. However, one
product was prenylated on carbon and the other on oxygen.
Forward carbon prenylation had been established using 28
(Scheme 1), which was puriﬁed and characterized by NMR as
described above. Of the two products of LynF upon reaction with
6, puriﬁed 28was found to be identical to the early eluting product
(Figure S4, Supporting Information).Moreover, no fragmentation
of the C-prenyl moiety on 28 could be observed in MS-MS
experiments. Similarly, for all LynF products, we observed that the
early eluting compound was prenylated on tyrosine but did not
lose isoprene in MS-MS, indicating C-prenylation.
In contrast, all late-eluting products evinced prominent loss of
isoprene (C5H8) in their MS-MS spectra. Loss of C5H8 from
prenylated phenols is diagnostic of O-prenylation, as shown in
previous studies.35!37 This reaction was more diﬃcult to char-
acterize by NMR, owing to the apparent instability of the
O-prenylated products. Fortuitously, we were able to isolate
one of these compounds, resulting from reaction of 15 (Figures 4
and S5, Supporting Information). NMR analysis of the puriﬁed
material conﬁrmed that the product (31) was O-prenylated and
conclusively demonstrated that O-prenylation occurred in the
reverse orientation. Puriﬁed 31was then added to aqueous buﬀer
at 37 !C (for buﬀer composition see Materials and Methods
Section), and it rapidly and spontaneously rearranged to form the
forward C-prenylated product 30 which was identical to the
previously NMR-characterized product, 29.
Reverse O-prenylated phenols are known to undergo the
Claisen rearrangement to yield forward ortho-C-prenylated
products.22,24,38,39 Thus, we realized that if the sole enzymatic
reaction catalyzed by LynF were reverse O-prenyltransfer on Tyr,
then thiswould lead to themixture of products we had consistently
observed with all substrates. Alternatively, we supposed that LynF
might carry out reverse O-prenyltransfer in addition to direct
electrophilic aromatic substitution in the forward direction on
carbon. To distinguish between these two possibilities, a kinetic
analysis for reactions containing 14 was performed in which C-
and O-prenyl products were followed over 24 h in reactions
performed in quadruplicate (Figure 5). The O-prenyl product
Figure 4. LynF catalyzes reverse O-prenylation of tyrosine. The aro-
matic/oleﬁn region of 1H NMR spectra are shown (A) for boc-tyrosine
(14), (B) the HPLC-puriﬁed intermediate LynF product (31), and
(C) the ﬁnal reaction product (30). These spectra clearly indicate that
the ﬁrst product of the LynF reaction is reverse-O-prenyl tyrosine, which
subsequently rearranges to give the C-prenylated product.
Figure 5. Time course of boc-L-Tyr (14) reaction followed by HPLC.
The reaction was performed in quadruplicate, with variation indicated
by error bars (A) and (B). Initial product of the reaction is almost
exclusively O-prenylated as shown at 1, 2, and 4 h time points (B). After
4 h, the level of O-prenylated intermediate reaches steady-state and its levels
are constant through 24 h, accompanied by steady increase in the concentra-
tion of C-prenylated ﬁnal product 29. This allowed kinetic constants for the
Claisen rearrangement to be directly determined, since at steady state the
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appeared ﬁrst, with a delayed onset of 29. After 4 h of reaction
time, a steady state was reached in which the rate of prenylation
was equal to the rate of the Claisen rearrangement. Interpretation
of the kinetic data, which assumed a unimolecular mechanism and
steady-state levels of O-prenyl intermediate, yielded a rate of
rearrangement of 8.3 μM/h and a rate constant for the Claisen
rearrangement (kwhere rate ofClaisen= k*[O-prenyl intermediate])
of 0.23 h!1. Taken together with the absence of reactivity observed
with analogues lacking a free phenolic!OH, these data show that the
initial enzymatic reaction is reverseO-prenylation, followed by slower
conversion to a forward C-prenylated phenol
Having shown that theO-prenylated compound is the product of
initial prenyltransfer, we sought to determine whether the rearran-
gement to the forward C-prenylated compound was enzyme
catalyzed. To do so, puriﬁedO-prenylated 31was added to enzyme,
buﬀer, or boiled enzyme. Under all three conditions, 31 was
eﬃciently converted into C-prenylated 30 without any appreciable
enzymatic acceleration (Figure S6, Supporting Information).
This spontaneousClaisen rearrangementmight seem surprising
given that in the synthetic literature, reverse prenylated phenols
require elevated temperatures for rearrangement.24,38 However,
these synthetic reactions take place in organic solvents, while we
have employed aqueous solvents. Indeed, the speed with which we
have observed reverse O-prenylated phenols to rearrange is
unsurprising in light of the known aqueous acceleration of the
Claisen rearrangement.40!45Herewe show by experiment that the
rearrangement goes to completion at 37 !C in aqueous buﬀers.
Consequently, our conditions may provide a particularly mild
reaction condition for the Claisen rearrangement for use in future
synthetic studies.
To further examine the rapid rearrangement observed with 31,
we purchased O-allyl-boc-L-tyrosine and examined it to see if its
rearrangement might be accelerated with enzyme or the buﬀer
conditions employed with 31. In contrast to the prenylated
substrates, this compound did not undergo the Claisen rearrange-
ment under the aforementioned conditions. Based upon these
results, it seems that the geminal methyl groups adjacent to the
phenolic oxygen are required to promote the Claisen rearrange-
ment at relatively low temperatures. This eﬀect can be rationalized
as an example of the gem substituent eﬀect, which is believed to
accelerate the Claisen rearrangement.46 Indeed, it has been shown
that the presence of bulky substituentsR- to oxygen can accelerate
the Claisen rearrangement and similar reactions,47,48 though to the
best of our knowledge this is the ﬁrst direct comparison of these
substrates in the aromatic Claisen rearrangement.
Phylogenetic analysis of LynF and homologues nicely ratio-
nalizes the observed pattern of reactivity, where LynF is most
closely related to TruF1 and PagF (Figure 6). In light of the
above biochemical evidence, TruF1 can be assigned the role of a
reverse O-prenyltransferase acting on Ser and Thr, while PagF
can be assigned the role of a forward O-prenyltransferase acting
onTyr. Thus, that LynFwould carry out reverseO-prenylation of
Tyr is unsurprising in light of its phylogenetic proﬁle.
Kinetic Measurements. LynF catalyzed reaction rates were
measured in triplicate using two different substrates: cyclo-
[APMPPYP] (6), and an unnatural substrate, boc-L-tyrosine
(14) (Figure S7, Supporting Information). UsingHPLC analysis,
the turnover numbers for 6 and 14 were similar (14 and 63 h!1,
respectively), as were Km values (4 and 14 mM, respectively).
These rates are slower than those typically reported for prenyl-
transferases.27,49 However, the apparent slowness of reactions
catalyzed by LynF is not unusual when compared with rates
observed with other cyanobactin biosynthetic enzymes. Some of
these reactions are quite slow, a fact that has been attributed to
their extremely broad substrate tolerance and by extension their
relatively low affinities for any given substrate.18!21
’DISCUSSION
To the best of our knowledge, LynF represents the ﬁrst
enzymatically characterized PT leading to the synthesis of riboso-
mal peptide natural products. Further, serine and threonineO-PTs
have not been previously described nor have tyrosine O-PTs
acting on ribosomal peptides.14 Although these post-translational
modiﬁcations are currently known only in the cyanobactin family
of natural products, cyanobactins are present in perhaps∼30% of
all cyanobacteria onEarth and therefore constitute amajor fraction
of bioactive natural products globally.50 Another salient feature of
this enzyme group is that it clearly acts on polypeptide products,
while most other natural product DMAPP transferases act on
starting amino acids or on small dipeptides. For example, forward
O-prenylated tyrosine has recently been characterized in sirodes-
min diketopiperazine biosynthesis.49,51 However, in this case
tyrosine itself is the substrate for prenylation, and the product
does not result from ribosomal synthesis.
Figure 6. Phylogenetic analysis of the TruF/LynF family. (A) Tru
F-group proteins cluster according to whether natural products are
prenylated (top) or nonprenylated (bottom). Chemical products are
shown for each TruF-like protein, where they exist. No TruF-like
sequence relatives can be identiﬁed outside of cyanobactin gene clusters
using either BLAST searching or sequence alignments with other PT
family proteins, indicating that this is a novel group of PTs. (B) Actual
product structures of prenylagaramide (left) and trunkamide (right)
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Phenols themselves are C- or O-prenylated in many small
molecule natural products.10 In all cases that have been character-
ized so far, it is thought that C-prenylated phenols arise from direct
electrophilic aromatic substitution.10 Although the Claisen rear-
rangement was long-predicted from ‘biomimetic’ chemistry, a
biochemical demonstration of its relevance as a route to C-pre-
nylated phenols was lacking. Here, we show that the Claisen
rearrangement route can indeed occur to aﬀord C-prenylated
products (Scheme 2). This route could easily be missed, since the
O-prenylated intermediates are short-lived and not easily detected
by commonly used analytical methods. For example, the inter-
mediates have extremely weak absorption at λ = 280 nm, and their
ﬂuorescence spectra are diﬀerent than for unsubstituted or C-pre-
nylated phenols. The rearrangement is relatively rapid and con-
tinues even after enzymes have been denatured or inactivated.
Given aqueous acceleration of the Claisen rearrangement and the
acceleration provided by the geminal methyl groups of the reverse
prenylation, the ease with which the Claisen rearrangement might
occur in a cellular context has perhaps been underestimated.
Overall, forward prenylation via electrophilic aromatic substitution
and reverse O-prenylation followed by the Claisen rearrangement
will be indistinguishable under many conditions.
We initially expected that the Claisen rearrangement might be
enzymatically accelerated. In synthetic chemistry, several guani-
dinium-based synthetic catalysts of the Claisen rearrangement
have been reported.38,52 Additionally, in the premier example of a
biological Claisen rearrangement, chorismate mutase has been
calculated to provide rate enhancements of >106.53 However, it is
clear from our results using puriﬁed reverse-O-prenylated 31 that
in this case the reaction is spontaneous. Given the spontaneous
nature of this transformation and the similarity to other reported
Claisen rearrangements, the simplest hypothesis is that 31
proceeds to 30 via the Claisen rearrangement and not via some
other, more complicated mechanism.
We have previously shown that proteins in this group were
involved in pathways to very sequence-diverse prenylated natural
products in vivo,16 and herewe show that puriﬁedLynF acceptsmany
diﬀerent cyclic substrates. This broad speciﬁcity is especially remark-
able in that LynF substrates share no common sequence features that
would provide robust enzyme recognition elements. In ribosomal
peptide natural product synthesis, enzymes commonly recognize
conserved motifs in a leader peptide, which is subsequently cleaved
and discarded, allowing the enzymes to modify diverse sequences.31
However, in this case the reaction proceeds after the leader sequence
and the recognition elements have already been removed.
The structure and catalytic mechanism of this new family of PTs
remains to be determined. Although the proteins bear no homol-
ogy to any other characterized protein outside of cyanobactin gene
clusters, it remains possible that they are structurally related to
known PTs. However, no putative ABBA-like required residues
are present in the correct places in these proteins (Figure S8,
Supporting Information). Since PTs are often deeply divergent
and sequence similarity is completely lacking for this protein class,
a ﬁnal comparison will await structural study. It is also unknown
why nonprenylating cyanobactin clusters usually contain (and
even require) LynF-like proteins.16,50 In these nonprenylating
cases, all enzymatic roles have been assigned, so that LynF
homologues serve no obvious enzymatic function.20,21 However,
removal of the LynF homologue from heterologous expression of
the nonprenylating pat pathway in E. coli abolishes compound
production.16 Possible roles include a chaperone function or
perhaps interaction with the leader sequence.
In conclusion, we show that the TruF/LynF group of proteins
represents a new family of PTs that catalyze unprecedented
enzymatic reactions and that are quite distinct from previously
characterized proteins. LynF represents the ﬁrst ribosomal pep-
tide natural product prenyltransferase to be characterized, open-
ing the door to the study of prenylated ribosomal peptide natural
products.
’MATERIALS AND METHODS
For detailed methods, see Materials and Methods in the Supporting
Information.
Substrates. Dimethylallyl pyrophosphate (DMAPP) was synthe-
sized following previously established procedures.54!56 Excepting 11,
12, and 26 whose synthesis and characterization has been reported
elsewhere,15,19 peptide substrates were synthesized at the University of
Utah DNA/peptide synthesis core facility. Synthesis of boc-protected
4-iodo-L-phenylalanine and 4-methoxy-L-phenylalanine was performed
according to previously established procedures.57 Boc-L-tyrosine, so-
dium hydrogen pyrophosphate, dimethylallyl bromide, tetrabutylam-
monium hydroxide, and dopamine HCl were purchased from Sigma.
N-acetyl-L-tyrosine and phenol were purchased from Fisher Scientific.
All other Tyr and Phe derivatives were purchased from ChemImpex.
Genes and Cloning. A codon-optimized version of lynF was
synthesized and cloned into pET28 in frame with the N-terminal his-
tag sequence using NdeI and EcoRI (Genscript). TruLy1 was cloned via
modification of a previously described vector,15 which was subsequently
cloned into pET28b using NdeI and BamHI.
Protein Expression and Purification. LynF was expressed in
BL21(DE3) cells, purified initially by Ni-NTA chromatography, which
was followed by size-exclusion chromatography to yield homogeneous
protein. Purification of TruLy1 was likewise performed by Ni-NTA
chromatography, with the main difference being that rather than attempt-
ing to isolate soluble protein, TruLy1 was strongly overexpressed with the
intent of driving the protein into inclusion bodies, after which time
purification under denaturing conditions was performed.
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Enzyme Assays. Enzyme reactions typically contained enzyme
(3.8 μM) and variable substrate concentration (100 μM for most
substrates; higher concentrations, i.e., 1 mM, were occasionally em-
ployed with boc-protected amino acid derivatives. Exceptions include
substrates 11 and 12, which were used at 20 μM final concentration as
well as substrates 9 and 10, which were used at 70 and 30 μM,
respectively). Several additives (1 M of NaCl, 40 mM of glycylglycine
pH of 9.0, 12 mM of MgCl2, 3 mM of tris(2-carboxyethyl) phosphine
(TCEP), and 1 mM of DMAPP) were added to all reactions. Reactions
were incubated at 37 !C for 24 h in a DNA Engine Peltier thermocycler
(Bio-Rad). Enzyme reactions with full-length precursor peptide con-
tained TruLy1 (28 μM), ATP (0.8 mM), with or without heterocyclase
enzyme TruD (90 nM), and additives as above. Controls were run to
ensure that LynF was active in the presence of TruD and TruLy1 and
vice versa. Products were characterized by MS or diode array (λ = 220
and 280 nm) and fluorescence (λ = 271 nm excitation and 303 nm
emission) HPLC. Reactions assessing the rate of rearrangement of
purified 31 were performed at 37 !C with time points taken at 0 and 8 h
and included the standard additives described above. For descriptions of
specific assays, see Materials and Methods in the Supporting Information.
Phylogenetic Tree Construction. The amino acid sequences of
LynF homologues from the functionally characterized cyanobactin
pathways were aligned using CLUSTALX. Maximum likelihood analysis
with molecular clock PROMLK (PHYLIP) using the bootstrap test
method (1000 replicates) was performed to assess the phylogenetic
relationship between the different homologues. The same tree branches
were also supported using other phylogenetic experiments such as
maximum parsimony (MEGA 4.0) using 1000 bootstrap replicates.
General Methods. ESI-MS and FT-ICR analyses were performed
at the University of Utah Mass Spectrometry and Proteomics core
facility. MALDI-MS analyses were performed on a Micromass MALDI
micro MX instrument (Waters). HPLC separations were performed on
a LaChrom Elite system (Hitachi). NMR spectra were collected on
either 400 or 500 MHz spectrometers (Varian). CD spectra were
collected on a Jasco J-815 spectrometer, and data were plotted in Excel.
’ASSOCIATED CONTENT
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Figure S1. LC-FT-ICR and MS-MS, or ESI-MS characterization of products of reactions containing: 
(a-d) cyclo[APMPPYP] (e-h) APMPPYP (i-l) cyclo[APMPPYPAPMPPP] (m-p), (q-t) 
cyclo[APMPPYPAPMPPYP] (u-x) cyclo[KKPYILP] (y-bb) cyclo[KPYILP] (cc-ff) KPYILP (gg-hh) 
boc-L-Tyr (ii) N-acetyl-L-Tyr.  Note that prenylated tyrosine is denoted by a lower-case ‘y’, while 
unmodified tyrosine is denoted by an upper-case ‘Y’ 
cyclo[APMPPyP] 











(c) MS-MS spectra for early (top) and late (bottom) eluting products of the reaction of LynF with 






cyclo[APMPPYP] 2nd peak (O-prenyl)


























169.10 - yP 329.19 329.15
300.14 - yPA 400.22 400.29
397.19 397.18 yPAP 497.28 497.25
494.24 494.28 yPAPM 628.32 628.34
725.37 725.33 yPAPMP 725.37 725.33
229.10 - PA 169.10 -
326.15 326.19 PAP 266.15 266.18
423.21 - PAPM 397.19 397.18
654.33 654.30 PAPMP 494.24 494.28
751.39 751.35 PAPMPP 591.30 591.34
229.10 -
326.15 326.19 Miscellaneous Ions
557.28 557.30 -H2O 804.41 804.38
654.33 654.30 -Acylium (C=O) 794.42 794.40
725.37 725.33 -Methyl sulfanyl radical 774.42 774.45
263.18 - -Prenyl 754.35 754.33
426.24 426.25 -Met side-chain 746.39 746.44
523.29 523.34 PyPAP y- a- cleavage 566.33 566.36
594.33 594.29 PPyPA -Prenyl 526.27 526.26






cyclo[APMPPYP]  1st peak (C-prenyl)


























169.10 - yP 329.19 329.26
300.14 - yPA 400.22 400.29
397.19 397.16 yPAP 497.28 497.31
494.24 494.32 yPAPM 628.32 628.35
725.37 725.32 yPAPMP 725.37 725.32
229.10 - PA 169.10 -
326.15 - PAP 266.15 266.19
423.21 - PAPM 397.19 -
654.33 654.32 PAPMP 494.24 494.32
751.39 751.47 PAPMPP 591.30 591.35
229.10 -
326.15 - Miscellaneous Ions
557.28 557.43 -H2O 804.41 804.40
654.33 654.32 -Acylium (C=O) 794.42 794.41
725.37 725.32 -Methyl sulfide 774.42 774.46
263.18 - -Met side-chain 746.39 746.39















































(g) MS-MS spectra for early (top) and late (bottom) eluting products of the reaction of LynF with 






APMPPYP 1st peak (C-prenyl)



































APMPPYP 2nd peak (O-prenyl)

























































































(k) MS-MS spectra for early (top) and late (bottom) eluting products of the reaction of LynF with 






cyclo[APMPPPAPMPPYP]   1st peak (C-prenyl)


























300.14 300.22 MPPPAPMPPy 1147.57 1147.52 PAPMPPy 822.42 822.38
397.19 397.14 MPPPAPMPPyP 1244.62 1244.51 PAPMPPyP 919.47 919.42
494.24 494.22 MPPPAPMPPyPA 1315.66 1315.57 PAPMPPyPAP 1087.56 1087.49
591.30 591.3 PPPA 363.20 363.21 PAPMPPyPAPM 1218.60 1218.53
759.39 759.28 PPPAP 460.26 460.28 PAPMPPyPAPMP 1315.66 1315.57
890.43 890.54 PPPAPM 591.30 591.3 APM 300.14 300.22
987.48 987.42 PPPAPMP 688.35 688.39 APMP 397.19 397.14
1084.53 1084.5 PPPAPMPP 785.40 785.47 APMPP 494.24 494.22
1315.66 1315.57 PPPAPMPPy 1016.53 1016.45 APMPPy 725.37 725.38
229.10 229.14 PPPAPMPPyP 1113.58 1113.52 APMPPyP 822.42 822.38
326.15 326.1 PPPAPMPPyPA 1184.62 1184.52 APMPPyPAPMP 1218.60 1218.53
423.21 423.22 PPA 266.15 266.15 APMPPyPAPMPP 1315.66 1315.57
520.26 520.28 PPAP 363.20 363.21 PM 229.10 229.14
591.30 591.3 PPAPM 494.24 494.22 PMP 326.15 326.1
688.35 688.39 PPAPMP 591.30 591.3 PMPP 423.21 423.22
819.39 819.3 PPAPMPP 688.35 688.39 PMPPy 654.33 654.31
916.44 916.46 PPAPMPPy 919.47 919.42 PMPPyP 751.38 751.41
1244.62 1244.51 PPAPMPPyP 1016.53 1016.45 PMPPyPA 822.42 822.38
229.10 229.14 PPAPMPPyPA 1087.56 1087.49 PMPPyPAP 919.47 919.42
326.15 326.1 PPAPMPPyPAP 1184.62 1184.52 PMPPyPAPM 1050.51 1050.43
423.21 423.22 PPAPMPPyPAPM 1315.66 1315.57 PMPPyPAPMP 1147.57 1147.52
494.24 494.22 PAP 266.15 266.15 PMPPyPAPMPP 1244.62 1244.51
591.30 591.3 PAPM 397.19 397.14 MP 229.10 229.14
819.39 819.3 PAPMP 494.24 494.22 MPP 326.15 326.1
916.44 916.46 PAPMPP 591.30 591.3 MPPy 557.28 557.36


























654.33 654.31 yPAPMPP 822.42 822.38 All, -acylium, +2 692.86 692.99
725.37 725.38 yPAPMPPP 919.47 919.42 PPPAPMPPY, y- a- cleavage +1 988.53 988.42
822.42 822.38 yPAPMPPPAP 1087.56 1087.49 PAPM -Met sidechain 321.16 321.25
953.46 953.48 yPAPMPPPAPM 1218.60 1184.52
1050.51 1050.43 yPAPMPPPAPMP 1315.66 1315.57
1147.57 1147.52 PAP 266.15 266.15
1244.62 1244.51 PAPM 397.19 397.14
1315.66 1315.57 PAPMP 494.24 494.22
426.24 426.22 PAPMPP 591.30 591.3
594.33 594.33 PAPMPPP 688.35 688.39
822.42 822.38 PAPMPPPA 759.39 759.28
919.47 919.42 PAPMPPPAP 856.44 856.33
1016.53 1016.45 PAPMPPPAPM 987.48 987.42
1113.58 1113.52 PAPMPPPAPMP 1084.53 1084.5
1184.62 1184.52
426.24 426.22  y- b- cleavages (+2)
594.33 594.33 PAPMPPPAP 428.72 428.83
725.37 725.38 PyPAPMPPP 508.77 508.83
822.42 822.38 PMPPyPAPM 525.76 525.76
919.47 919.42 APMPPPAPMPP 542.77 542.87
1016.53 1016.45 PPAPMPPyPAP 592.82 592.69
1087.56 1087.49 PAPMPPyPAPM 609.81 609.84
1184.62 1184.52 PMPPyPAPMPP 622.81 623.00
1315.66 1315.57 PPyPAPMPPPAP 641.34 641.52
725.37 725.38 PAPMPPyPAPMP 658.34 658.31
(l) MS-MS assignments for prenylated cyclo[APMPPPAPMPPYP] early (this page) and late (next 






cyclo[APMPPPAPMPPYP]   2nd peak (O-prenyl)


























397.19 397.17 MPPPAPMPPyP 1244.62 1244.59 PAPMPPyPA 990.51 990.48
494.24 494.26 MPPPAPMPPyPA 1315.66 1315.52 PAPMPPyPAP 1087.56 1087.50
591.30 591.30 PPPA 363.20 363.22 PAPMPPyPAPM 1218.60 1218.69
759.39 759.31 PPPAP 460.26 460.42 PAPMPPyPAPMP 1315.66 1315.52
890.43 890.45 PPPAPM 591.30 591.30 APMP 397.19 397.17
987.48 987.38 PPPAPMP 688.35 688.32 APMPP 494.24 494.26
1084.53 1084.64 PPPAPMPP 785.40 785.52 APMPPy 725.37 725.32
1315.66 1315.52 PPPAPMPPy 1016.53 1016.46 APMPPyP 822.42 822.35
229.10 229.08 PPPAPMPPyPA 1184.62 1184.51 APMPPyPAP 990.51 990.48
326.15 326.18 PPA 266.15 266.13 APMPPyPAPM 1121.55 1121.48
423.21 432.19 PPAP 363.20 363.22 APMPPyPAPMP 1218.60 1218.69
591.30 591.30 PPAPM 494.24 494.26 APMPPyPAPMPP 1315.66 1315.52
688.35 688.32 PPAPMP 591.30 591.30 PM 229.10 229.08
819.39 819.36 PPAPMPP 688.35 688.32 PMP 326.15 326.18
916.44 916.43 PPAPMPPy 919.47 919.42 PMPP 423.21 423.19
1244.62 1244.59 PPAPMPPyP 1016.53 1016.46 PMPPyPA 822.42 822.35
229.10 229.08 PPAPMPPyPA 1087.56 1087.50 PMPPyPAP 919.47 919.42
326.15 326.18 PPAPMPPyPAP 1184.62 1184.51 PMPPyPAPM 1050.51 1050.49
423.21 423.19 PPAPMPPyPAPM 1315.66 1315.52 PMPPyPAPMP 1147.57 1147.44
494.24 494.26 PAP 266.15 266.13 PMPPyPAPMPP 1244.62 1244.59
591.30 591.30 PAPM 397.19 397.17 MP 229.10 229.08
722.34 722.36 PAPMP 494.24 494.26 MPP 326.15 326.18
819.39 819.36 PAPMPP 591.30 591.30 MPPy 557.28 557.53
916.44 916.43 PAPMPPy 822.42 822.35 MPPyPA 725.37 725.42
1147.57 1147.44 PAPMPPyP 919.47 919.42 MPPyPAP 822.42 822.35


























1050.51 1050.49 yPAPMPPPAPM 1218.60 1218.69 +1, -Prenyl 1344.65 1344.53
1147.57 1147.44 yPAPMPPPAPMP 1315.66 1315.52 APMPPPAPMPPy -Prenyl 1315.66 1315.52
1244.62 1244.59 PAP 266.15 266.13
1315.66 1315.52 PAPM 397.19 397.17
426.24 426.29 PAPMP 494.24 494.26
523.29 523.34 PAPMPP 591.30 591.30
594.33 594.35 PAPMPPP 688.35 688.32
822.42 822.35 PAPMPPPA 759.39 759.31
919.47 919.42 PAPMPPPAP 856.44 856.39
1016.53 1016.46 PAPMPPPAPM 987.48 987.38
1184.62 1184.51 PAPMPPPAPMP 1084.53 1084.64
426.24 426.29
594.33 594.35  y- b- cleavages (+2)
725.37 725.42 PMPPPAPMPP 507.25 507.41
822.42 822.35 APMPPPAPMPP 542.77 542.73
919.47 919.42 PPPAPMPPyPA 592.81 592.62
1016.53 1016.46 PPyPAPMPPPAP 641.34 641.54
1087.56 1087.50
1184.62 1184.51 Miscellaneous Ions
1315.66 1315.52 PPPAPMPPyPA, -Prenyl, +2 607.30 607.41
725.37 725.42 +2 -Prenyl, -Methyl Sulfide 648.83 648.90
822.42 822.35 +2, -Prenyl, -Acylium 658.83 658.68
919.47 919.42 +2, -Prenyl 672.82 672.90
990.51 990.48 PPPAPMPPy -Prenyl 948.46 948.43























































(o) MS-MS spectra for early (top) and late (bottom) eluting singly prenylated products of the reaction 





cyclo[APMPPYPAPMPPYP] 1st peak (C-prenyl)


























397.19 397.11 MPPYPAPMPPyPA 1478.72 1478.54 PAPMPPyP 919.47 919.44
494.24 494.44 PPY 358.18 358.22 PAPMPPyPA 990.51 990.48
754.36 754.31 PPYPA 526.27 526.27 PAPMPPyPAPM 1218.60 1218.53
922.45 922.41 PPYPAP 623.32 623.26 APMP 397.19 397.11
1150.54 1150.39 PPYPAPM 754.36 754.31 APMPP 494.24 494.44
1247.60 1247.45 PPYPAPMP 851.41 851.43 APMPPyP 822.42 822.35
1478.72 1478.54 PPYPAPMPP 948.47 948.45 APMPPyPA 893.46 893.51
229.10 229.12 PPYPAPMPPy 1179.59 1179.47 APMPPyPAP 990.51 990.48
326.15 326.25 PPYPAPMPPyPA 1347.68 1347.58 APMPPyPAPM 1121.55 1121.39
586.27 586.33 PYP 358.18 358.22 APMPPyPAPMP 1218.60 1218.53
683.32 683.39 PYPAP 526.27 526.27 APMPPyPAPMPPY 1478.72 1478.54
754.36 754.31 PYPAPMP 754.36 754.31 PM 229.10 229.12
851.41 851.43 PYPAPMPP 851.41 851.43 PMP 326.15 326.25
982.45 982.35 PYPAPMPPy 1082.54 1082.51 PMPPy 654.33 654.35
1079.51 1079.44 PYPAPMPPyP 1179.59 1179.47 PMPPyPA 822.42 822.35
1407.68 1407.57 PYPAPMPPyPAP 1347.68 1347.58 PMPPyPAP 919.47 919.44
229.10 229.12 PYPAPMPPyPAPM 1478.72 1478.54 PMPPyPAPM 1050.51 1050.51
326.15 326.25 YPAPMPP 754.36 754.31 PMPPyPAPMP 1147.57 1147.53
586.27 586.33 YPAPMPPy 985.48 985.32 PMPPyPAPMPPY 1407.68 1407.57
754.36 754.31 YPAPMPPyP 1082.54 1082.51 MP 229.10 229.12
982.45 982.35 YPAPMPPyPAPMP 1478.72 1478.54 MPP 326.15 326.25
1079.51 1079.44 PAP 266.15 266.18 MPPyP 654.33 654.35
1310.63 1310.53 PAPM 397.19 397.11 MPPyPAP 822.42 822.35
1407.68 1407.57 PAPMP 494.24 494.44 MPPyPAPM 953.46 953.57
1478.72 1478.54 PAPMPPy 822.42 822.35 MPPyPAPMP 1050.51 1050.51


























1147.57 1147.33 PAPMP 494.24 494.44 PAPMPPyP 919.47 919.44
1310.63 1310.54 PAPMPPY 754.36 754.31 PAPMPPyPA 990.51 990.48
1407.68 1407.57 PAPMPPYP 851.41 851.43 PAPMPPyPAPM 1218.60 1218.53
1478.72 1478.54 PAPMPPYPA 922.45 922.41 APMP 397.19 397.11
426.24 426.20 PAPMPPYPAP 1019.50 1019.39 APMPP 494.24 494.44
594.33 594.35 PAPMPPYPAPM 1150.54 1150.39 APMPPyP 822.42 822.35
822.42 822.35 PAPMPPYPAPMP 1247.60 1247.45 APMPPyPA 893.46 893.51
919.47 919.44 APMPPyPAP 990.51 990.48
1016.53 1016.55 y- b- cleavages (+2) APMPPyPAPM 1121.55 1121.39
1179.59 1179.47 PPYPAPMPPyPAP 722.87 723.08 APMPPyPAPMP 1218.60 1218.53
1347.68 1347.58 PMPPYPAPMPPy 704.35 704.36 APMPPyPAPMPPY 1478.72 1478.54
426.24 426.20 PyPAPMPPYPAP 674.34 674.50 PM 229.10 229.12
594.33 594.35 PPyPAPMPPYP 638.82 638.82 PMP 326.15 326.25
725.37 725.31 PAPMPPYPAPMP 624.30 624.46 PMPPy 654.33 654.35
822.42 822.35 PMPPyPA 822.42 822.35
919.47 919.44 Miscelaneous Ions PMPPyPAP 919.47 919.44
1082.54 1082.51 PAPM y- a- cleavage 369.20 329.29 PMPPyPAPM 1050.51 1050.51
1179.59 1179.47 PAPM -Met sidechain 321.16 321.31 PMPPyPAPMP 1147.57 1147.53
1347.68 1347.58 PMPPyPAPMPPY 1407.68 1407.57
1478.72 1478.54 MP 229.10 229.12
822.42 822.35 MPP 326.15 326.25
1082.54 1082.51 MPPyP 654.33 654.35
1478.72 1478.54 MPPyPAP 822.42 822.35
266.15 266.18 MPPyPAPM 953.46 953.57
397.19 397.11 MPPyPAPMP 1050.51 1050.51
(p) MS-MS assignments for singly prenylated cyclo[APMPPYPAPMPPYP] early (this page) and late 





cyclo[APMPPYPAPMPPYP] 2nd peak (O-prenyl)


























300.14 299.94 PPYP 455.23 455.40 YPAPMPPyPAPM 1,381.67 1,381.54
397.19 397.14 PPYPA 526.27 526.33 YPAPMPPyPAPMP 1,478.72 1,478.47
494.24 494.28 PPYPAP 623.32 623.43 PAP 266.15 266.23
754.36 754.43 PPYPAPM 754.36 754.43 PAPM 397.19 397.14
922.45 922.38 PPYPAPMP 851.41 851.42 PAPMP 494.24 494.28
1,150.54 1,150.45 PPYPAPMPP 948.47 948.54 PAPMPPy 822.42 822.39
1,247.60 1,247.60 PPYPAPMPPy 1,179.59 1,179.49 PAPMPPyPA 990.51 990.48
1,478.72 1,478.47 PPYPAPMPPyP 1,276.64 1,276.48 PAPMPPyPAPM 1,218.60 1,218.51
229.10 229.08 PPYPAPMPPyPA 1,347.68 1,347.60 APM 300.14 299.94
586.27 586.30 PYP 358.18 358.23 APMP 397.19 397.14
683.32 683.13 PYPA 429.21 429.36 APMPP 494.24 494.28
754.36 754.43 PYPAP 526.27 526.33 APMPPyP 822.42 822.39
851.41 851.42 PYPAPMP 754.36 754.43 APMPPyPAP 990.51 990.48
982.45 982.37 PYPAPMPP 851.41 851.42 APMPPyPAPM 1,121.55 1,121.51
1,079.51 1,079.40 PYPAPMPPy 1,082.54 1,082.45 APMPPyPAPMP 1,218.60 1,218.51
1,407.68 1,407.52 PYPAPMPPyP 1,179.59 1,179.49 APMPPyPAPMPP 1,315.66 1,315.55
229.10 229.08 PYPAPMPPyPA 1,250.63 1,250.73 APMPPyPAPMPPY 1,478.72 1,478.47
586.27 586.30 PYPAPMPPyPAP 1,347.68 1,347.60 PM 229.10 229.08
754.36 754.43 PYPAPMPPyPAPM 1,478.72 1,478.47 PMPPy 654.33 654.38
982.45 982.37 YPA 332.16 332.38 PMPPyPA 822.42 822.39
1,079.51 1,079.40 YPAP 429.21 429.36 PMPPyPAPM 1,050.51 1,050.47
1,310.63 1,310.66 YPAPMPP 754.36 754.43 PMPPyPAPMP 1,147.57 1,147.46
1,407.68 1,407.60 YPAPMPPyP 1,082.54 1,082.45 PMPPyPAPMPPY 1,407.68 1,407.52
1,478.72 1,478.47 YPAPMPPyPA 1,153.57 1,153.43 MP 229.10 229.08
358.18 358.23 YPAPMPPyPAP 1,250.63 1,250.73 MPPy 557.28 557.92cyclo[APMPPYPAPMPPYP] 2nd peak (O-prenyl)


























654.33 654.38 PAP 266.15 266.23
822.42 822.39 PAPM 397.19 397.14
1,050.51 1,050.47 PAPMP 494.24 494.28
1,147.57 1,147.46 PAPMPPY 754.36 754.43
1,310.63 1,310.66 PAPMPPYP 851.41 851.42
1,407.68 1,407.52 PAPMPPYPA 922.45 922.38
1,478.72 1,478.47 PAPMPPYPAPM 1,150.54 1,150.45
426.24 426.23 PAPMPPYPAPMP 1,247.60 1,247.60
594.33 594.29
822.42 822.39 y- b- cleavages (+2)
1,179.59 1,179.49 MPPYPAPMPPyPA 739.86 739.82
1,347.68 1,347.60 PMPPYPAPMPPy 704.34 704.32
426.24 426.23 MPPYPAPMPP 540.26 540.27
594.33 594.29
822.42 822.39 Miscellaneous Ions
1,082.54 1,082.45 PyPAPMPPYPAP +2 674.34 674.51
1,179.59 1,179.49 PPyPAPMPPYPAP -prenyl +2 688.84 688.96
1,250.63 1,250.73 PPyPAPMPPYPAP +2 722.87 723.08
1,347.68 1,347.60 PYPAPMPPYP -prenyl +1 1,111.53 1,111.48
1,478.72 1,478.47 APMPPYPAPMP -prenyl +1 1,150.54 1,150.45




























































(s) MS-MS spectra for early (top) and late (bottom) eluting doubly prenylated products of the 





cyclo[APMPPYPAPMPPYP] 1st peak 


























397.19 397.17 PPyPAPMPP 1016.53 1016.45 PAPMPPyPAPMP 1315.66 1315.55
725.37 725.40 PPyPAPMPPy 1247.66 1247.57
990.51 990.40 PPyPAPMPPyP 1344.71 1344.76 y- b- cleavage (+2)
1121.55 1121.41 PPyPAPMPPyPA 1415.75 1415.59 PPyPAPMPPyPAP 756.90 757.07
1218.60 1218.48 PyP 426.24 426.28 PyPAPMPPyPAP 708.38 708.30
1315.66 1315.55 PyPA 497.27 497.35 PPyPAPMPPyP 672.35 672.83
1546.79 1546.40 PyPAP 594.33 594.28 APMPPyPAPMPP 657.83 658.47
326.15 326.18 PyPAPM 725.37 725.40 PyPAPMPPyP 623.83 624.14
423.21 423.13 PyPAPMPP 919.47 919.48 APMPPyPAPMP 609.30 609.98
654.33 654.26 PyPAPMPPy 1150.61 1150.59
919.47 919.48 PyPAPMPPyP 1247.66 1247.57 Miscellaneous Ions
1050.51 1050.35 PyPAPMPPyPAP 1415.75 1415.59 PAPM -Met sidechain 321.16 321.21
1147.57 1147.56 PyPAPMPPyPAPM 1546.79 1546.40 PAPM y- a- cleavage 369.20 369.22
1475.75 1475.56 yPAP 497.27 497.35 PyPAP y- a- cleavage 566.33 566.27
326.15 326.18 yPAPMP 725.37 725.40 PMPPyPA -Met sidechain 746.39 746.39
557.28 557.30 yPAPMPPyP 1150.61 1150.59 APMPPyP y- a- cleavage 794.43 794.31
654.33 654.26 yPAPMPPyPA 1221.64 1221.67
725.37 725.40 yPAPMPPyPAPMP 1546.79 1546.40
1050.51 1050.35 PAP 266.15 266.04
1147.57 1147.56 PAPM 397.19 397.17
1475.75 1475.56 PAPMP 494.24 494.10
426.24 426.28 PAPMPPyP 919.47 919.48
594.33 594.28 PAPMPPyPA 990.51 990.40
691.38 691.16 PAPMPPyPAP 1087.56 1087.74
919.47 919.48 PAPMPPyPAPM 1218.60 1218.48
cyclo[APMPPYPAPMPPYP] 2nd peak


































PAPM y- a- 
cleavage





APMPPyP y- a- 
cleavage
PPyPAPMPPyPAP 
-1 prenyl, +2 ion





397.19 397.17 PyPAP 594.33 594.34 PPyPAPMPPyPAP -prenyl, +2 722.87 723.13
725.37 725.38 PyPAPM 725.37 725.38 All, -prenyl, +2 788.39 788.45
990.51 990.52 PyPAPMPP 919.47 919.49 PPyPAPMPPy, -prenyl +1 1179.59 1179.53
1121.55 1121.56 PyPAPMPPy 1150.61 1150.46 PPyPAPMPPyPA, -prenyl +1 1347.68 1347.65
1218.60 1218.43 PyPAPMPPyP 1247.66 1247.55 PyPAPMPPyPAP -prenyl +2 674.34 674.55
1315.66 1315.68 PyPAPMPPyPAP 1415.75 1415.75
423.21 423.26 yPAPMP 725.37 725.38
654.33 654.38 yPAPMPPyP 1150.61 1150.46
919.47 919.49 PAP 266.15 266.10
1050.51 1050.51 PAPM 397.19 397.17
1475.75 1475.66 PAPMPPyP 919.47 919.49
557.28 557.38 PAPMPPyPA 990.51 990.52
654.33 654.38 PAPMPPyPAPM 1218.60 1218.43
725.37 725.38 PAPMPPyPAPMP 1315.66 1315.68
1050.51 1050.51
1475.75 1475.66 y- b- cleavages (+2)
426.24 426.28 PyPAPMPPyPAP 708.38 708.66
523.29 523.43 PPyPAPMPPyPAP 756.90 756.79
594.33 594.34
691.38 691.37 Miscellaneous Ions
919.47 919.49 PAPM -Met sidechain 321.16 321.20
1016.53 1016.41 PAPM y- a- cleavage 369.20 369.11
1247.66 1247.55 PyPAP y- a- cleavage 566.33 566.41
1415.75 1415.75 PMPPyPA -Met sidechain 746.39 746.40












(t) MS-MS assignments for doubly prenylated cyclo[APMPPYPAPMPPYP] early (top) and late 











(v) LC-FT-ICR chromatogram selected for mass of prenylated cyclo[KKPYILP]; in this case alone 
was only a single broad chromatographic peak observed, most likely indicating that C- and O-




































257.20 - ILPKKP 677.47 -
354.25 354.27 LP 211.14 -
585.37 - LPK 339.24 339.28
698.46 698.44 LPKK 467.33 467.34
811.54 811.53 LPKKP 564.39 -
226.16 - LPKKPy 795.51 795.45
457.28 - PK 226.16 -
570.36 - PKK 354.25 354.27
683.45 - PKKP 451.30 -
780.50 780.49 PKKPy 682.43 682.43
329.18 329.17 PKKPyI 795.51 795.45
442.27 442.16
555.35 555.24 y- b- cleavages (+2)
652.40 - KKPyI 349.74 349.83
780.50 780.49 PKKPyI 398.26 398.35
345.22 345.23 PKKPy 341.72 341.87
458.30 -
555.35 555.24 Miscellaneous Ions
683.45 - All -prenyl +1 840.54 840.46
811.54 811.53 All -prenyl +2 420.77 420.85
227.18 227.21 All -NH3, +2 446.29 446.31
324.23 - All -acylium, +2 440.81 440.98
452.32 - Py y- a- cleavage +1 301.19 301.21
580.42 580.39
(x) MS-MS assignments for prenylated cyclo[KKPYILP] single peak; assignments consistent with 















             
 S32 
(aa) MS-MS spectra for early (top) and late (bottom) eluting products of reaction of LynF with 





cyclo[KPYILP] 1st peak (C-prenyl)

























226.16 226.23 KPyIL 342.23 342.25
457.28 457.37 PKPyI 334.22 334.27
570.36 570.39
683.45 683.41 Miscellaneous Ions
329.18 329.17 All -H2O 762.49 762.44
442.27 442.25 All -acylium 752.51 752.41
555.35 555.32 PKPy -H2O 536.32 536.34

















cyclo[KPYILP] 2nd peak (O-prenyl)

























226.16 226.26 KPyIL 342.23 -
457.28 - PKPyI 334.22 -
570.36 -
683.45 - Miscellaneous Ions
329.18 329.11 All -H2O 762.49 762.47
442.27 442.22 All -acylium 752.51 752.49
555.35 555.25 All -prenyl 712.44 712.39
652.40 652.38 All -H2O, -prenyl 694.43 694.42
345.22 345.11 PKPy -H2O 536.32 536.30






















































(ee) MS-MS spectra for early (top) and late (bottom) eluting products of reaction of LynF with 







KPYILP 1st peak (C-prenyl)













































KPYILP 2nd peak (O-prenyl)































































































Figure S2. Precursor peptides are not substrates for prenyltransfer (a) ESI-MS intact analysis of time 
points taken from a reaction containing TruLy1, LynF and standard additives at 0, 6, 12, 24 h 
(deconvoluted spectra shown); expected mass of unmodified TruLy1 is 9104 Da.  No reaction is 
observed even after 24 h incubation at 37 °C (b) Incorporation of tritiated DMAPP into various 











































Figure S3.  NMR characterization of substrates cyclo[APMPPYP] and boc-L-tyrosine (a) HSQC of 
cyclo[APMPPYP] (b) HSQC of prenylated cyclo[APMPPYP] (c) Overlay of (a) and (b) data  (d) 



















































129.86 7.06 Tyr Cδ1 130.08 6.92
114.96 6.67 Tyr Cδ2 126.85 6.89
61.12 4.01 C2 of 3-methyl-2-buten-1-
yl adduct
122.9 5.23
60.15 4.25 Tyr Cε 114.61 6.68
60.25 4.50 Pro Cα 61.07 4.02
58.64 4.69 Pro Cα 60.13 4.22
53.66 4.50 Pro Cα 60.13 4.50
49.52 4.82 Pro Cα 58.59 4.69
47.22 3.91 Tyr Cα 53.57 4.50
47.22 3.67 Met Cα 49.48 4.81
3.53 Ala Cα 47.24 3.91
46.74 3.81 Pro Cδ 47.06 3.66
46.12 3.41 3.53
3.34 Pro Cδ 46.75 3.79
46.09 3.24 3.62
3.09 Pro Cδ 46.02 3.40
39.51 2.49 Pro Cδ 45.79 3.22
34.53 3.11 3.05
2.74 DMSO 39.51 3.49
31.4 1.98 Tyr Cβ 34.61 3.08
1.88 2.70
30.82 2.19 C1 of 3-methyl-2-buten-1-
yl adduct
28.13 3.15
2.12 Pro Cβ 31.34 1.88
30.48 2.07 30.87 2.02
1.88 Met Cγ 30.83 2.20
28.57 2.50 2.12
2.40 Pro Cβ 30.52 2.05
28.36 2.21 1.89
1.71 Met Cβ 29.18 2.39
27.68 2.24 Pro Cβ 28.45 2.21
1.67 1.71
25.5 2.02 Pro Cβ 27.62 2.24
1.91 1.67
24.89 1.96 Pro Cγ 25.39 2.02
1.83 1.90
21.5 1.89 trans methyl of 3-methyl-2-
buten-1-yl adduct
25.27 1.65
1.65 Pro Cγ 24.82 1.97
21.14 1.77 1.83
1.61 Pro Cγ 21.43 1.91
17.32 1.20 1.62
15.42 1.21 Pro Cγ 21.03 1.77
14.54 2.03 1.58
1.99 cis methyl of 3-methyl-2-
buten-1-yl adduct
17.31 1.65
1.58 Ala Cβ (rotamers) 17.31 1.20
15.45 1.21



















































Figure S4. Spectral properties of C- and O-prenylated tyrosyl componds (a) Left: LC-FT-ICR peaks 
and chromatograms selected for the mass of prenylated cyclo[APMPPYP] from unpurified reaction 
mixtures; note that two separable compounds corresponding to the mass of cyclo[APMPPYP] are 
present.  Right: Analysis by LC-FT-ICR of the NMR-characterized C-prenylated cyclo[APMPPYP]; 
for this compound only a single peak with a mass corresponding to prenylated cyclo[APMPPYP] is 
observed (b) MS-MS spectra for early (top) and late (bottom) eluting-species observed in initial 
cyclo[APMPPYP] reaction mixtures and tables of assignments; assignments for early-eluting species 
consistent with C-prenylation, while those for the late-eluting species consistent with O-prenylation 
(c) Table of assignments for O- and C-prenylated compounds (d) MS-MS spectrum for NMR-
characterized C-prenylated cyclo[APMPPYP]; MS-MS shows no loss of isoprene (e) Table of 






















APMPPYP 1st peak (C-prenyl)



































APMPPYP 2nd peak (O-prenyl)























































cyclo[APMPPYP] NMR-characterized C-prenyl reference compound


























169.10 - yP 329.19 329.24
300.14 - yPA 400.22 -
397.19 397.19 yPAP 497.28 497.24
494.24 494.28 yPAPM 628.32 628.34
725.37 725.35 yPAPMP 725.37 725.35
229.10 - PA 169.10 -
326.15 - PAP 266.15 266.28
423.21 423.35 PAPM 397.19 397.19
654.33 654.30 PAPMP 494.24 494.28
751.39 751.32 PAPMPP 591.30 -
229.10 -
326.15 - Miscellaneous Ions
557.28 557.29 -Acylium (C=O) 794.42 794.38
654.33 654.30 -Methyl sulfide 774.42 774.40
725.37 725.35 -Met side-chain 746.39 746.43
195.11 - -H2O 804.41 804.39
426.24 426.24 PyPAP y- a- cleavage 566.33 566.38
523.29 523.34 PAPM y- a- cleavage 369.20 369.21
594.33 594.30 PAPM -Met sidechain 321.16 321.22













Figure S5.  Analysis of reverse O-prenylated intermediate and C-prenylated product (a) 1H NMR of 
boc-D-Tyr reverse O-prenylated intermediate (b) 2D COSY spectrum of boc-D-Tyr reverse O-
prenylated intermediate (c) 1H NMR of boc-D-Tyr forward C-prenylated final product (d) circular 
dichroism spectral overlays of (top) boc-L-Tyr (blue) and boc-D-Tyr (red) and (bottom) C-prenyl 









































































Figure S6.  Non-enzymatic rearrangement of reverse O-prenylated tyrosine.  Bar graph showing 
proportions of reverse O-prenylated intermediate and C-prenylated final product after incubation at 
37 °C for 0 and 8 h under different conditions.  The O-prenylated intermediate is sufficiently unstable 
that after islolation it was partially rearranged.   Proportions of products determined by integration of 






















Best-fit values for Boc-L-Tyr kinetics
     Vmax 5.7E-05 M/h
     Km 14.0 mM
     kcat 63.3 h-1
Std. Error
     Vmax 3.9E-06 M/h
     Km 1.6 mM
95% Confidence Intervals
     Vmax 4.9e-005 to 6.6e-005 M/h
















Figure S7.  Kinetics of prenylation of cyclo[APMPPYP] and boc-L-tyrosine. Rates were measured 
by integration of product peaks observed in the monitoring of the HPLC elution 220 nm. Both the C- 
and O-prenylated products were summed to obtain the total amount of prenylated products at each 
point.  Areas were then plotted on a calibration curve created via injections of known quantities of 
boc-L-Tyr to derive concentrations (a) Kinetics for reaction of Boc-L-Tyr with LynF (b) Kinetics for 























Best-fit values for cyclo[APMPPYP] kinetics
     Vmax 2.4E-05 M/h
     Km 4.2 mM
     kcat 13 h-1
Std. Error
     Vmax 8.3E-07 M/h
     Km 0.4 mM
95% Confidence Intervals
     Vmax 2.2e-005 to 2.5e-005 M











































































TruF1           ---------MIMTTTWPDSYAKERRIQRLRHHFESFDVERAFPLPLFEQAVLSLDSCPLL 
LynF            ------MTIMAIANRVPYNYLREQRIQFMHAHQDAFDVSTVFPLPLFEKLVTELEGSNVI 
AcyF            ----------MIANVTQKDRFQEQKLQFIRNHQQAFDVEPIYPLPLFEDFVMNVEGDCSI 
PagF            ----------MIVNVIQKDRLKEQKLQFIRNHQQAFDVEPIYPLPLFEDFVTSIEGDCSL 
Mic843F         ----------MIVADIQKSSLKEQRLQFIRNHQQAFDVEPIYPLRLFEDFVMGVEGDCTI 
ArtF            ---------MNCTSVLQQNHLREKRLQFIRAHQTAFDVEPVFPLQVFEDFVFGVEGDCTI 
TheF            -------------------MPREQRLQFIKAHQAAFEVEPLYPLALFEALVETFDEDCAL 
OscF            MIILSASDSTRPIFTLPKPLTQEQKLHCINAHRQAFDVQPLYPLDIFQDFITKTDGIDTI 
 
MicF1           ---------MTLTSMLKNNHLKARRLQFLRGHQEAFDVEPTFMLSLFEEAVLGIEETCGV 
MicF2           ---------MTLTSMLTNNHLKARRLQFLRGYQEAFDVEPNFMLSLFEEAVLGIEETCGV 
TenF            ---------MTLTSMLQNNRLKDRRLQFIRTHQEAFDVEPTFILSLFEEAVLGIEGTCGV 
PatF            ---------MDLIDRLQNNQRKDRRLQFVRTHQEAFDVKPTFPLPLFEEAILEIEGSCSV 
TruF2           ---------MVLSQLSKQTNLRENRLRCIRTHLEAFDIEPVLQISLFEEVIMEVEGSCNV 
 
 
TruF1           EPSFKVQEGILFAGRVTTST-GT-EDWQHLISTALNFFDAVESRVEVTIDRGLLEKFLTL 
LynF            ELSCKIEADKLLAGRFLIFS-DQENNWHQSLAQALQFLDSIESRVGVEINRESLDKFLAA 
AcyF            EASCKIELDKLIASRFMFFFKDKAQQWQKYLHQSLTFFNRVENLVGVQVDYSLLRQFLGS 
PagF            EASCKIESDKLIASRFLLFFEDKTQEWQKYLHQSLTFFGLVENRVGVKINYSLLQQFLGS 
Mic843F         QASCKIELDQLIASRFMLFFKDKAQEWQNYLAQSLAFFRQVENRVGVKLDYSLLQQFLGL 
ArtF            EASCKVESDHLIASRFLLFFQEMTQSWPQKLDQAFRFFHQTENQVGVRLDYGLLQHFLGD 
TheF            EASCKIEFDQLIASRFLIFF---SQNFEQNLARVLNFMTQVNQRVDVQINTDLLYHFLGQ 
OscF            EASCKIEADKLQAARFVALS---SQEIERKLTEFLTFFRQVESRVDVQLNYDLLHKFLGK 
 
MicF1           ESKCNVEKDQLFAIDFQVCN-DQGRTWPMSLTHAVKFMDKIESTVGVRLNRNLLEQFATL 
MicF2           ESKCNVEKDQLFAIDFQVCN-DQGRTWPMSLTHAVKFMDKIESTVGVRLNRNLLEQFATL 
TenF            ELMCHVEGDQLFAVDFQVSN-ER-HTWPRSLTDAVKFLDKVESQVGVRLNRDLLQQFVAV 
PatF            ESSCQVEGDRLQGGRYEVCN-NQGTTWPESLTHAFKLLDKIDSQLGVRINRDSFDRFAAA 
TruF2           KCSCKVERDRLFACQFTLAY-SQ-QKWPKTLKYNAILFDKIKSQVGICIDSSKFEQFSRL 
 
 
TruF1           HQNSDKIEASLMGIDLRPNVKESSLKVHLRLDPQQDADELVMTAIDLDGGDYSPELTQVL 
LynF            HINSGKIMGISTGLDLRPELENSSVKIHIMLG--ENSEELVRTAIAIDGSHYPVELAQVL 
AcyF            DFDFRKVTVLSAGIDLRSNIAESSLKMHIRIKDYPE---KLDQALSLAS-NAED--LISV 
PagF            SFDFSKVTVLSAGIDLRNNLAESSLKMHIRIKDYPE---KLDKAFALSD-GAAD--GNYL 
Mic843F         NFNFSKITVFSTGIDLRTNLADSSLKMHIRLKDYPE---KINQALLLTS-DSDD--LIAV 
ArtF            DFDFSKISVLSTGIDLRQNLADSSLKMHITIEDYPE---KIATAFSLAK-LPRDKFHQIL 
TheF            KFDFRKMIRLATGVDLRSNLADSSLKIHIRLEDYPE---KIESALALHG-NPDDASYWAD 
OscF            SFDFSKVTRITTGVDLRPNISDSSLKIHIRLNDHPENLKKIEAALTLDG-NDSTAQRWIA 
 
MicF1           HMDSHKIENNTVGIDLRPKNEDSCIKVCLHLGSEEEPEELVRTALELDGGSYSPELLQVL 
MicF2           HLDSHKIQDNTVGIDLRPRNEDSCIKVYLHLGSEEEPEELVRTALELDGGSYSPELLQVL 
TenF            HIGSSKILNNTIGIDLRPRHENSCIKVYMHIEHEEDPEELVRTALKLDGDSYSSEMLQVL 
PatF            HVNSRKIINNTIGVHLGSKLEDSSVMLYIHIKPEEDTEELARTALVLDGGRYSDELTRVL 
TruF2           HVNSDKILDSTVGIDLRPKSQDSCIRISVHLEPKESPEELVRTALALDNATYTSELTQVF 
 
 
Figure S8.  Multiple sequence alignments of LynF relatives.  Highlighted in yellow are residues 
conserved across all known LynF homologues, in green are residues conserved across enzymes 











TruF1           LKDTFLIGFDFFLDGGSAVEMYTICPGKKPLAMLGKKGAYLKPYVLSNFSHKVTSLLQEV 
LynF            LKDTMMIGFDFFLNGHSEVELYISCSRKKDSLPN-NRGESTRYYIRQKFSPKVSSLLDAS 
AcyF            RPFLSLVGFDFYFNGRSEIELYPEIQAEDFAKSE------TQNLVWRHFPKFVLDPLEVT 
PagF            KDFVNLIGFDFYFNGKSEIEIYAEVQEDDFFKPE------INNLVWQHFPKTALQPLKAS 
Mic843F         RDFLSIVGFDFYFDGRSAIKIYPEVAETDFFKPE------TQDKVWRHLPKFVLEPLKAT 
ArtF            LSSVSLIGFDFYLDGRSEIELYASLKEEEFNSPH------VQSFLTSNFCASALKPLAAS 
TheF            LNAIANIGLDFYLDGRSEIEFYPELSEERFQQPE------MQVLLQQMFPPFVLAPLKAS 
OscF            LQTVHLIGFDFYLNGRSEIELYCELTEKQFQQPD------IQSFLQQTFPPFVLEPLKVS 
 
MicF1           LKSTIVIGFNLFLNGYSDIELWALAPGEQYEITNSDRGKYLKHYIQRNFSPKVNSLLKEC 
MicF2           LKSTIVIGFNLFLNGYSDLELWATCPGEQYEVPNSDRGKYLKQYVQNNFSQKINDLLRES 
TenF            LKSTIIIGFNIFFNGYSDVELLVATVGDKYESHKFNRGKYLKHYIQKNFSLKANYMLRES 
PatF            LRDTMVIGFELFFDGRSRVDLGPCAPGK--SGTLKMKGKHLEQYTQKNLSRKVNSIFREG 
TruF2           LQDCTAIIFECFFDGRSRIELGAVAPGKKHGFSG-NHGRALTAYAQKYFSPKAVSLSEVS 
            
 
TruF1           AALTVGFSKEN-PRPVLYFEFETLREVKYNLLFNSLGDKIYDFCLHNQIENFVSIGVTEP 
LynF            DFFVGGFSKAN-VEPVLYYAFENIKDIPKYFVFNDLGNRVYDFCRSQDSITMTWIGINER 
AcyF            GSFLVGFSKAN-PNPVLYYNLKNKQDLANYFKLNDAAQRVHSFYQNQDILPHMWVGTVQK 
PagF            SLFFTGLSKAN-NNPVLYYHLKNRQDLTNYFKLNDTAQRVHSFYQHQDILPYMWVGTAQK 
Mic843F         SLFGFGFSKTN-NNPVLYYRLKNRQDLTNYFKLNDTAQRVHSFYQHQDILSSVWLGTAQQ 
ArtF            SAFYMGLSIAN-ENPVLYYLLKNKQELQNYFRLNDTGNRVHSLL---------------- 
TheF            EIFGFGLSKAN-PSAVLYYQLKNKQDLPSYFAINDKAHQVHGYYLHQDTRPYMCVGVAQS 
OscF            SVFFTGLSKDN-TEPVLYYCLKDKKDLLSYFPINDTAQRVHAFYQNQPVYSSMWVGVAQG 
 
MicF1           TFFCVSFFHKK--EPVIIFHYEDTKEIPKNFFFNSLGDRIYSFCQGQDCMTYAGVAVTER 
MicF2           TFLVVSFSNQK--EPALIFHYEDIKEIPKNFLLNSLGDRIYSFCQGQDCMTYAGVAVTER 
TenF            NILLVSFSQAKKVNPLLIFHYEDIKDIRKYFSFNSLGDRSYSFFQSQDCITYAGVSVREL 
PatF            YLFGAFFSKTR-VEPILFFYHSIIKDLPKYFTFNSLGDKIYNFCQSQGCITDVAIAVTET 
TruF2           DLFGMTISKYK-AEPVLHFGFNNIKDISNYFLFNTLGNRIYSFCQNQDCILLAIIGVNEK 
 
 
TruF1           DLEKRRLENFRFYYRKAV--------------- 
LynF            DLDRERLNNFRLYYRRSFG-------------- 
AcyF            ELEKTRIENVRLYYYKFFN-------------- 
PagF            ELEKTRIENIRLYYYKSFKMESN---------- 
Mic843F         ELEKTRIENVRLYYYKLFGKL------------ 
ArtF            --------------------------------- 
TheF            ELAKTRIDQIRLYYHQFFKVQNP---------- 
OscF            ELQKTRIDNIRLYYSKKNYSK------------ 
 
MicF1           ELEKDRLENFSILYNQRDECKPLLHIKKREDFS 
MicF2           ELEKDRLENFSILYNQRDECKPLLHIKKREDFS 
TenF            ELQKDRLEKFSLFYNKRDKCQHLPLFSTLNE-- 
PatF            ELEKSRLENFCFYYDQWDECKPSSDYDTERHLH 







Figure S9.  Sizing column chromatogram for LynF and resulting SDS-PAGE gel (a) Size-exclusion 
chromatogram showing elution of LynF.  Protein elution was detected at 280 nm, and is shown in 
mAu; along the x-axis is time in minutes and fraction number (the fraction size was 4.5 mL).  Purest 
fractions ultimately used for experiments are highlighted with box (b) SDS-PAGE gel showing 
analysis of size-exclusion chromatography fractions; fractions 13-15 of size purification used for 
most experiments described in paper.  Key to abbreviations: E1=Ni-NTA elution 1, E2=Ni-NTA 
elution 2, T=after treatment with thrombin to cleave his-tag, Inj=sample of material injected on sizing 
column, 8-27=sizing column fraction number, L=ladder, Std=previously prepared LynF sample 















Materials and Methods 
Synthesis of substrates. 
Dimethylallyl pyrophosphate (DMAPP) was synthesized following previously established 
procedures.1-3  Briefly,  disodium dihydrogen pyrophosphate (15 mmol, 3.3g) was dissolved in 15 mL 
of a 10% (v/v) solution of ammonium hydroxide.  That solution was put over a column containing 
Dowex AG 50W-X8 column (58 mequiv, acidic form), and eluted with 110 mL of deionized water to 
give the free acid.   The eluent was titrated to pH 7.3 (as measured by a pH meter) with a 40% 
solution of tetra-n-butylammonium hydroxide.  The solution was then dried by lyophilization to give 
tris(tetra-n-butylammonium) hydrogen pyrophosphate (32).  Next, 32 (2.5 mmol, 2.3g) was dissolved 
in 2.5 mL of acetonitrile.  The pyrophosphate solution was placed on ice, with stirring under a 
blanket of argon.  Dimethylallyl bromide (1.2 mmol, 1 M in acetonitrile) was then added dropwise to 
the pyrophsophate solution.  The reaction proceeded for 2 h, during which time it was allowed to 
come to room temperature.  After solvent removal, the residue was dissolved in ion-exchange buffer 
(1:49 v/v Isopropanol : 25 mM aqueous ammonium bicarbonate) and run on a column containing 
Dowex AG 50W-X8 (18.8 mequiv, ammonium form).  Finally, chromatography on cellulose (2, 3) 
afforded dimethylallyl pyrophosphate, ammonium salt.  1H NMR (400 MHz, D2O) ! 5.39 (1H, t, 
J=7.03 Hz), 4.39 (2H, dd, JH,H=6.64 Hz, JH,P=6.64 Hz), 1.70 (3H, s), 1.66 (3H, s); 31P NMR (162 
MHz, D2O) ! -5.96 (1P, d, JP,P=21.7 Hz), -9.23 (1P, d, JP,P=20.6). 
 Unless otherwise noted, peptide substrates were synthesized at the University of Utah 
DNA/peptide synthesis core facility using standard Fmoc chemistry.  Cyclic peptide 6 was cyclized 
in solution, leading to small amounts of 9 and 10.  HPLC purification effected purification of 6 from 
9 and 10, which co-eluted and were used as a mixture in prenyltransferase experiments.   Substrates 
11 and 12 were was synthesized as a linear precursor (KKPYILPAYDGE) and then enzymatically 
cyclized as reported elsewhere.4  Synthesis and characterization of 26 and 27 has been previously 
reported.5,6  
 Boc-protection of 4-iodo-L-phenylalnine and 4-methoxy-L-phenylalanine was performed 
according to previously established procedures.7 Briefly, to a stirred solution of amino acid (0.3 M in 
50/50 THF/H2O) was added di-tert-butyl dicarbonate (1.1 equiv), and triethylamine (1 equiv).  The 
reactions were stirred at room temperature until the starting material was consumed, as determined by 
TLC.  Reaction mixtures were then dried by rotary evaporation to remove THF, and then lyophilized.  
The residue was then dissolved in aqueous sodium hydroxide (1 M, 2 equiv) and extracted twice with 
CH2Cl2; the solutions were acidified and extracted three times with CH2Cl2.  The acid extracts were 
then combined and dried by rotary evaporation.  Prior to use in enzyme reactions, small amounts of 
each boc-protected amino acid were subjected to additional purification by reversed-phase HPLC.  
To wit, the amino acid derivatives were injected on a C18 onyx monolithic semiprep column 
(Phenomenex) on a linear gradient from 50% buffer A (H2O, 0.05% TFA) to 100% buffer B 
(acetonitrile) over 60 minutes.   
Boc-4-iodo-L-Phe: 1H NMR (400 MHz, CDCl3)  ! 7.62 (2H, br), 6.93 (2H, br), 4.90 (1H, s), 
4.56 (1H, br), 3.13 (1H, br), 3.03 (1H, br), 1.42 (9H, s); 13C NMR (100 MHz, DMSO d6) ! 173.4, 
155.4, 137.9, 136.8, 131.6, 92.2, 78.1, 54.9, 35.9, 28.1.  Boc-4-methoxy-L-Phe: 1H NMR (400 MHz, 
DMSO d6) ! 7.14 (2H, br), 6.83 (2H, br), 4.00 (1H, br), 3.70 (3H, br), 2.91 (1H, br), 2.74 (1H, ap t, 
J=10.8 Hz), 1.31 (9H, s). 13C NMR (100 MHz, DMSO d6) ! 173.7, 157.9, 155.5, 130.1, 129.9, 113.6, 
78.0, 55.5, 55.0, 35.6, 28.2. 
 Boc-L-tyrosine, sodium hydrogen pyrophosphate, dimethylallyl bromide, 
tetrabutylammonium hydroxide, and dopamine HCl were purchased from Sigma.  N-acetyl-L-
tyrosine and phenol were purchased from Fisher Scientific.  All other Tyr and Phe derivatives were 








Genes and Cloning 
A codon-optimized version of lynF was synthesized and cloned into pET28 in frame with the 
N-terminal his-tag sequence using NdeI and EcoRI (Genscript).  The vector pRSF-truE1-DlacI was 
described previously.8 Oligonucleotides were designed to swap the region of truE1 encoding patellin 
2 (TVPTLC) for a region encoding a cassette found in the lyn pathway (VCMPCYP).  The resulting 
construct (pRSF-LynE-Dlac) was confirmed using DNA sequencing.  This construct was then cloned 
into pET28b using NdeI and BamHI.   
 
Protein Expression and Purification 
The plasmid encoding lynF was transformed into BL21(DE3) cells via electroporation and 
grown at 30 °C.  Colonies were picked the following day and grown overnight in 2 x 45 mL starter 
cultures (LB media, 50 µg/mL kanamycin) at room temperature.  The starter cultures were then used 
to inoculate 8 x 1 L cultures (LB, 50 µg/mL kanamycin) in 2.8 L Fernbach flasks and grown at 30 °C 
until an A600 of 0.4 was reached.  Upon reaching the desired optical density, the temperature was 
lowered to 15 °C and IPTG (0.1 mM final concentration) was added, and expression was allowed to 
proceed overnight.  Cells were then pelleted by centrifugation, and frozen at -80 °C until purification.  
Cell lysis was performed according to previously established procedures.  Briefly, cells were 
resuspended in cold lysis buffer (200 mM NaCl, 50 mM Tris pH 7.5, 100 µM EDTA, 5 mL per gram 
of cell paste) to which lysozyme (600 µg/mL), PMSF (1 mM), and imidazole (10 mM) were added.  
The suspension was then incubated on ice with stirring for 1 h, after which time MgCl2 (10 mM) and 
DNase I (20 µg/mL) were added and incubation on ice was continued for a further 0.5 h.  After lysis 
was complete, the suspension was centrifuged at 14,000 RPM in a JA-20 rotor for 1 h at 4 °C.   
Cleared lysates were then passed through a 0.45 µm syringe filter, and then ATP (2 mM) was added.  
Lysate was then applied to a gravity column containing a 5 mL bed of nickel-NTA resin (Qiagen).  
The lysate was allowed to equilibrate on resin for 15 minutes and then allowed to flow through.  The 
column was then washed with 20 column volumes of wash buffer (500 mM NaCl, 25 mM imidazole, 
2 mM ATP pH 8.0), and then eluted with 2 x 15 mL of elution buffer (750 mM NaCl, 250 mM 
imidazole pH 8.0).  In order to cleave the his-tag, thrombin was added to the eluents (33 nM), which 
were then placed in 8,000 MWCO dialysis tubing and stirred in dialysis buffer (0.5 M NaCl, 25 mM 
HEPES pH 8.0) overnight at 4 °C.   Following dialysis, LynF-containing fractions were concentrated 
and run on an S-75 sizing column, for which an isocratic buffer (0.5 M NaCl, 25 mM HEPES pH 8.0) 
was employed.  Fractions were tested for activity, the portion eluting between 65 and 77 mL was 
significantly more active as determined by MALDI-MS analysis of reactions containing 6.  The 
active fractions were then dialyzed into storage buffer (0.5 M NaCl, 25 mM HEPES pH 8.0, 10% 
glycerol), flash frozen in liquid nitrogen, and frozen at -80 °C until use.  
Expression of truLy1 was performed in a similar fashion, with the main difference being that 
rather than attempting to isolate soluble protein, truLy1 was strongly overexpressed with the intent of 
driving the protein into inclusion bodies, after which time purification under denaturing conditions 
was performed.  To wit, 8 x 1L cultures (sLB: 10 g/L soytone, 10 g/L NaCl, 5 g/L yeast extract, 50 
µg/mL kanamycin) containing the truLy1 plasmid were grown at 37 °C and upon reaching an A600 
of 0.4, induced with 1 mM IPTG and allowed to grow overnight.  Cell lysis and denaturing Ni-NTA 
purification was effected according to the manufacturer’s protocol (Qiagen).  The concentration of 
TruLy1 was assessed by amino acid analysis.      
  
Enzyme Assays  
Enzyme reactions typically contained enzyme (3.8 µM), variable substrate concentration 
(100 µM for most substrates; higher concentrations, i.e. 1 mM, were occasionally employed with 







20 µM final concentration as well as substrates 9, and 10, which were used at 70 and 30 µM, 
respectively), and several additives (1 M NaCl, 40 mM glycylglycine pH 9.0, 12 mM MgCl2, 3 mM 
tris(2-carboxyethyl) phosphine (TCEP), and 1 mM DMAPP).  Reactions were incubated at 37 °C for 
24 h in a DNA Engine Peltier thermocycler (Bio-Rad).  Enzyme reactions with full-length precursor 
peptide contained TruLy1 (28 µM), ATP (0.8 mM), with or without heterocyclase enzyme TruD (90 
nM), and additives as above.  Controls were run to ensure that LynF was active in the presence of 
TruD and TruLy1, and vice versa.   
 Reactions prepared for kinetic analysis of boc-L-Tyr were prepared in triplicate, and 
contained variable substrate concentrations (1, 2, 4, 8, and 16 mM), constant enzyme (0.9 µM), 
DMSO (4% v/v) for solubility, and additives as described above.  The reactions were incubated for 3 
h at 37 °C as above, halted by addition of guanidinium HCl (1 M), and then frozen at -80 °C until 
HPLC analysis.  A sample of each reaction (15 µL) was injected onto a 214MS C4 5µ column 
(Grace-Vydac) and run on a linear gradient from 99% buffer A (H2O, 0.5% TFA) / 1% buffer B 
(AcN) to 0% A / 100% B over 45 minutes. Peaks corresponding to O-prenyl and C-prenyl products 
were integrated, and summed to arrive at the total integrated area corresponding to prenylated 
product.  The integrated areas were plotted on a calibration curve to determine what molar amounts 
of product they represented.  The data were then analyzed using GraphPad Prism to derive kinetic 
curves and parameters.   
 Kinetic analysis of cyclo[APMPPYP] was performed in a similar fashion, with variable 
substrate concentrations (0.9, 2.1, 3.3, 6.6, 9, and 10.1 mM) and constant enzyme (1.8 µM).  
Reactions were incubated as above and quenched in an identical manner.  HPLC conditions differed 
only in that the run began by holding the solvent mixture at 99% buffer A / 1% buffer B for the first 5 
minutes, then stepped to 80% buffer A / 20% buffer B at which time a linear gradient to 60% buffer 
A / 40% buffer B over 34 minutes was begun.   Additionally, controls were run with both boc-L-Tyr 
and cyclo[APMPPYP] to ensure that the rate of product formation was linear over the first several 
hours.  To wit, reactions containing boc-L-Tyr (1, 4, and 8 mM), constant enzyme (0.9 µM), DMSO 
(4% v/v) for solubility, and additives as described above were incubated at 37 °C.  Aliquots were 
removed at three time points (2, 4, and 6 h), and analyzed as above.  A similar set of controls was 
performed containing cyclo[APMPPYP] (2.1, 3.3, and 6.6 mM), constant enzyme (1.8 µM), DMSO 
(4% v/v), and additives as described above.  Data presented in figure 5 were generated via analysis of 
a time-course of the LynF (5.4 µM) reaction with boc-L-Tyr (1 mM) containing standard additives.  
Reaction aliquots (17.5 µL) were removed at 1, 2, 4, 6, and 24 h and immediately mixed with 
guanidinium HCl (3.5 µL, 6 M) and then placed at -80 °C until HPLC analysis. 
 Experiments assaying prenylation of TruLy1 were performed as follows: LynF (1.5 µM) or 
buffer control was incubated with either TruLy1 (14 µM), boc-L-Tyr (14 µM), cyclo[APMPPYP] (14 
µM), without substrate, additives as above with the exception of DMAPP, and 3H-labeled DMAPP 
(0.1 µM) (American Radiolabeled Chemicals), which had previously been dried under a stream of 
argon, and resuspended in ultrapure water.  Reactions were covered with a mineral oil overlay (30 
µL) and placed in a heat-block at 37 °C for 24h.  Once complete, reaction aliquots (20 µL) were then 
quenched by addition of acid (2 M HCl in 80% EtOH, 4 µL), incubated a further 30 minutes to 
hydrolyze any remaining DMAPP.  The resulting mixture was then added to a 7 mL scintillation vial 
along with water (150 µL), and placed in a sand-bath at 110 °C for 1.5 h.  Resolubilization was then 
effected via addition of Soluene 350 (1 mL) (Perkin-Elmer), and heating in a sand bath at 50 °C for 1 
h.  Scintillation fluid (up to 7 mL) (Hionic-Fluor, Perkin-Elmer) was then added.  Samples were 
placed in the dark for 30 minutes and then read by scintillation counting (5 minutes per sample).  
Radioassay samples were also analyzed by autoradiography, in which case a reaction aliquot (15 µL) 
was mixed with 6X SDS-PAGE buffer (0.6 M DTT, 0.35 M tris pH 6.8, 30% (v/v) glycerol, 10% 







polyacrylamide gel.  After staining with Coomassie R250, gels were destained, and enhanced for 
autoradiography using En3hance (Perkin-Elmer) according to the manufacturer’s instructions.  Film 
(BioMax XAR, Kodak) was then exposed to the enhanced gel at -80 °C for at least 24 h and then 
developed.  Lastly, possible prenylation of TruLy1 was assessed via ESI-MS intact analysis, as well 
as by proteolytic digest followed by LC-FT-ICR.  In those cases, LynF (1.5 µM) was incubated with 
TruLy1 (14 µM) or boc-L-Tyr (640 µM), additives as above, and ATP (800 µM).  Reactions were 
run at 37 °C  for 24h; samples were taken at 0, 6, 12, and 24h time points, and were then analyzed by 
ESI-MS.  Control reactions were run containing TruD (90 nM), or lacking ATP and TruD, and also 
analyzed by ESI-MS after 24h incubation.  Boc-L-Tyr containing reactions were analyzed by HPLC 
as positive controls.  Samples analyzed by LC-FT-ICR were digested either with previously 
characterized cyanobactin protease PatA (2 µM) including added calcium (10 mM),6 or with trypsin 
and chymotrypsin. 
Isolation of O-prenylated intermediate was performed as follows: a crude fraction of LynF 
(6.3 µM) was incubated with boc-D-Tyr (3.5 mM, 8.8 µmol), DMSO (1% v/v) for solubility, and 
additives as above.  The reaction was allowed to proceed for 48 h at 37 °C.  The reaction was then 
acidified (pH 4) with 1 M HCl and then extracted 5X with methylene chloride.  The combined 
organic phases were then dried, and purified by HPLC.  Purification was performed using a Onyx 
monolithic C18 semi-preparative column on a linear gradient from 99% buffer A (H2O, 0.05% TFA) 
/ 1% buffer B (AcN) to 100% buffer B over 60 minutes.  The dominant C-prenylated product was 
purified along with the O-prenyl product.  
 To assess whether the conversion of reverse O-prenylated Tyr to forward C-prenylated Tyr 
was accelerated by LynF, the O-prenylated intermediate was purified as above, and then incubated at 
37 °C with additives as above, excepting DMAPP, and either LynF (2.3 µM), boiled LynF (2.3 µM), 
or buffer only.  Time points were taken at 0 and 8 h, and then frozen at -80 °C until analysis.   
 
Phylogenetic Tree Construction  
The amino acid sequences of LynF homologues from the functionally characterized 
cyanobactin pathways were aligned using CLUSTALX. Maximum likelihood analysis with 
molecular clock PROMLK (PHYLIP) using the bootstrap test method (1000 replicates) was 
performed to assess the phylogenetic relationship between the different homologues. The same tree 
branches were also supported using other phylogenetic experiments such as Maximum Parsimony 
(MEGA 4.0) using 1000 bootstrap replicates. 
 
Preparative Enzymatic Synthesis 
Preparative synthesis of prenylated boc-L-Tyr was performed as follows: a crude fraction of 
LynF (6.3 µM) was incubated with boc-L-Tyr (3.5 mM, 17.8 µmol) and additives as above.  The 
reaction was incubated at 37 °C for 48 h and extracted as described above for boc-D-Tyr.  
Purification was accomplished using a Vydac C4 214TP1010 semi preparative column on a linear 
gradient from 99% buffer A (H2O, 0.05% TFA) / 1% buffer B (AcN) to 100% buffer B over 45 
minutes.   
Preparative synthesis of prenylated boc-D-Tyr was performed as described in the previous 
section.  The purified O- and C-prenylated products were subjected to NMR analysis: Boc-4-O-(2-
methylbut-3-en-2-yl)-D-tyrosine: 1H NMR (500 MHz, CDCl3)  ! 7.01 (2H, d, J=8.5 Hz), 6.90 (2H, 
d, J=8.5 Hz), 6.10 (1H, dd, J=17.3, 10.5), 5.14 (1H, ap d, J=17.8), 5.11 (1H, ap d, J=11.5), 4.88 (1H, 
s), 4.49 (1H, br), 3.10 (1H, br), 2.98 (1H, br), 1.42 (6H, s), 1.40 (9H, s).  Boc-3-(3-methylbut-2-en-1-
yl)-D-tyrosine: 1H NMR (500 MHz, CDCl3) ! 6.90 (1H, d, J=8.0 Hz), 6.89 (1H, s), 6.71 (1H, d, 
J=8.0 Hz), 5.27 (1H, t, J=6.6 Hz), 4.86 (1H, s), 4.47 (1H, br), 3.30 (2H, d, J=7.0 Hz), 3.07 (1H, m), 






Preparative synthesis of prenylated cyclo[APMPPYP] was performed by incubation of sizing-
column purified LynF (5 µM) with cyclo[APMPPYP] (0.4 mM) and additives as above.  The reaction 
was incubated at 37 °C for 88 h, and then frozen at -20 °C.  Purification was accomplished using a 
Vydac C4 214TP1010 semi preparative column on a linear gradient from 99% buffer A (H2O, 0.05% 
TFA) / 1% buffer B (AcN) to 100% buffer B over 45 minutes.   
Preparative synthesis of prenylated boc-D-Tyr was performed as described in the previous 
section.  The purified O- and C-prenylated products were subjected to NMR analysis: Boc-4-O-(2-
methylbut-3-en-2-yl)-D-tyrosine: 1H NMR (500 MHz, CDCl3)  ! 7.01 (2H, d, J=8.5 Hz), 6.90 (2H, 
d, J=8.5 Hz), 6.10 (1H, dd, J=17.3, 10.5), 5.14 (1H, ap d, J=17.8), 5.11 (1H, ap d, J=11.5), 4.88 (1H, 
s), 4.49 (1H, br), 3.10 (1H, br), 2.98 (1H, br), 1.42 (6H, s), 1.40 (9H, s).  Boc-3-(3-methylbut-2-en-1-
yl)-D-tyrosine: 1H NMR (500 MHz, CDCl3) ! 6.90 (1H, d, J=8.0 Hz), 6.89 (1H, s), 6.71 (1H, d, 
J=8.0 Hz), 5.27 (1H, t, J=6.6 Hz), 4.86 (1H, s), 4.47 (1H, br), 3.30 (2H, d, J=7.0 Hz), 3.07 (1H, m), 
3.00 (1H, br), 1.75 (6H, ap s), 1.41 (9H, s) 
Preparative synthesis of prenylated cyclo[APMPPYP] was performed by incubation of sizing-
column purified LynF (5 µM) with cyclo[APMPPYP] (0.4 mM) and additives as above.  The reaction 
was incubated at 37 °C for 88 h, and then frozen at -20 °C.  Purification was accomplished using a 
Vydac C4 214TP1010 semi preparative column; the run was begun by holding the solvent mixture at 
99% buffer A / 1% buffer B for the first 5 minutes, then stepped to 80% buffer A / 20% buffer B at 
which time a linear gradient to 60% buffer A / 40% buffer B over 55 minutes was begun.  
 
General Methods 
 ESI-MS, and FT-ICR analyses were performed at the University of Utah Mass Spectrometry 
and Proteomics core facility.  MALDI-MS analyses were performed on a Micromass MALDI micro 
MX instrument (Waters).   HPLC separations were performed on a LaChrom Elite system (Hitachi).  
NMR spectra were collected either on 400 or 500 MHz spectrometers (Varian).   CD spectra were 









Table S1.  Substrates used in this study.    
# Substrate Result Analytical Method(s) 
3 TruLy1 precursor peptide NR ESI-MS, LC-FT-ICR, radioassay, autoradiography 
4 TruD-treated TruLy1 NR ESI-MS, LC-FT-ICR, radioassay, autoradiography 
5 APMPPYPSYDDAE NR MALDI-MS, HPLC 
6 cyclo[APMPPYP]  48% MALDI-MS, HPLC, LC-FT-ICR, NMR, radioassay 
7 APMPPYP  12% MALDI-MS, HPLC, LC-FT-ICR 
8 N-acetyl APMPPYP  10% HPLC 
9 cyclo[APMPPPAPMPPYP] 47% MALDI-MS, LC-FT-ICR 
10 cyclo[APMPPYPAPMPPYP] 43% MALDI-MS, LC-FT-ICR 
12 cyclo[KKPYILP] 37% MALDI-MS, LC-FT-ICR 
12 cyclo[KPYILP] 94% MALDI-MS, LC-FT-ICR 
13 KPYILP 1% MALDI-MS, LC-FT-ICR 
14 Boc-L-Tyr 71% HPLC, FT-ICR, NMR, CD, radioassay 
15 Boc-D-Tyr 66% HPLC, NMR, CD 
16 Boc-4-cyano-L-Phe NR HPLC 
17 Boc-O-allyl-L-Tyr NR HPLC 
18 Boc-4-iodo-L-Phe NR HPLC 
19 Boc-4-methoxy-L-Phe NR HPLC 
20 L-Phe NR HPLC 
21 N-acetyl-L-Tyr 3% HPLC, ESI-MS 
22 L-Tyr NR HPLC 
23 Dopamine NR HPLC 
24 Phenol NR HPLC 
25 L-Trp NR HPLC 
26 cyclo[QGGRGDWP]  NR MALDI-MS 
















Table S2.  Summary of FT-ICR data 
Substrate  Producta Expected m/z Observed m/z !ppm 
6 cyclo[APMPPyP] 822.4219 (M+H+) 822.4216 -0.36 
7 APMPPyP 840.4324 (M+H+) 840.4328 -0.47 
9 cyclo[APMPPPAPMPPyP] 706.8589 (M+2H2+) 706.8593 +0.56 
10 cyclo[APMPPyPAPMPPYP] 788.3906 (M+2H2+) 788.3912 +0.76 
10 cyclo[APMPPyPAPMPPyP] 822.4219 (M+2H2+) 822.4227 +0.97 
11 cyclo[KKPyILP] 454.8020 (M+2H2+) 454.8019 -0.22 
12 cyclo[KPyILP] 780.5018 (M+H+) 780.5013 -0.64 
13 KPyILP 798.5124 (M+H+) 798.5137 +1.6 
14 O- and C-prenyl boc-L-Tyr 350.1962 (M+H+) 350.1966 +1.1 
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1.1  Conclusions 
 
 In the prior chapters, I have shown the extensive characterization of a number of 
enzymes important in the biosynthesis of a group of natural products, the cyanobactins.  
A question that naturally suggests itself prior to conducting such an investigation, but 
which due to convention is most likely to be posed at the conclusion of such an inquiry, is 
the simplest: why?  
 Indeed, why study natural products biosynthesis?  Further, why study the 
particular natural products that were the focus of this work?  Beyond the more 
fundamental questions one might ask regarding the benefits to the accruing of human 
knowledge, here I shall attempt to answer the question about the topics specifically 
treated in this work.  Further, since the theoretical benefits of such an inquiry are, by 
nature, more difficult to specify, only the practical benefits of such an inquiry will be 
addressed.   
 To answer the general question first, natural products make up a large fraction of 
clinically-used drugs.  Further, natural products are still actively researched as a source of 
new molecular entities of interest for drug development.  Still, what benefit can the 
understanding of their biosynthetic origins provide?  First, although some natural 
products are sufficiently potent and selective for their targets that the raw natural product 
itself is used as a drug, frequently this is not the case.  When a natural product possesses a 
useful activity, but is either insufficiently potent or excessively nonselective, the most 
obvious solution is to modify its structure so as to remedy its defects.  These aims can be 
successfully achieved by the application of traditional medicinal chemistry, in particular 
via total chemical synthesis of the natural product and analogues therefrom, it can also be 
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difficult, expensive, and poor-yielding.  An alternative is the use of a biosynthetically-
based medicinal chemistry program, using biosynthetic knowledge to create derivatives 
of the natural product(s).  In this case, genetic alteration (genetic disruptions, 
substitutions, or additions) can be expected to alter the chemical products of the pathway.  
However, such an attempt would be entirely quixotic without a strong prior foundation of 
biochemical knowledge supporting the notion that the pathway will remain functional 
when modified, and that the desired products will result from whatever modification.   
 Another important consequence of the study of natural products biosynthesis is 
the development of novel catalysts.  To make a gross generalization: all natural products 
are synthesized by enzyme catalysts.  Interestingly, however, these catalysts frequently 
carry out transformations that would be difficult for synthetic chemists to perform.  
Indeed, as noted above, the chemical synthesis of complex natural products can 
frequently be quite difficult.  Thus, another benefit to the study of natural products 
biosynthesis is the isolation of catalysts specific for a given transformation.  Biochemical 
study of these catalysts can then answer the question of how generalizable the activity of 
a given catalyst is.  If an enzyme catalyst were sufficiently robust and chemically useful, 
then it could also find application outside of the natural pathway.  In particular, enzymes 
can be employed to synthesize fine chemicals or pharmaceuticals that are entirely 
unrelated to the enzymes’ natural substrates.(1)  
 With regard to the study of cyanobactin biosynthesis both of the above-described 
benefits could potentially apply.  First, several cyanobactins possess quite promising anti-
cancer activities.(2-4)  However, none of these compounds has been sufficiently 
promising to advance far into clinical trials.  Consequently, since the work described in 
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the preceding chapters (as well as in other published works) shows that the cyanobactin 
biosynthetic enzymes are broadly tolerant of amino acid substitutions in the natural-
product encoding sequences, it should be possible to employ the natural pathway to 
synthesize novel derivatives, which may someday find use in medical practice.   
 The preceding chapters have suggested several biosynthetic strategies for 
achieving the above aim.  First, in chapters 3 and 4, we have shown that the 
circularization catalyst, PatG is broadly accepting of profoundly unnatural subsrates, thus 
PatG’s substrate selectivity does not pose a roadblock to the possibility of incorporating 
non-natural amino acids into cyanobactins.  A more conservative approach involves 
mutation of existing cyanobactins using the 20 canonical amino acids, and again the 
plausibility of this approach is supported by chapters 3 and 4, as well as chapters 5 and 7. 
Looking beyond the contents of this work, future engineering efforts on cyanobactins 
(and others) could employ addition of tayloring domains—such as cytochrome P450s—to 
existing pathways to create new chemical diversity.  Directed evolution may also be a 
fruitful strategy to direct foreign peptide modifying enzymes to the cyanobactin leader 
peptide, or to evolve altered chemical reactivity within cyanobactin modifying enzymes.   
As for the biocatalytic use of cyanobactin enzymes, it is likely too early to tell 
whether any enzymes described in this work will find such use.  However, several of the 
enzymes described herein are certainly promising for use as catalysts outside of their 
natural contexts.  For one, if the heterocyclase enzymes’ substrate selectivity and 
catalytic mechanism were fully understood so that they could be directed to modify 
wholly different sequences that do not possess the standard cyanobactin leader peptide, 
they could prove quite useful for the introduction of heterocycles into diverse protein and 
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peptide substrates.  Additionally, the prenyltransferase enzymes are also potentially quite 
promising since of all enzymes presented it seems that their substrate selectivity is most 
relaxed—acting on small molecule phenols as well as linear and cyclic peptides.   
 In closing, then, the study of natural products biosynthesis should not be ignored 
in the drive towards increased reliance upon biotechnological tools to support human 
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